

UNIVERSITY OF PENNSYLVANIA - PERELMAN SCHOOL OF MEDICINE
Curriculum Vitae

Date: 12/31/2025

Carl H. June, M.D.

Address: 3400 Civic Center Boulevard, Building 421
8th Floor, Room 123, Smilow Center for Translational Research
Philadelphia, PA. 19104-5156 USA

Citizenship: U.S. citizen

Education:

1975	B.S.	United States Naval Academy (Biology)
1979	M.D.	Baylor College of Medicine (Medicine)

Honorary Degrees:

1999	M.A.	University of Pennsylvania
2017	Ph.D.	Katholieke Universiteit Leuven
2021	Sc.D.	Albany Medical College
2025	Sc.D.	Drexel Medical College

Postgraduate Training and Fellowship Appointments:

1978-1979	Research Fellow, World Health Organization Immunology Research and Training Center, Geneva, Switzerland
1979-1980	Internship: Basic Medicine, National Naval Medical Center, Bethesda, Maryland
1980-1982	Residency: Internal Medicine, National Naval Medical Center, Bethesda, Maryland
1982-1983	Chief Resident: Internal Medicine, National Naval Medical Center, Bethesda, Maryland
1983-1985	Fellow in Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington

Military Service:

1975-1996	United States Navy Medical Officer
-----------	------------------------------------

Faculty Appointments:

1980-1982	Teaching Fellow, Department of Medicine, Uniformed Services, University of the Health Sciences, Bethesda, MD
1982-1983	Instructor, Department of Medicine, Uniformed Services University
1986-1990	Assistant Professor, Department of Medicine, Uniformed Services
1990-1995	Associate Professor, Department of Medicine, Uniformed Services
1995-1999	Professor, Department of Medicine, Uniformed Services

1999-2001	University of Professor of Molecular and Cellular Engineering, University of Pennsylvania School of Medicine
2001-2012	Professor of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine
2004-present	Professor of Medicine, University of Pennsylvania School of Medicine (Secondary)
2012-present	Richard W. Vague Professor in Immunotherapy, University of Pennsylvania School of Medicine

Other Appointments:

1999-present	Director, Translational Research Program
2015-present	Director, Center for Cellular Immunotherapies
2016-present	Director, Parker Institute for Cancer Immunotherapy at the University of Pennsylvania
2018-present	Visiting Professor, Graduate School of Medicine, Chiba University

Specialty Certification:

1982	American Board of Internal Medicine
1985	American Board of Internal Medicine Subspecialty of Oncology

Licensure:

1979-1997	Licensed Physician, Texas
1997-2000	Licensed Physician, Maryland
1999-present	Licensed Physician, Commonwealth of Pennsylvania

Awards, Honors and Membership in Honorary Societies:

1978	Alpha Omega Alpha Medical Society
1978	Michael E. DeBakey Scholar award for the Outstanding Medical Student, Baylor College of Medicine
1983-1992	American Federation for Clinical Research
1991	Fellow, American College of Physicians
1992-2006	American Society for Clinical Investigation
1996	Dexter Conrad Award, Office of Naval Research, Navy's highest award for Scientific Achievement
1996	Legion of Merit, US Navy
1997	Frank Brown Berry Prize in Federal Medicine
2001	Burroughs Wellcome Fund Award: visiting professor in the basic medical sciences
2002	Lifetime Achievement Award, Leukemia and Lymphoma Society of America
2002	William Osler Award, University of Pennsylvania School of Medicine
2005-2009	Bristol-Myers Squibb Freedom to Discover Award

2005	Federal Laboratory Award for Excellence in Technology Transfer
2006	American Association of Physicians
2012	Earnest Beutler Lecture and Prize, American Society of Hematology
2012	Elected to Institute of Medicine
2012	Top 10 Clinical Research Achievement Award/Clinical Research Forum
2013	Richard V Smalley Award, Society for Immunotherapy of Cancer
2013	Philadelphia Award
2014	Hamdan Award for Medical Research Excellence
2014	Taubman Prize for Excellence in Translational Medical Science
2014	Karl Landsteiner Memorial Award, AABB
2014	Elected to American Academy of Arts & Sciences
2014	Steinman Award for Human Immunology Research, American Association of Immunologists
2014	Aubrey Evans Award / Ronald McDonald House
2015	AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
2015	E. Donnall Thomas Award Lecture / American Society for Blood and Marrow Transplantation
2015	Watanabe Prize for Translational Research / Indiana University and Eli Lilly
2015	Paul Ehrlich and Ludwig Darmstaedter Prize
2015	Debrecen Award for Molecular Medicine / University of Debrecen
2015	Lifetime Achievement Award Lecture / Miami Winter Symposium
2016	Novartis Prize for Immunology, (shared with S. Rosenberg and Z. Eshhar), International Congress of Immunology
2016	The John Scott Award (shared w E. Charpentier, J. Doudna and F. Zheng)
2017	Karnofsky Prize, ASCO
2018	Passano Award (shared with M. Sadelain)
2018	Albany Medical Prize (shared with J. Allison and S. Rosenberg)
2019	ACTS Distinguished Investigator: Translation from Proof-of-Concept to Applicability for Widespread Clinical Practice Award
2019	Harrington Prize, American Society for Clinical Investigation
2020	Genome Valley Excellence Award, BioAsia 2020
2020	Elected member, American Philosophical Society
2020	Elected member, National Academy of Sciences
2021	Dan David Prize 2021 "Future": molecular medicine (shared

	with Zelig Eshhar and Steven Rosenberg)
2021	Sanford Lorraine Cross Award
2022	Clarivate Highly Cited Researchers 2022 (0.1% of the world's researchers)
2022	Keio Medical Science Prize
2023	Lifetime Achievement in Cancer Research, AACR
2023	Lombardy Prize in Research (shared w S. Rosenberg)
2024	Breakthrough Prize in Life Sciences (shared with Michel Sadelain)
2024	Warren Alpert Foundation Prize (shared w Sadelain, Eshhar and Brentjens)
2025	Richard N. Merkin Prize in Biomedical Technology (shared w Sadelain, Levine and Riviere)
2025	Broermann Medical Innovation Award (shared w M. Sadelain)
2025	J. Allyn Taylor International Prize in Medicine
2025	Balzan Prize in Medicine

Memberships in Professional and Scientific Societies and Other Professional Activities:

International:

1999-Present	American Society of Gene and Cell Therapy (Advisory Council 2010-2015 (elected position) Chair, Clinical and Regulatory Affairs Committee 2006-2010 Chair, Genetic Vaccines Committee 2005-2007)
2002-2010	Leukemia & Lymphoma Society (Member, SCOR Review Subcommittee 2002-present)
2007-2010	Foundation for the Accreditation of Cellular Therapy (Member, Board of Directors, 2007 to 2010)
2008-Present	Danish Council for Strategic Research (Member, Scientific Advisory Committee 2008 to present)
2008-2009	International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation (Member)
2008-2010	Telethon Fondazione Onlus (HSR-TIGET External Review Committee, University of San Raffaele 2008-Present)
2009-2010	United Kingdom Quinquennial Review

National:

1986-Present	American Society Hematology (Member, Scientific Subcommittee on Transplantation 1996-2001)
--------------	--

Chair, Scientific Committee on Lymphocyte Biology 2002-2005)

- 1994-Present National Institutes of Health (Member, Allergy and Immunology Transplantation Study Section, National Institute of Allergy and Infectious Diseases 1994-1998
Member, National Cancer Institute Subcommittee D (Clinical Studies) 2005-2007
Member, Network Steering Committee, Immune Tolerance Network 1999-2002
Member, NCI Internal Review Committee, 2007), Member, NCI Board of Scientific Counselors (2010-2014)
- 1995-Present Clinical Immunology Society (Member, Development Committee 2003-2005
Elected Councilor 2005 to 2009
President, 2009 to 2010)
- 1999-2008 Juvenile Diabetes Research Foundation International (Member, Medical Science Review Committee 1999-2001
Scientific Reviewer, 2007-2008)
- 2006-Present Alliance for Cancer Gene Therapy (Member, Scientific Steering Committee 2006 present)
- 2006-Present International Society for Biological Therapy of Cancer (Elected Member, Board of Directors, 2008-2011)
- 2008-Present Multiple Myeloma Research Foundation (Member, Technology Advisory Board, 2009 - present)
- 2009-Present Gabrielle's Angel Foundation for Cancer Research (Medical Advisory Board 2009-present)
- Local:
- 2003-2008 Pacific Ovarian Cancer Research Consortium (Member, External Advisory Committee for the Ovarian Cancer SPORE, Fred Hutchinson Cancer Research Center)
- 2004-2007 Roger Williams Medical Center, Providence, RI (Member, External Advisory Committee, Centers of Biomedical Research Excellence (COBRE))
- 2005-Present Memorial Sloan Kettering Cancer Center (Member, External Advisory Committee, SPORE in ovarian cancer
Member, External Advisory Committee, Center for Cell Therapy)
- 2006-2008 Dana Farber Harvard Cancer Center (Member, Center for Human Cell Therapy External Advisory Board 2006
Harvard Cancer Center External Advisory Committee 2007)
- 2007-2011 H. Lee Moffitt Cancer Center (Member, External Advisory Committee)

2008-Present	University of Minnesota (Member, NCI External Advisory Committee for PO1 2008-present)
2010-Present	Stanford University Cancer Center (Member, External Scientific Advisory Committee)
2012-present	Duke Cancer Institute, Duke University (Member, Scientific Advisory Board) (Member, External Scientific Advisory Committee)

Editorial Positions:

1997-Present	Editorial Board, Journal of Clinical Immunology
1998-1993	Associate Editor, Journal of Immunology
1998-Present	Section Editor, Clinical Immunology
2001-Present	Associate Editor, Cancer Biology & Therapy
2001-Present	Editorial Board, Clinical and Applied Immunology Reviews
2001-Present	Editorial Board, Human Gene Therapy
2007-2009	Cancer Research, Associate Editor
2008-2010	Member, Editorial Board, Gene Therapy
2008-2010	Board of Consulting Editors, Journal of Clinical Investigation
2009-Present	Editorial Board, Science Translational Medicine
2015-Present	Editorial Board, Cancer Immunology Research
2019-Present	Editorial Board, Blood Advances

Academic and Institutional Committees:

1999-2000	Member, Department of Anesthesiology Review Committee, University of Pennsylvania School of Medicine
2000-2008	Member, Faculty Advisory Committee, Office Human Research, University of Pennsylvania
2000-2003	Member, Committee on Appointments and Promotions, University of Pennsylvania School of Medicine
2000-2001	Member, Department of Microbiology Review Committee, University of Pennsylvania School of Medicine
2002-2004	Member, Search Committee for Chief, Division of Allergy, Immunology and Infectious Diseases at Children's Hospital of Philadelphia
2003-2006	Academic Review Committee, University of Pennsylvania School of Medicine
2003-present	Member, Awards Committee, University of Pennsylvania School of Medicine
2003-present	Member, Advisory Committee Clinician Educator Faculty, University of Pennsylvania School of Medicine
2003	Member, Search Committee, Vice Provost for Research University of Pennsylvania
2003	Member, Search Committee for Chair, Department of Medicine, University of Pennsylvania School of Medicine

2005-2019	Chair, Scientific Advisory Committee, Clinical Cell and Vaccine Production Facility
2005-2010	Member, Steering Committee, Penn Center in Clinical Immunology
2006-2020	Member, Steering Committee, Institute for the Translational Medicine and Therapeutics
2007-2012	Chair, Scientific Advisory Committee, Human Immunology Core
2007-2009	Member, Advisory Committee, Abramson Cancer Center Developmental Therapeutics Program
2008-2010	Member, Advisory Committee, Center for Research on Reproduction and Women's Health
2008-2012	Member of the Clinical Research Computing Unit Advisory Committee for the Department of Biostatistics and Epidemiology

Major Academic and Clinical Teaching Responsibilities:

2011-Present	CAMB 610
--------------	----------

Lectures by Invitation (example, 2014):

Jan, 2014	Hopkins Visiting Professor Baltimore, MD
Jan, 2014	Asilomar midwinter
Jan, 2014	Sidra mtg, Doha Qatar
Feb, 2014	LLS Black Tie Event, Philadelphia
Feb, 2014	Harvard, Cambridge, MA
Feb, 2014	Toronto/Princess Margaret
Feb, 2014	ACT mtg London
Feb, 2014	AAAS Chicago, IL
Mar, 2014	NLDR, Noosa Australia
Mar, 2014	NCI BSC Bethesda
Mar, 2014	MDACC, Houston Tx
Mar, 2014	Keystone, Whistler, Canada
Mar, 2014	Univ Chicago
Apr, 2014	AAP/ASCI, Chicago IL
Apr, 2014	INCA, Brazil
Apr, 2014	Frontiers Human Disease Symposium, Pfizer, NYC
Apr, 2014	Duke, Raleigh Durham, NC
	Matthews Lecture
	EAB, DCI
Apr, 2014	AACR San Diego
Apr, 2014	CIS, Baltimore, MD
Apr, 2014	UCSF Tumor Board
Apr, 2014	NIBR, Cambridge, MA
May, 2014	EMBO, Bertinoro, IT
May, 2014	TRANSLATE, Berlin, Germany
May, 2014	Penn in San Diego
May, 2014	CIMT, Mainz Germany

May, 2014	AAI, Pittsburgh
May, 2014	ACOS, Taipei, Taiwan
Jun, 2014	Cancer Research Inst SAB, NYC
Jun, 2014	FOCIS, Chicago, IL
Jun, 2014	Norwegian Cancer Symposium
Jun, 2014	SIAT, Hong Kong, Shenzhen China
Jun, 2014	ASCO, Chicago
Jun, 2014	U Minnesota PO1 SAB
Jun, 2014	NCI, Bethesda, MD
Jul, 2014	AACR Snowmass Course Aspen, CO
Jul, 2014	NCI BSC Bethesda
Jul, 2014	NIH Vaccine Branch SAB, Rockville
Aug, 2014	Google Camp, Verdura Sicily
Sep, 2014	BIOCAPS- News challenges in Immunotherapy Santiago de Compostela
Sep, 2014	Prostate Cancer Foundation Philadelphia, PA
Sep, 2014	ESMO Congress Madrid, Spain
Sep, 2014	AACR, Philadelphia
Sep, 2014	Yale, New Haven
Sep, 2014	SU2C, Hollywood
Sep, 2014	Zeitgeist Google, Phoenix AZ
Oct, 2014	Cancer immunology and Immunotherapy: Delivering the Promise Bethesda, MD
Oct, 2014	Stem Cell Meeting La Jolla, CA

Organizing Roles in Scientific Meetings:

May, 2007	Chair Scientific symposium gene based vaccines, American Society of Gene Therapy National Meeting Seattle, WA
Jun, 2007	Organizer, Satellite Symposium on Immunoassessment, Federation of Clinical Immunology Societies San Francisco, CA
Jun, 2007	Chair, Symposium on Tolerance, Federation of Clinical Immunology Societies National Meeting San Diego, CA
Feb, 2008	Organizer, Oncology Biologics Development Primer, International Society for Biological Therapy of Cancer Gaithersburg, MD
Apr, 2008	Co-chair, Major Symposium H: Can Basic Advances in Immunology Generate Effective Cancer Therapies? San Diego, CA
May, 2008	Member, Program Committee, American Society for Clinical

	Oncology National Meeting Chicago, IL
Jun, 2008	Organizer, Satellite Symposium on Immunoassessment, Federation of Clinical Immunology Societies Boston, MA
Feb, 2009	Organizer, 12th Annual Translational Research Cancer Center Consortium Meeting Philadelphia, PA
Oct, 2009	Co-Organizer, 24th Annual Meeting International Society for Biological Therapy of Cancer Washington, DC
Apr, 2010	Member, Program Committee, American Association for Cancer Research Annual Meeting Washington DC
Feb, 2018	Co-Organizer, Emerging Cellular Therapies: T Cells and Beyond Keystone Symposium

Bibliography:

(Google Scholar h-index 205 with >195,000 citations):

Research Publications, peer reviewed (print or other media):

1. June CH.: Alcoholic ketoacidosis and isopropyl alcohol intoxication. Archives of Internal Medicine 138(4): 660, Apr 1978.
2. June CH., Contreras CE., Perrin LH., Lambert PH., Miescher PA.: Circulating and tissue-bound immune complex formation in murine malaria. Journal of Immunology 122(6): 2154-61, Jun 1979.
3. June CH., Contreras CE., Perrin LH., Lambert P.: Improved detection of immune complexes in human and mouse serum using a microassay adaptation of the C1Q binding test. Journal of Immunological Methods 31(1-2): 23-9, 1979.
4. Contreras CE., June CH., Perrin LH., Lambert PH.: Immunopathological aspects of Plasmodium berghei infection in five strains of mice. I. Immune complexes and other serological features during the infection. Clinical & Experimental Immunology 42(3): 403-11, Dec 1980.
5. Mackey LJ., Hochmann A., June CH., Contreras CE., Lambert PH.: Immunopathological aspects of Plasmodium berghei infection in five strains of mice. II. Immunopathology of cerebral and other tissue lesions during the infection. Clinical & Experimental Immunology 42(3): 412-20, Dec 1980.
6. Russell AS., June CH.: On the nature of early mortality in murine malaria. Journal of Parasitology 66(6): 1065-6, Dec 1980.
7. June CH., Browning MD., Pyatt RS.: Renal computed tomography is abnormal in pyelonephritis. Lancet 2(8289): 93-4, Jul 10 1982.
8. June CH., Benjamin SB.: Bright yellow--the extended spectrum of Gilbert's syndrome. American Journal of Gastroenterology 79(6): 482-4, Jun 1984.

9. Thompson CB., June CH., Sullivan KM., Thomas ED.: Association between cyclosporin neurotoxicity and hypomagnesaemia. *Lancet* 2(8412): 1116-20, Nov 17 1984.
10. June CH., Browning MD., Smith LP., Wenzel DJ., Pyatt RS., Checchio LM., Amis ES Jr.: Ultrasonography and computed tomography in severe urinary tract infection. *Archives of Internal Medicine* 145(5): 841-5, May 1985.
11. June CH., Thompson CB., Kennedy MS., Nims J., Thomas ED.: Profound hypomagnesemia and renal magnesium wasting associated with the use of cyclosporine for marrow transplantation. *Transplantation* 39(6): 620-4, Jun 1985.
12. June CH., Thompson CB., Kennedy MS., Loughran TP Jr., Deeg HJ.: Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients. *Transplantation* 41(1): 47-51, Jan 1986.
13. June CH., Beatty PG., Shulman HM., Rinaldi MG.: Disseminated *Fusarium moniliforme* infection after allogeneic marrow transplantation. *Southern Medical Journal* 79(4): 513-5, Apr 1986.
14. June CH., Ledbetter JA., Rabinovitch PS., Martin PJ., Beatty PG., Hansen JA.: Distinct patterns of transmembrane calcium flux and intracellular calcium mobilization after differentiation antigen cluster 2 (E rosette receptor) or 3 (T3) stimulation of human lymphocytes. *Journal of Clinical Investigation* 77(4): 1224-32, Apr 1986.
15. Wallis WJ., Hickstein DD., Schwartz BR., June CH., Ochs HD., Beatty PG., Klebanoff SJ., Harlan JM.: Monoclonal antibody-defined functional epitopes on the adhesion-promoting glycoprotein complex (CDw18) of human neutrophils. *Blood* 67(4): 1007-13, Apr 1986.
16. Martin PJ., Ledbetter JA., Morishita Y., June CH., Beatty PG., Hansen JA.: A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. *Journal of Immunology* 136(9): 3282-7, May 1 1986.
17. Ledbetter JA., June CH., Martin PJ., Spooner CE., Hansen JA., Meier KE.: Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation. *Journal of Immunology* 136(11): 3945-52, Jun 1 1986.
18. Rabinovitch PS., June CH., Grossmann A., Ledbetter JA.: Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. *Journal of Immunology* 137(3): 952-61, Aug 1 1986.
19. Ledbetter JA., Parsons M., Martin PJ., Hansen JA., Rabinovitch PS., June CH.: Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. *Journal of Immunology* 137(10): 3299-305, Nov 15 1986.
20. Ledbetter JA., Gentry LE., June CH., Rabinovitch PS., Purchio AF.: Stimulation of T cells through the CD3/T-cell receptor complex: role of cytoplasmic calcium, protein kinase C translocation, and

phosphorylation of pp60c-src in the activation pathway. *Molecular & Cellular Biology* 7(2): 650-6, Feb 1987.

21. Ledbetter JA., June CH., Grosmaire LS., Rabinovitch PS.: Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. *Proceedings of the National Academy of Sciences of the United States of America* 84(5): 1384-8, Mar 1987.
22. June CH., Rabinovitch PS., Ledbetter JA.: CD5 antibodies increase intracellular ionized calcium concentration in T cells. *Journal of Immunology* 138(9): 2782-92, May 1 1987.
23. Anasetti C., Martin PJ., June CH., Hellstrom KE., Ledbetter JA., Rabinovitch PS., Morishita Y., Hellstrom I., Hansen JA.: Induction of calcium flux and enhancement of cytolytic activity in natural killer cells by cross-linking of the sheep erythrocyte binding protein (CD2) and the Fc-receptor (CD16). *Journal of Immunology* 139(6): 1772-9, Sep 15 1987.
24. Dennis G., June CH., Mizuguchi J., Ohara J., Witherspoon K., Finkelman FD., McMillan V., Mond JJ.: Glucocorticoids suppress calcium mobilization and phospholipid hydrolysis in anti-Ig antibody-stimulated B cells. *Journal of Immunology* 139(8): 2516-23, Oct 15 1987.
25. June CH., Ledbetter JA., Gillespie MM., Lindsten T., Thompson CB.: T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. *Molecular & Cellular Biology* 7(12): 4472-81, Dec 1987.
26. Ledbetter JA., Rabinovitch PS., June CH., Song CW., Clark EA., Uckun FM.: Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19. *Proceedings of the National Academy of Sciences of the United States of America* 85(6): 1897-901, Mar 1988.
27. Ledbetter JA., June CH., Rabinovitch PS., Grossmann A., Tsu TT., Imboden JB.: Signal transduction through CD4 receptors: stimulatory vs. inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor. *European Journal of Immunology* 18(4): 525-32, Apr 1988.
28. Francois DT., Katona IM., June CH., Wahl LM., Feuerstein N., Huang KP., Mond JJ.: Anti-Ig-mediated proliferation of human B cells in the absence of protein kinase C. *Journal of Immunology* 140(10): 3338-43, May 15 1988.
29. Linette GP., Hartzman RJ., Ledbetter JA., June CH.: HIV-1-infected T cells show a selective signaling defect after perturbation of CD3/antigen receptor. *Science* 241(4865): 573-6, Jul 29 1988.
30. Francois DT., Katona IM., June CH., Wahl LM., Mond JJ.: Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and -gamma on human B-cell proliferation induced by various B-cell mitogens. *Clinical Immunology & Immunopathology* 48(3): 297-306, Sep 1988.
31. Lindsten T., June CH., Thompson CB.: Transcription of T cell antigen receptor genes is induced by protein kinase C activation. *Journal of Immunology* 141(5): 1769-74, Sep 1 1988.
32. Lindsten T., June CH., Thompson CB.: Multiple mechanisms regulate c-myc gene expression during normal T cell activation. *EMBO Journal* 7(9): 2787-94, Sep 1988.

33. Lindsten T., June CH., Thompson CB., Leiden JM.: Regulation of 4F2 heavy-chain gene expression during normal human T-cell activation can be mediated by multiple distinct molecular mechanisms. *Molecular & Cellular Biology* 8(9): 3820-6, Sep 1988.
34. Ledbetter JA., Rabinovitch PS., Hellstrom I., Hellstrom KE., Grosmaire LS., June CH.: Role of CD2 cross-linking in cytoplasmic calcium responses and T cell activation. *European Journal of Immunology* 18(10): 1601-8, Oct 1988.
35. Lindsten T., June CH., Thompson CB.: Stimulation of the antigen receptor complex leads to transcriptional activation of the c-myc gene in normal human T cells. *Current Topics in Microbiology & Immunology* 141: 223-30, 1988.
36. Ledbetter JA., Norris NA., Grossmann A., Grosmaire LS., June CH., Uckun FM., Cosand WL., Rabinovitch PS.: Enhanced transmembrane signalling activity of monoclonal antibody heteroconjugates suggests molecular interactions between receptors on the T cell surface. *Molecular Immunology* 26(2): 137-45, Feb 1989.
37. Spielberg H., June C., Cereb N., Nystrom-Rosander C., Deeg HJ.: Differential sensitivity of human leukocyte subpopulations to ultraviolet light. *Transplantation Proceedings* 21(1 Pt 1): 180-1, Feb 1989.
38. Thompson CB., Lindsten T., Ledbetter JA., Kunkel SL., Young HA., Emerson SG., Leiden JM., June CH.: CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. *Proceedings of the National Academy of Sciences of the United States of America* 86(4): 1333-7, Feb 1989.
39. Irving SG., June CH., Zipfel PF., Siebenlist U., Kelly K.: Mitogen-induced genes are subject to multiple pathways of regulation in the initial stages of T-cell activation. *Molecular & Cellular Biology* 9(3): 1034-40, Mar 1989.
40. Lindsten T., June CH., Ledbetter JA., Stella G., Thompson CB.: Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. *Science* 244(4902): 339-43, Apr 21 1989.
41. Takashi T., Steinberg AD., June CH., Gause WC.: Responsiveness of fetal and adult CD4-, CD8-thymocytes to T cell activation. *Journal of Immunology* 142(8): 2641-6, Apr 15 1989.
42. Sanders ME., Makgoba MW., June CH., Young HA., Shaw S.: Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor-mediated activation. *European Journal of Immunology* 19(5): 803-8, May 1989.
43. June CH., Jackson KM., Ledbetter JA., Leiden JM., Lindsten T., Thompson CB.: Two distinct mechanisms of interleukin-2 gene expression in human T lymphocytes. *Journal of Autoimmunity* 2 Suppl: 55-65, Jun 1989.
44. Leiden JM., Yang LH., Morle GD., June CH., Lindsten T., Thompson CB., Karpinski B.: The 4F2 heavy chain gene: a molecular model of inducible gene expression in human T cells. *Journal of Autoimmunity* 2 Suppl: 67-79, Jun 1989.

45. June CH., Ledbetter JA., Lindsten T., Thompson CB.: Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes. *Journal of Immunology* 143(1): 153-61, Jul 1 1989.
46. Thyphronitis G., Tsokos GC., June CH., Levine AD., Finkelman FD.: IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin 4 and suppressed by interferon gamma. *Proceedings of the National Academy of Sciences of the United States of America* 86(14): 5580-4, Jul 1989.
47. Brunswick M., June CH., Finkelman FD., Dintzis HM., Inman JK., Mond JJ.: Surface immunoglobulin-mediated B-cell activation in the absence of detectable elevations in intracellular ionized calcium: a model for T-cell-independent B-cell activation. *Proceedings of the National Academy of Sciences of the United States of America* 86(17): 6724-8, Sep 1989.
48. Brunswick M., June CH., Finkelman FD., Mond JJ.: Different patterns of inositol polyphosphate production are seen in B lymphocytes after cross-linking of sIg by anti-Ig antibody or by a multivalent anti-Ig antibody dextran conjugate. *Journal of Immunology* 143(5): 1414-21, Sep 1 1989.
49. Guba SC., Stella G., Turka LA., June CH., Thompson CB., Emerson SG.: Regulation of interleukin 3 gene induction in normal human T cells. *Journal of Clinical Investigation* 84(6): 1701-6, Dec 1989.
50. Frenkel N., Schirmer EC., Wyatt LS., Katsafanas G., Roffman E., Danovich RM., June CH.: Isolation of a new herpesvirus from human CD4+ T cells.[erratum appears in *Proc Natl Acad Sci U S A* 1990 Oct;87(19):7797] *Proceedings of the National Academy of Sciences of the United States of America* 87(2): 748-52, Jan 1990.
51. Imboden JB., June CH., McCutcheon MA., Ledbetter JA.: Stimulation of CD5 enhances signal transduction by the T cell antigen receptor. *Journal of Clinical Investigation* 85(1): 130-4, Jan 1990.
52. Mond JJ., Balapure A., Feuerstein N., June CH., Brunswick M., Lindsberg ML., Witherspoon K.: Protein kinase C activation in B cells by indolactam inhibits anti-Ig-mediated phosphatidylinositol biphosphate hydrolysis but not B cell proliferation. *Journal of Immunology* 144(2): 451-5, Jan 15 1990.
53. June CH., Fletcher MC., Ledbetter JA., Samelson LE.: Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. *Journal of Immunology* 144(5): 1591-9, Mar 1 1990.
54. Tsokos GC., Lambris JD., Finkelman FD., Anastassiou ED., June CH.: Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. *Journal of Immunology* 144(5): 1640-5, Mar 1 1990.
55. Turka LA., Ledbetter JA., Lee K., June CH., Thompson CB.: CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. *Journal of Immunology* 144(5): 1646-53, Mar 1 1990.
56. Ledbetter JA., Imboden JB., Schieven GL., Grosmaire LS., Rabinovitch PS., Lindsten T., Thompson CB., June CH.: CD28 ligation in T-cell activation: evidence for two signal transduction pathways. *Blood* 75(7): 1531-9, Apr 1 1990.

57. Bhat NK., Thompson CB., Lindsten T., June CH., Fujiwara S., Koizumi S., Fisher RJ., Papas TS.: Reciprocal expression of human ETS1 and ETS2 genes during T-cell activation: regulatory role for the protooncogene ETS1. *Proceedings of the National Academy of Sciences of the United States of America* 87(10): 3723-7, May 1990.
58. June CH., Ledbetter JA., Linsley PS., Thompson CB.: Role of the CD28 receptor in T-cell activation. [Review] [58 refs] *Immunology Today* 11(6): 211-6, Jun 1990.
59. Lee KP., Taylor C., Petryniak B., Turka LA., June CH., Thompson CB.: The genomic organization of the CD28 gene. Implications for the regulation of CD28 mRNA expression and heterogeneity. *Journal of Immunology* 145(1): 344-52, Jul 1 1990.
60. Rehe GT., Katona IM., Brunswick M., Wahl LM., June CH., Mond JJ.: Activation of human B lymphocytes by nanogram concentrations of anti-IgM-dextran conjugates. *European Journal of Immunology* 20(8): 1837-42, Aug 1990.
61. Frenkel N., Schirmer EC., Katsafanas G., June CH.: T-cell activation is required for efficient replication of human herpesvirus 6. *Journal of Virology* 64(9): 4598-602, Sep 1990.
62. Nakayama T., June CH., Munitz TI., Sheard M., McCarthy SA., Sharrow SO., Samelson LE., Singer A.: Inhibition of T cell receptor expression and function in immature CD4+CD8+ cells by CD4. *Science* 249(4976): 1558-61, Sep 28 1990.
63. June CH., Fletcher MC., Ledbetter JA., Schieven GL., Siegel JN., Phillips AF., Samelson LE.: Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. *Proceedings of the National Academy of Sciences of the United States of America* 87(19): 7722-6, Oct 1990.
64. Samelson LE., Fletcher MC., Ledbetter JA., June CH.: Activation of tyrosine phosphorylation in human T cells via the CD2 pathway. Regulation by the CD45 tyrosine phosphatase. *Journal of Immunology* 145(8): 2448-54, Oct 15 1990.
65. Frenkel N., Roffman E., Schirmer EC., Katsafanas G., Wyatt LS., June CH.: Cellular and growth-factor requirements for the replication of human herpesvirus 6 in primary lymphocyte cultures. [Review] [22 refs] *Advances in Experimental Medicine & Biology* 278: 1-8, 1990.
66. Horak ID., Popovic M., Horak EM., Lucas PJ., Gress RE., June CH., Bolen JB.: No T-cell tyrosine protein kinase signalling or calcium mobilization after CD4 association with HIV-1 or HIV-1 gp120. *Nature* 348(6301): 557-60, Dec 6 1990.
67. Murakami S., Miyake K., June CH., Kincade PW., Hodes RJ.: IL-5 induces a Pgp-1 (CD44) bright B cell subpopulation that is highly enriched in proliferative and Ig secretory activity and binds to hyaluronate. *Journal of Immunology* 145(11): 3618-27, Dec 1 1990.
68. Mond JJ., Feuerstein N., June CH., Balapure AK., Glazer RI., Witherspoon K., Brunswick M.: Bimodal effect of phorbol ester on B cell activation. Implication for the role of protein kinase C. *Journal of Biological Chemistry* 266(7): 4458-63, Mar 5 1991.

69. Bohjanen PR., Petryniak B., June CH., Thompson CB., Lindsten T.: An inducible cytoplasmic factor (AU-B) binds selectively to AUUUA multimers in the 3' untranslated region of lymphokine mRNA. *Molecular & Cellular Biology* 11(6): 3288-95, Jun 1991.
70. June CH.: Signal transduction in T cells. [Review] [39 refs] *Current Opinion in Immunology* 3(3): 287-93, Jun 1991.
71. Zacharchuk CM., Mercep M., June CH., Weissman AM., Ashwell JD.: Variations in thymocyte susceptibility to clonal deletion during ontogeny. Implications for neonatal tolerance. *Journal of Immunology* 147(2): 460-5, Jul 15 1991.
72. Snapper CM., Yamada H., Mond JJ., June CH.: Cross-linkage of Ly-6A/E induces Ca^{2+} translocation in the absence of phosphatidylinositol turnover and mediates proliferation of normal murine B lymphocytes. *Journal of Immunology* 147(4): 1171-9, Aug 15 1991.
73. Spielberg H., June CH., Blair OC., Nystrom-Rosander C., Cereb N., Deeg HJ.: UV irradiation of lymphocytes triggers an increase in intracellular Ca^{2+} and prevents lectin-stimulated Ca^{2+} mobilization: evidence for UV- and nifedipine-sensitive Ca^{2+} channels. *Experimental Hematology* 19(8): 742-8, Sep 1991.
74. Nakayama T., Samelson LE., Nakayama Y., Munitz TI., Sheard M., June CH., Singer A.: Ligand-stimulated signaling events in immature $CD4+CD8+$ thymocytes expressing competent T-cell receptor complexes. *Proceedings of the National Academy of Sciences of the United States of America* 88(22): 9949-53, Nov 15 1991.
75. Perez VL., Rowe T., Justement JS., Butera ST., June CH., Folks TM.: An HIV-1-infected T cell clone defective in IL-2 production and Ca^{2+} mobilization after CD3 stimulation. *Journal of Immunology* 147(9): 3145-8, Nov 1 1991.
76. Lindsberg ML., Brunswick M., Yamada H., Lees A., Inman J., June CH., Mond JJ.: Biochemical analysis of the immune B cell defect in xid mice. *Journal of Immunology* 147(11): 3774-9, Dec 1 1991.
77. Bohjanen PR., Petryniak B., June CH., Thompson CB., Lindsten T.: AU RNA-binding factors differ in their binding specificities and affinities. *Journal of Biological Chemistry* 267(9): 6302-9, Mar 25 1992.
78. Feldmann M., June CH., McMichael A., Maini R., Simpson E., Woody JN.: T-cell-targeted immunotherapy. *Immunology Today* 13(3): 84-5, Mar 1992.
79. Kennedy IC., June CH., O'Shea JJ.: Expression of the human epidermal growth factor receptor in a murine T-cell hybridoma. A transmembrane protein tyrosine kinase can synergize with the T-cell antigen receptor. *Journal of Biological Chemistry* 267(7): 4924-9, Mar 5 1992.
80. Thompson CB., Wang CY., Ho IC., Bohjanen PR., Petryniak B., June CH., Miesfeldt S., Zhang L., Nabel GJ., Karpinski B., et al.: cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel Ets-related protein, Elf-1. *Molecular & Cellular Biology* 12(3): 1043-53, Mar 1992.

81. Alexander RB., Bolton ES., Koenig S., Jones GM., Topalian SL., June CH., Rosenberg SA.: Detection of antigen specific T lymphocytes by determination of intracellular calcium concentration using flow cytometry. *Journal of Immunological Methods* 148(1-2): 131-41, Apr 8 1992.
82. June CH.: Analysis of lymphocyte activation and metabolism by flow cytometry. [Review] [54 refs] *Current Opinion in Immunology* 4(2): 200-4, Apr 1992.
83. Niklinska BB., Yamada H., O'Shea JJ., June CH., Ashwell JD.: Tyrosine kinase-regulated and inositol phosphate-independent Ca^{2+} elevation and mobilization in T cells. *Journal of Biological Chemistry* 267(10): 7154-9, Apr 5 1992.
84. Vandenberghe P., Freeman GJ., Nadler LM., Fletcher MC., Kamoun M., Turka LA., Ledbetter JA., Thompson CB., June CH.: Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. *Journal of Experimental Medicine* 175(4): 951-60, Apr 1 1992.
85. Nakayama T., Ueda Y., Yamada H., Shores EW., Singer A., June CH.: In vivo calcium elevations in thymocytes with T cell receptors that are specific for self ligands. *Science* 257(5066): 96-9, Jul 3 1992.
86. Turka LA., Fletcher MC., Craighead N., Thompson CB., June CH.: Defective signal transduction by the CD2 molecule in immature T-cell receptor/CD3- thymocytes. *Proceedings of the National Academy of Sciences of the United States of America* 89(18): 8706-10, Sep 15 1992.
87. Volarevic S., Niklinska BB., Burns CM., Yamada H., June CH., Dumont FJ., Ashwell JD.: The CD45 tyrosine phosphatase regulates phosphotyrosine homeostasis and its loss reveals a novel pattern of late T cell receptor-induced Ca^{2+} oscillations. *Journal of Experimental Medicine* 176(3): 835-44, Sep 1 1992.
88. Graber M., June CH., Samelson LE., Weiss A.: The protein tyrosine kinase inhibitor herbimycin A, but not genistein, specifically inhibits signal transduction by the T cell antigen receptor. *International Immunology* 4(11): 1201-10, Nov 1992.
89. Green JM., Turka LA., June CH., Thompson CB.: CD28 and staphylococcal enterotoxins synergize to induce MHC-independent T-cell proliferation. *Cellular Immunology* 145(1): 11-20, Nov 1992.
90. Van Seventer GA., Bonvini E., Yamada H., Conti A., Stringfellow S., June CH., Shaw S.: Costimulation of T cell receptor/CD3-mediated activation of resting human CD4^{+} T cells by leukocyte function-associated antigen-1 ligand intercellular cell adhesion molecule-1 involves prolonged inositol phospholipid hydrolysis and sustained increase of intracellular Ca^{2+} levels. *Journal of Immunology* 149(12): 3872-80, Dec 15 1992.
91. Boise LH., Petryniak B., Mao X., June CH., Wang CY., Lindsten T., Bravo R., Kovary K., Leiden JM., Thompson CB.: The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and JunB. *Molecular & Cellular Biology* 13(3): 1911-9, Mar 1993.
92. June CH., Linette GP., Pierce PF., Jin NR., Lum LG.: Potential clinical applications of signal transduction measurements in marrow transplantation and HIV-1 infection. *Annals of the New York Academy of Sciences* 677: 225-32, Mar 20 1993.

93. Rabinovitch PS., June CH., Kavanagh TJ.: Introduction to functional cell assays. [Review] [45 refs] *Annals of the New York Academy of Sciences* 677: 252-64, Mar 20 1993.
94. Volarevic S., Niklinska BB., Burns CM., June CH., Weissman AM., Ashwell JD.: Regulation of TCR signaling by CD45 lacking transmembrane and extracellular domains. *Science* 260(5107): 541-4, Apr 23 1993.
95. Yamada H., June CH., Finkelman F., Brunswick M., Ring MS., Lees A., Mond JJ.: Persistent calcium elevation correlates with the induction of surface immunoglobulin-mediated B cell DNA synthesis. *Journal of Experimental Medicine* 177(6): 1613-21, Jun 1 1993.
96. Siegel JN., June CH., Yamada H., Rapp UR., Samelson LE.: Rapid activation of C-Raf-1 after stimulation of the T-cell receptor or the muscarinic receptor type 1 in resting T cells. *Journal of Immunology* 151(8): 4116-27, Oct 15 1993.
97. Weinstein SL., June CH., DeFranco AL.: Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14. *Journal of Immunology* 151(7): 3829-38, Oct 1 1993.
98. Fletcher MC., Samelson LE., June CH.: Complex effects of phenylarsine oxide in T cells. Induction of tyrosine phosphorylation and calcium mobilization independent of CD45 expression. *Journal of Biological Chemistry* 268(31): 23697-703, Nov 5 1993.
99. Brunswick M., June CH., Mond JJ.: B lymphocyte immunoglobulin receptor desensitization is downstream of tyrosine kinase activation. *Cellular Immunology* 156(1): 240-4, Jun 1994.
100. June CH., Bluestone JA., Nadler LM., Thompson CB.: The B7 and CD28 receptor families. [Review] [93 refs] *Immunology Today* 15(7): 321-31, Jul 1994.
101. June CH., Vandenberghe P., Thompson CB.: The CD28 and CTLA-4 receptor family. [Review] [150 refs] *Chemical Immunology* 59: 62-90, 1994.
102. Niklinska BB., Hou D., June C., Weissman AM., Ashwell JD.: CD45 tyrosine phosphatase activity and membrane anchoring are required for T-cell antigen receptor signaling. *Molecular & Cellular Biology* 14(12): 8078-84, Dec 1994.
103. Selvey LA., Morse HC 3rd., June CH., Hodes RJ.: Analysis of antigen receptor signaling in B cells from mice with a retrovirus-induced acquired immunodeficiency syndrome. *Journal of Immunology* 154(1): 171-9, Jan 1 1995.
104. Abe R., Vandenberghe P., Craighead N., Smoot DS., Lee KP., June CH.: Distinct signal transduction in mouse CD4⁺ and CD8⁺ splenic T cells after CD28 receptor ligation. *Journal of Immunology* 154(3): 985-97, Feb 1 1995.
105. King CL., Stupi RJ., Craighead N., June CH., Thyphronitis G.: CD28 activation promotes Th2 subset differentiation by human CD4⁺ cells. *European Journal of Immunology* 25(2): 587-95, Feb 1995.

106. Perrin PJ., Scott D., Quigley L., Albert PS., Feder O., Gray GS., Abe R., June CH., Racke MK.: Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. *Journal of Immunology* 154(3): 1481-90, Feb 1 1995.
107. Harlan DM., Abe R., Lee KP., June CH.: Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion. [Review] [135 refs] *Clinical Immunology & Immunopathology* 75(2): 99-111, May 1995.
108. Boise LH., Minn AJ., June CH., Lindsten T., Thompson CB.: Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division. *Proceedings of the National Academy of Sciences of the United States of America* 92(12): 5491-5, Jun 6 1995.
109. Levine BL., Ueda Y., Craighead N., Huang ML., June CH.: CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4⁺ T cells and induce similar patterns of cytokine secretion in vitro. *International Immunology* 7(6): 891-904, Jun 1995.
110. Ueda Y., Levine BL., Huang ML., Freeman GJ., Nadler LM., June CH., Ward SG.: Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. *International Immunology* 7(6): 957-66, Jun 1995.
111. Boise LH., Minn AJ., Noel PJ., June CH., Accavitti MA., Lindsten T., Thompson CB.: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. *Immunity* 3(1): 87-98, Jul 1995.
112. Harlan DM., Barnett MA., Abe R., Pechhold K., Patterson NB., Gray GS., June CH.: Very-low-dose streptozotocin induces diabetes in insulin promoter-mB7-1 transgenic mice. *Diabetes* 44(7): 816-23, Jul 1995.
113. Jin NR., Lum LG., Buren EV., Lerman SP., Walker AL., June CH.: Signal transduction by B and T cells early after bone marrow transplantation: B cell calcium flux responses are intact whereas lack of CD4 cells accounts for impaired T cell responses. *Bone Marrow Transplantation* 16(1): 103-9, Jul 1995.
114. Hakim FT., Cepeda R., Gray GS., June CH., Abe R.: Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules. *Journal of Immunology* 155(4): 1757-66, Aug 15 1995.
115. Racke MK., Scott DE., Quigley L., Gray GS., Abe R., June CH., Perrin PJ.: Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. *Journal of Clinical Investigation* 96(5): 2195-203, Nov 1995.
116. Weng NP., Levine BL., June CH., Hodes RJ.: Human naive and memory T lymphocytes differ in telomeric length and replicative potential. *Proceedings of the National Academy of Sciences of the United States of America* 92(24): 11091-4, Nov 21 1995.
117. Perrin PJ., Scott D., June CH., Racke MK.: B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. [Review] [47 refs] *Immunologic Research* 14(3): 189-99, 1995.

118. Perrin PJ., Scott D., Davis TA., Gray GS., Doggett MJ., Abe R., June CH., Racke MK.: Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis. *Journal of Neuroimmunology* 65(1): 31-9, Mar 1996.
119. Ward SG., June CH., Olive D.: PI 3-kinase: a pivotal pathway in T-cell activation?. [Review] [116 refs] *Immunology Today* 17(4): 187-97, Apr 1996.
120. Hickey TE., Blair PJ., Perfetto S., Smoot DS., Wagner KF., St Louis DC., Mayers DL., Siegel JN., June CH.: Intact antigen receptor-mediated calcium signals in patients with early stage HIV-1 infection. *Journal of Immunology* 156(10): 4012-7, May 15 1996.
121. Levine BL., Mosca JD., Riley JL., Carroll RG., Vahey MT., Jagodzinski LL., Wagner KF., Mayers DL., Burke DS., Weislow OS., St Louis DC., June CH.: Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. *Science* 272(5270): 1939-43, Jun 28 1996.
122. Saha B., Harlan DM., Lee KP., June CH., Abe R.: Protection against lethal toxic shock by targeted disruption of the CD28 gene. *Journal of Experimental Medicine* 183(6): 2675-80, Jun 1 1996.
123. Weng NP., Levine BL., June CH., Hodes RJ.: Regulated expression of telomerase activity in human T lymphocyte development and activation. *Journal of Experimental Medicine* 183(6): 2471-9, Jun 1 1996.
124. Davis TA., Craighead N., Williams AJ., Scadron A., June CH., Lee KP.: Primary porcine endothelial cells express membrane-bound B7-2 (CD86) and a soluble factor that co-stimulate cyclosporin A-resistant and CD28-dependent human T cell proliferation. *International Immunology* 8(7): 1099-111, Jul 1996.
125. Perrin PJ., Maldonado JH., Davis TA., June CH., Racke MK.: CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. *Journal of Immunology* 157(4): 1333-6, Aug 15 1996.
126. King CL., Xianli J., June CH., Abe R., Lee KP.: CD28-deficient mice generate an impaired Th2 response to *Schistosoma mansoni* infection. *European Journal of Immunology* 26(10): 2448-55, Oct 1996.
127. Levine BL., Ueda Y., Faith A., June CH.: Signal transduction properties of the T cell activation monoclonal antibody panel: ubiquitous increase in cellular substrate tyrosine phosphorylation in the absence of detectable calcium mobilization. *Tissue Antigens* 48(4 Pt 1): 319-24, Oct 1996.
128. Saha B., Jaklic B., Harlan DM., Gray GS., June CH., Abe R.: Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. *Journal of Immunology* 157(9): 3869-75, Nov 1 1996.
129. Perfetto SP., Hickey TE., Blair PJ., Maino VC., Wagner KF., Zhou S., Mayers DL., St Louis D., June CH., Siegel JN.: Measurement of CD69 induction in the assessment of immune function in asymptomatic HIV-infected individuals. *Cytometry* 30(1): 1-9, Feb 15 1997.

130. Carroll RG., Riley JL., Levine BL., Feng Y., Kaushal S., Ritchey DW., Bernstein W., Weislow OS., Brown CR., Berger EA., June CH., St Louis DC.: Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. *Science* 276(5310): 273-6, Apr 11 1997.
131. Palmer LD., Weng N., Levine BL., June CH., Lane HC., Hodes RJ.: Telomere length, telomerase activity, and replicative potential in HIV infection: analysis of CD4+ and CD8+ T cells from HIV-discordant monozygotic twins. *Journal of Experimental Medicine* 185(7): 1381-6, Apr 7 1997.
132. Perrin PJ., Davis TA., Smoot DS., Abe R., June CH., Lee KP.: Mitogenic stimulation of T cells reveals differing contributions for B7-1 (CD80) and B7-2 (CD86) costimulation. *Immunology* 90(4): 534-42, Apr 1997.
133. Weng N., Levine BL., June CH., Hodes RJ.: Regulation of telomerase RNA template expression in human T lymphocyte development and activation. *Journal of Immunology* 158(7): 3215-20, Apr 1 1997.
134. Blair PJ., Boise LH., Perfetto SP., Levine BL., McCrary G., Wagner KF., St Louis DC., Thompson CB., Siegel JN., June CH.: Impaired induction of the apoptosis-protective protein Bcl-xL in activated PBMC from asymptomatic HIV-infected individuals. *Journal of Clinical Immunology* 17(3): 234-46, May 1997.
135. Blair PJ., Riley JL., Carroll RG., St Louis DC., Levine BL., Saha B., Lee KP., Perrin PJ., Harlan DM., June CH.: CD28 co-receptor signal transduction in T-cell activation. [Review] [57 refs] *Biochemical Society Transactions* 25(2): 651-7, May 1997.
136. Gause WC., Chen SJ., Greenwald RJ., Halvorson MJ., Lu P., Zhou XD., Morris SC., Lee KP., June CH., Finkelman FD., Urban JF., Abe R.: CD28 dependence of T cell differentiation to IL-4 production varies with the particular type 2 immune response. *Journal of Immunology* 158(9): 4082-7, May 1 1997.
137. Pechhold K., Patterson NB., Craighead N., Lee KP., June CH., Harlan DM.: Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. *Journal of Immunology* 158(10): 4921-9, May 15 1997.
138. Levine BL., Bernstein W., Craighead N., Thompson CB., Lindsten T., St Louis DC., June CH.: Ex vivo replicative potential of adult human peripheral blood CD4+ T cells. *Transplantation Proceedings* 29(4): 2028, Jun 1997.
139. Rennert P., Furlong K., Jellis C., Greenfield E., Freeman GJ., Ueda Y., Levine B., June CH., Gray GS.: The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion. *International Immunology* 9(6): 805-13, Jun 1997.
140. Riley JL., Carroll RG., Levine BL., Bernstein W., St Louis DC., Weislow OS., June CH.: Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. *Journal of Immunology* 158(11): 5545-53, Jun 1 1997.
141. Levine BL., Bernstein WB., Connors M., Craighead N., Lindsten T., Thompson CB., June CH.: Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. *Journal of Immunology* 159(12): 5921-30, Dec 15 1997.

142. Weng NP., Palmer LD., Levine BL., Lane HC., June CH., Hodes RJ.: Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. [Review] [86 refs] *Immunological Reviews* 160: 43-54, Dec 1997.
143. Blair PJ., Riley JL., Levine BL., Lee KP., Craighead N., Francomano T., Perfetto SJ., Gray GS., Carreno BM., June CH.: CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. *Journal of Immunology* 160(1): 12-5, Jan 1 1998.
144. Lovett-Racke AE., Trotter JL., Lauber J., Perrin PJ., June CH., Racke MK.: Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells.[erratum appears in *J Clin Invest* 1998 Apr 1;101(7):1542] *Journal of Clinical Investigation* 101(4): 725-30, Feb 15 1998.
145. McDyer JF., Goletz TJ., Thomas E., June CH., Seder RA.: CD40 ligand/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12- and/or CD28-dependent manner. *Journal of Immunology* 160(4): 1701-7, Feb 15 1998.
146. Ranga U., Woffendin C., Verma S., Xu L., June CH., Bishop DK., Nabel GJ.: Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. *Proceedings of the National Academy of Sciences of the United States of America* 95(3): 1201-6, Feb 3 1998.
147. Horspool JH., Perrin PJ., Woodcock JB., Cox JH., King CL., June CH., Harlan DM., St Louis DC., Lee KP.: Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. *Journal of Immunology* 160(6): 2706-14, Mar 15 1998.
148. Davis TA., Saini AA., Blair PJ., Levine BL., Craighead N., Harlan DM., June CH., Lee KP.: Phorbol esters induce differentiation of human CD34+ hemopoietic progenitors to dendritic cells: evidence for protein kinase C-mediated signaling. *Journal of Immunology* 160(8): 3689-97, Apr 15 1998.
149. Yang LP., Riley JL., Carroll RG., June CH., Hoxie J., Patterson BK., Ohshima Y., Hodes RJ., Delespesse G.: Productive infection of neonatal CD8+ T lymphocytes by HIV-1. *Journal of Experimental Medicine* 187(7): 1139-44, Apr 6 1998.
150. Carroll RG., Riley JL., Levine BL., Blair PJ., St Louis DC., June CH.: The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes. [Review] [50 refs] *Seminars in Immunology* 10(3): 195-202, Jun 1998.
151. Levine BL., Cotte J., Small CC., Carroll RG., Riley JL., Bernstein WB., Van Epps DE., Hardwick RA., June CH.: Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. *Journal of Hematotherapy* 7(5): 437-48, Oct 1998.
152. Riley JL., Levine BL., Craighead N., Francomano T., Kim D., Carroll RG., June CH.: Naive and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: implicatip6s for transmission and pathogenesis. *Journal of Virology* 72(10): 8273-80, Oct 1998.

153. Brice GT., Riley JL., Villinger F., Mayne A., Hillyer CD., June CH., Ansari AA.: Development of an animal model for autotransfusion therapy: in vitro characterization and analysis of anti-CD3/CD28 expanded cells. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 19(3): 210-20, Nov 1 1998.
154. Liebowitz DN., Lee KP., June CH.: Costimulatory approaches to adoptive immunotherapy. [Review] [85 refs] *Current Opinion in Oncology* 10(6): 533-41, Nov 1998.
155. Kim YJ., Mantel PL., June CH., Kim SH., Kwon BS.: 4-1BB costimulation promotes human T cell adhesion to fibronectin. *Cellular Immunology* 192(1): 13-23, Feb 25 1999.
156. St Louis DC., Woodcock JB., Fransozo G., Blair PJ., Carlson LM., Murillo M., Wells MR., Williams AJ., Smoot DS., Kaushal S., Grimes JL., Harlan DM., Chute JP., June CH., Siebenlist U., Lee KP.: Evidence for distinct intracellular signaling pathways in CD34+ progenitor to dendritic cell differentiation from a human cell line model. *Journal of Immunology* 162(6): 3237-48, Mar 15 1999.
157. Liu K., Schoonmaker MM., Levine BL., June CH., Hodes RJ., Weng NP.: Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. *Proceedings of the National Academy of Sciences of the United States of America* 96(9): 5147-52, Apr 27 1999.
158. Garlie NK., LeFever AV., Siebenlist RE., Levine BL., June CH., Lum LG.: T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. *Journal of Immunotherapy* 22(4): 336-45, Jul 1999.
159. Kaushal S., Landay AL., Lederman MM., Connick E., Spritzler J., Kuritzkes DR., Kessler H., Levine BL., St Louis DC., June CH.: Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells.[comment] *Clinical Immunology* 92(1): 14-24, Jul 1999.
160. Perrin PJ., June CH., Maldonado JH., Ratts RB., Racke MK.: Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. *Journal of Immunology* 163(3): 1704-10, Aug 1 1999.
161. Khoshnan A., Kempia SJ., Bennett BL., Bae D., Xu W., Manning AM., June CH., Nel AE.: Primary human CD4+ T cells contain heterogeneous I kappa B kinase complexes: role in activation of the IL-2 promoter. *Journal of Immunology* 163(10): 5444-52, Nov 15 1999.
162. Shibuya TY., Wei WZ., Zormeier M., Ensley J., Sakr W., Mathog RH., Meleca RJ., Yoo G., June CH., Levine B., Lum LG.: Anti-CD3/anti-CD28 monoclonal antibody-coated suture enhances the immune response of patients with head and neck squamous cell carcinoma.[comment] *Archives of Otolaryngology -- Head & Neck Surgery* 125(11): 1229-34, Nov 1999.
163. Marini AM., Ueda Y., June CH.: Intracellular survival pathways against glutamate receptor agonist excitotoxicity in cultured neurons. Intracellular calcium responses. *Annals of the New York Academy of Sciences* 890: 421-37, 1999.
164. Blair PJ., Riley JL., Harlan DM., Abe R., Tadaki DK., Hoffmann SC., White L., Francomano T., Perfetto SJ., Kirk AD., June CH.: CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation

response that results in secretion of immunomodulatory cytokines and apoptosis. *Journal of Experimental Medicine* 191(4): 651-60, Feb 21 2000.

165. Shibuya TY., Wei WZ., Zormeier M., Ensley J., Sakr W., Mathog RH., Meleca RJ., Yoo GH., June CH., Levine BL., Lum LG.: Anti-CD3/anti-CD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma. *Archives of Otolaryngology -- Head & Neck Surgery* 126(4): 473-9, Apr 2000.

166. Riley JL., Schlienger K., Blair PJ., Carreno B., Craighead N., Kim D., Carroll RG., June CH.: Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. *Journal of Experimental Medicine* 191(11): 1987-97, Jun 5 2000.

167. Mitsuyasu RT., Anton PA., Deeks SG., Scadden DT., Connick E., Downs MT., Bakker A., Roberts MR., June CH., Jalali S., Lin AA., Pennathur-Das R., Hege KM.: Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. *Blood* 96(3): 785-93, Aug 1 2000.

168. Laux I., Khoshnan A., Tindell C., Bae D., Zhu X., June CH., Effros RB., Nel A.: Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. *Clinical Immunology* 96(3): 187-97, Sep 2000.

169. Schlienger K., Craighead N., Lee KP., Levine BL., June CH.: Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells. *Blood* 96(10): 3490-8, Nov 15 2000.

170. Broeren CP., Gray GS., Carreno BM., June CH.: Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile. *Journal of Immunology* 165(12): 6908-14, Dec 15 2000.

171. Harada Y., Tanabe E., Watanabe R., Weiss BD., Matsumoto A., Ariga H., Koiwai O., Fukui Y., Kubo M., June CH., Abe R.: Novel role of phosphatidylinositol 3-kinase in CD28-mediated costimulation. *Journal of Biological Chemistry* 276(12): 9003-8, Mar 23 2001.

172. Harada Y., Tokushima M., Matsumoto Y., Ogawa S., Otsuka M., Hayashi K., Weiss BD., June CH., Abe R.: Critical requirement for the membrane-proximal cytosolic tyrosine residue for CD28-mediated costimulation in vivo. *Journal of Immunology* 166(6): 3797-803, Mar 15 2001.

173. Riley JL., Blair PJ., Musser JT., Abe R., Tezuka K., Tsuji T., June CH.: ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. *Journal of Immunology* 166(8): 4943-8, Apr 15 2001.

174. Hamad AR., Srikrishnan A., Mirmonsef P., Broeren CP., June CH., Pardoll D., Schneck JP.: Lack of coreceptor allows survival of chronically stimulated double-negative alpha/beta T cells: implications for autoimmunity. *Journal of Experimental Medicine* 193(10): 1113-21, May 21 2001.

175. June, C H. Abe, R. Rabinovitch, P S.: Measurement of intracellular calcium ions by flow cytometry. *Current Protocols in Cytometry*(Chapter 9), Unit 9.8, May 2001.

176. Woo EY., Chu CS., Goletz TJ., Schlienger K., Yeh H., Coukos G., Rubin SC., Kaiser LR., June CH.: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. *Cancer Research* 61(12): 4766-72, Jun 15 2001.
177. Nichols KE., Koretzky GA., June CH.: SAP: natural inhibitor or grand SLAM of T cell activation? *Nature Immunology* 2(8): 665-6, Aug 2001.
178. June CH.: Can't get any help? New approaches for adoptive immunotherapy of cancer.[comment] *Journal of Immunotherapy* 24(5): 389-91, Sep-Oct 2001.
179. Thomas AK., June CH.: The promise of T-lymphocyte immunotherapy for the treatment of malignant disease. [Review] [93 refs] *Cancer Journal* 7 Suppl 2: S67-75, Nov-Dec 2001.
180. Levine BL., Bernstein WB., Aronson NE., Schlienger K., Cotte J., Perfetto S., Humphries MJ., Ratto-Kim S., Birx DL., Steffens C., Landay A., Carroll RG., June CH.: Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. *Nature Medicine* 8(1): 47-53, Jan 2002.
181. Villinger F., Brice GT., Mayne AE., Bostik P., Mori K., June CH., Ansari AA.: Adoptive transfer of simian immunodeficiency virus (SIV) naive autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. *Blood* 99(2): 590-9, Jan 15 2002.
182. Maus MV., Thomas AK., Leonard DG., Allman D., Addya K., Schlienger K., Riley JL., June CH.: Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. *Nature Biotechnology* 20(2): 143-8, Feb 2002.
183. Chu CS., Woo EY., Toll AJ., Rubin SC., June CH., Carroll RG., Schlienger K.: Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patients. *Clinical Immunology* 102(3): 291-301, Mar 2002.
184. Woo EY., Yeh H., Chu CS., Schlienger K., Carroll RG., Riley JL., Kaiser LR., June CH.: Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. *Journal of Immunology* 168(9): 4272-6, May 1 2002.
185. Deeks SG., Wagner B., Anton PA., Mitsuyasu RT., Scadden DT., Huang C., Macken C., Richman DD., Christopherson C., June CH., Lazar R., Broad DF., Jalali S., Hege KM.: A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. *Molecular Therapy: the Journal of the American Society of Gene Therapy* 5(6): 788-97, Jun 2002.
186. Frauwirth KA., Riley JL., Harris MH., Parry RV., Rathmell JC., Plas DR., Elstrom RL., June CH., Thompson CB.: The CD28 signaling pathway regulates glucose metabolism. *Immunity* 16(6): 769-77, Jun 2002.
187. Riley JL., Mao M., Kobayashi S., Biery M., Burchard J., Cavet G., Gregson BP., June CH., Linsley PS.: Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4

receptors. *Proceedings of the National Academy of Sciences of the United States of America* 99(18): 11790-5, Sep 3 2002.

188. Kovacs B., Maus MV., Riley JL., Derimanov GS., Koretzky GA., June CH., Finkel TH.: Human CD8⁺ T cells do not require the polarization of lipid rafts for activation and proliferation. *Proceedings of the National Academy of Sciences of the United States of America* 99(23): 15006-11, Nov 12 2002.

189. Marovich MA., Mascola JR., Eller MA., Louder MK., Caudrelier PA., El-Habib R., Ratto-Kim S., Cox JH., Currier JR., Levine BL., June CH., Bernstein WB., Robb ML., Schuler-Thurner B., Steinman RM., Birx DL., Schlesinger-Frankel S.: Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. *Journal of Infectious Diseases* 186(9): 1242-52, Nov 1 2002.

190. Thomas AK., Maus MV., Shalaby WS., June CH., Riley JL.: A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. *Clinical Immunology* 105(3): 259-72, Dec 2002.

191. Maus MV., Riley JL., Kwok WW., Nepom GT., June CH.: HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4⁺ T cells. *Clinical Immunology* 106(1): 16-22, Jan 2003.

192. Schlienger K., Chu CS., Woo EY., Rivers PM., Toll AJ., Hudson B., Maus MV., Riley JL., Choi Y., Coukos G., Kaiser LR., Rubin SC., Levine BL., Carroll RG., June CH.: TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. *Clinical Cancer Research* 9(4): 1517-27, Apr 2003.

193. Oelke M., Maus MV., Didiano D., June CH., Mackensen A., Schneck JP.: Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. *Nature Medicine* 9(5): 619-24, May 2003.

194. Parry RV., Rumbley CA., Vandenberghe LH., June CH., Riley JL.: CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. *Journal of Immunology* 171(1): 166-74, Jul 1 2003.

195. Shalaby WS., Yeh H., Woo E., Hendren S., Corbett JT., Gray H., June CH., Shalaby SW.: Development of novel substrates for tumor immunotherapy. *Journal of Controlled Release* 91(1-2): 209-24, Aug 28 2003.

196. Laport GG., Levine BL., Stadtmauer EA., Schuster SJ., Luger SM., Grupp S., Bunin N., Strobl FJ., Cotte J., Zheng Z., Gregson B., Rivers P., Vonderheide RH., Liebowitz DN., Porter DL., June CH.: Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34⁺-selected hematopoietic cell transplantation. *Blood* 102(6): 2004-13, Sep 15 2003.

197. Parry RV., June CH.: Calcium-independent calcineurin regulation.[comment] *Nature Immunology* 4(9): 821-3, Sep 2003.

198. Zhang H., Merchant MS., Chua KS., Khanna C., Helman LJ., Telford B., Ward Y., Summers J., Toretsky J., Thomas EK., June CH., Mackall CL.: Tumor expression of 4-1BB ligand sustains tumor lytic T cells.[see comment] *Cancer Biology & Therapy* 2(5): 579-86, Sep-Oct 2003.
199. Vonderheide RH., June CH.: A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy. [Review] [73 refs] *Immunologic Research* 27(2-3): 341-56, 2003.
200. Rapoport AP., Levine BL., Badros A., Meisenberg B., Ruehle K., Nandi A., Rollins S., Natt S., Ratterree B., Westphal S., Mann D., June CH.: Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. *Bone Marrow Transplantation* 33(1): 53-60, Jan 2004.
201. Zhang Y., Joe G., Zhu J., Carroll R., Levine B., Hexner E., June C., Emerson SG.: Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. *Blood* 103(10): 3970-8, May 15 2004.
202. Humeau LM., Binder GK., Lu X., Slepushkin V., Merling R., Echeagaray P., Pereira M., Slepushkina T., Barnett S., Dropulic LK., Carroll R., Levine BL., June CH., Dropulic B.: Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. *Molecular Therapy: the Journal of the American Society of Gene Therapy* 9(6): 902-13, Jun 2004.
203. Maus MV., Kovacs B., Kwok WW., Nepom GT., Schlienger K., Riley JL., Allman D., Finkel TH., June CH.: Extensive replicative capacity of human central memory T cells. *Journal of Immunology* 172(11): 6675-83, Jun 1 2004.
204. Sauer MG., Ericson ME., Weigel BJ., Herron MJ., Panoskaltsis-Mortari A., Kren BT., Levine BL., Serody JS., June CH., Taylor PA., Blazar BR.: A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. *Cancer Research* 64(11): 3914-21, Jun 1 2004.
205. Shalaby WS., Yeh H., Woo E., Corbett JT., Gray H., June CH., Shalaby SW.: Absorbable microparticulate cation exchanger for immunotherapeutic delivery. *Journal of Biomedical Materials Research Part B, Applied Biomaterials*: 69(2):173-82, 2004 May 15. Jun 2004.
206. Chemnitz JM., Parry RV., Nichols KE., June CH., Riley JL.: SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. *Journal of Immunology* 173(2): 945-54, Jul 15 2004.
207. Godfrey WR., Ge YG., Spoden DJ., Levine BL., June CH., Blazar BR., Porter SB.: In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. *Blood* 104(2): 453-61, Jul 15 2004.

208. Taylor PA., Panoskaltsis-Mortari A., Swedin JM., Lucas PJ., Gress RE., Levine BL., June CH., Serody JS., Blazar BR.: L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. *Blood* 104(12): 3804-12, Dec 1 2004.
209. Godfrey, Wayne R. Spoden, Darrin J. Ge, Ying G. Baker, Seth R. Liu, Baoling. Levine, Bruce L. June, Carl H. Blazar, Bruce R. Porter, Stephen B.: Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. *Blood* 105(2): 750-8, Jan 15 2005.
210. Manilla P., Rebello T., Afable C., Lu X., Slepushkin V., Humeau LM., Schonely K., Ni Y., Binder GK., Levine BL., MacGregor RR., June CH., Dropulic B.: Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector.[erratum appears in *Hum Gene Ther.* 2005 Feb;16(2):279]. [Review] [39 refs] *Human Gene Therapy* 16(1): 17-25, Jan 2005.
211. Riley JL., June CH.: The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. [Review] [135 refs] *Blood* 105(1): 13-21, Jan 1 2005.
212. DeLong, Peter. Carroll, Richard G. Henry, Adam C. Tanaka, Tomoyuki. Ahmad, Sajjad. Leibowitz, Michael S. Sterman, Daniel H. June, Carl H. Albelda, Steven M. Vonderheide, Robert H.: Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. *Cancer Biology & Therapy* 4(3): 342-6, Mar 2005.
213. Perez EE., Riley JL., Carroll RG., von Laer D., June CH.: Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. *Clinical Immunology* 115(1): 26-32, Apr 2005.
214. Porter DL., June CH.: T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!. [Review] [103 refs] *Bone Marrow Transplantation* 35(10): 935-42, May 2005.
215. Li, Lequn. Godfrey, Wayne R. Porter, Stephen B. Ge, Ying. June, Carl H. Blazar, Bruce R. Boussiotis, Vassiliki A.: CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. *Blood* 106(9): 3068-73, Nov 1 2005.
216. Milone, Michael C. June, Carl H.: Adoptive immunotherapy: new ways to skin the cat?. [Review] [34 refs] *Clinical Immunology* 117(2): 101-3, Nov 2005.
217. Rapoport, Aaron P. Stadtmauer, Edward A. Aqui, Nicole. Badros, Ashraf. Cotte, Julio. Chrisley, Lisa. Veloso, Elizabeth. Zheng, Zhaohui. Westphal, Sandra. Mair, Rebecca. Chi, Nina. Ratterree, Bashi. Pochran, Mary Francis. Natt, Sabrina. Hinkle, Joanne. Sickles, Cheryl. Sohal, Ambika. Ruehle, Kathleen. Lynch, Christian. Zhang, Lei. Porter, David L. Luger, Selina. Guo, Chuanfa. Fang, Hong-Bin. Blackwelder, William. Hankey, Kim. Mann, Dean. Edelman, Robert. Frasc, Carl. Levine, Bruce L. Cross, Alan. June, Carl H.: Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.[see comment]. *Nature Medicine* 11(11): 1230-7, Nov 2005.
218. Huang, Xin. Wilber, Andrew C. Bao, Lei. Tuong, Dong. Tolar, Jakub. Orchard, Paul J. Levine, Bruce L. June, Carl H. McIvor, R Scott. Blazar, Bruce R. Zhou, Xianzheng.: Stable gene

transfer and expression in human primary T cells by the Sleeping Beauty transposon system. *Blood* 107(2): 483-91, Jan 15 2006.

219. Porter, David L. Levine, Bruce L. Bunin, Nancy. Stadtmauer, Edward A. Luger, Selina M. Goldstein, Steven. Loren, Alison. Phillips, Julie. Nasta, Sunita. Perl, Alexander. Schuster, Steven. Tsai, Donald. Sohal, Ambika. Veloso, Elizabeth. Emerson, Stephen. June, Carl H.: A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. *Blood* 107(4): 1325-31, Feb 15 2006.

220. Dropulic, Boro. June, Carl H.: Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. [Review] [105 refs] *Human Gene Therapy* 17(6): 577-88, Jun 2006.

221. Porter, Stephen B. Liu, Baoling. Rogosheske, John. Levine, Bruce L. June, Carl H. Kohl, Virginia K. Wagner, John E. Miller, Jeffrey S. Blazar, Bruce R.: Suppressor function of umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-versus-host disease drugs. *Transplantation* 82(1): 23-9, Jul 15 2006.

222. Fowler, Daniel H. Odom, Jeanne. Steinberg, Seth M. Chow, Catherine K. Foley, Jason. Kogan, Yelena. Hou, Jeannie. Gea-Banacloche, Juan. Sportes, Claude. Pavletic, Steven. Leitman, Susan. Read, Elizabeth J. Carter, Charles. Kolstad, Arne. Fox, Rebecca. Beatty, Gregory L. Vonderheide, Robert H. Levine, Bruce L. June, Carl H. Gress, Ronald E. Bishop, Michael R.: Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. *Biology of Blood & Marrow Transplantation* 12(11): 1150-60, Nov 2006.

223. Levine, Bruce L. Humeau, Laurent M. Boyer, Jean. MacGregor, Rob-Roy. Rebello, Tessio. Lu, Xiaobin. Binder, Gwendolyn K. Slepushkin, Vladimir. Lemiale, Franck. Mascola, John R. Bushman, Frederic D. Dropulic, Boro. June, Carl H.: Gene transfer in humans using a conditionally replicating lentiviral vector. *Proceedings of the National Academy of Sciences of the United States of America* 103(46): 17372-7, Nov 14 2006.

224. Serman, Daniel H. Gillespie, Colin T. Carroll, Richard G. Coughlin, Christina M. Lord, Elaina M. Sun, Jing. Haas, Andrew. Recio, Adri. Kaiser, Larry R. Coukos, George. June, Carl H. Albelda, Steven M. Vonderheide, Robert H.: Interferon beta adenoviral gene therapy in a patient with ovarian cancer. *Nature Clinical Practice Oncology* 3(11): 633-9, Nov 2006.

225. June, C. H., Blazar, B. R.: Clinical application of expanded CD4 + 25 + cells. *Seminars Immunol* 18(2): 77-88, 2006.

226. Christian, Natalie A. Milone, Michael C. Ranka, Shraddha S. Li, Guizhi. Frail, Paul R. Davis, Kevin P. Bates, Frank S. Therien, Michael J. Ghoroghchian, P Peter. June, Carl H. Hammer, Daniel A.: Tat-functionalized near-infrared emissive polymersomes for dendritic cell labeling. *Bioconjugate Chemistry* 18(1): 31-40, Jan-Feb 2007.

227. Czerniecki, Brian J. Koski, Gary K. Koldovsky, Ursula. Xu, Shuwen. Cohen, Peter A. Mick, Rosemarie. Nisenbaum, Harvey. Pasha, Terry. Xu, Min. Fox, Kevin R. Weinstein,

- Susan. Orel, Susan G. Vonderheide, Robert. Coukos, George. DeMichele, Angela. Araujo, Louis. Spitz, Francis R. Rosen, Mark. Levine, Bruce L. June, Carl. Zhang, Paul J.: Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. *Cancer Research* 67(4): 1842-52, Feb 15 2007.
228. Riley, James L. June, Carl H.: The road to recovery: translating PD-1 biology into clinical benefit. *Trends in Immunology* 28(2): 48-50, Feb 2007.
229. Carroll, Richard G. June, Carl H.: Programming the next generation of dendritic cells.[comment]. *Molecular Therapy* 15(5): 846-8, May 2007.
230. June, Carl H.: Principles of adoptive T cell cancer therapy. [Review] [125 refs] *Journal of Clinical Investigation* 117(5): 1204-12, May 2007.
231. Suhoski, Megan M. Golovina, Tatiana N. Aqui, Nicole A. Tai, Victoria C. Varela-Rohena, Angel. Milone, Michael C. Carroll, Richard G. Riley, James L. June, Carl H.: Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. *Molecular Therapy: the Journal of the American Society of Gene Therapy* 15(5): 981-8, May 2007.
232. June, Carl H.: Adoptive T cell therapy for cancer in the clinic. [Review] [131 refs] *Journal of Clinical Investigation* 117(6): 1466-76, Jun 2007.
233. Stermn, Daniel H. Recio, Adri. Carroll, Richard G. Gillespie, Colin T. Haas, Andrew. Vachani, Anil. Kapoor, Veena. Sun, Jing. Hodinka, Richard. Brown, Jennifer L. Corbley, Michael J. Parr, Michael. Ho, Mitchell. Pastan, Ira. Machuzak, Michael. Benedict, William. Zhang, Xin-qiao. Lord, Elaina M. Litzky, Leslie A. Heitjan, Daniel F. June, Carl H. Kaiser, Larry R. Vonderheide, Robert H. Albelda, Steven M. Kanther, Michelle.: A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. *Clinical Cancer Research* 13(15 Pt 1): 4456-66, Aug 1 2007.
234. Hexner, Elizabeth O. Danet-Desnoyers, Gwenn-Ael H. Zhang, Yi. Frank, Dale M. Riley, James L. Levine, Bruce L. Porter, David L. June, Carl H. Emerson, Stephen G.: Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. *Biology of Blood & Marrow Transplantation* 13(10): 1135-44, Oct 2007.
235. Zhang, Hua. Snyder, Kristen M. Suhoski, Megan M. Maus, Marcela V. Kapoor, Veena. June, Carl H. Mackall, Crystal L.: 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. *Journal of Immunology* 179(7): 4910-8, Oct 1 2007.
236. Lenzi, Renato. Edwards, Robert. June, Carl. Seiden, Michael V. Garcia, Michael E. Rosenblum, Michael. Freedman, Ralph S.: Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. *Journal of Translational Medicine* 5: 66, 2007.

237. Plesa, Gabriela. Dai, Jihong. Baytop, Cliff. Riley, James L. June, Carl H. O'Doherty, Una.: Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. *Journal of Virology* 81(24): 13938-42, Dec 2007.
238. Rossi, John J. June, Carl H. Kohn, Donald B.: Genetic therapies against HIV. [Review] [32 refs] *Nature Biotechnology* 25(12): 1444-54, Dec 2007.
239. Chu, Christina S. Kim, Sarah H. June, Carl H. Coukos, George.: Immunotherapy opportunities in ovarian cancer. [Review] [184 refs] *Expert Review of Anticancer Therapy* 8(2): 243-57, Feb 2008.
240. Huang, Xin. Guo, Hongfeng. Kang, Johnthomas. Choi, Suet. Zhou, Tom C. Tammana, Syam. Lees, Christopher J. Li, Zhong-Ze. Milone, Michael. Levine, Bruce L. Tolar, Jakub. June, Carl H. Scott McIvor, R. Wagner, John E. Blazar, Bruce R. Zhou, Xianzheng.: Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. *Molecular Therapy* 16(3): 580-9, Mar 2008.
241. Basu, Samik. Golovina, Tatiana. Mikheeva, Tatiana. June, Carl H. Riley, James L.: Cutting edge: Foxp3-mediated induction of p12 allows human T regulatory cells to preferentially expand in rapamycin. *Journal of Immunology* 180(9): 5794-8, May 1 2008.
242. Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, June C, Kaiser LR, Ling LE, Albelda SM.: Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancer. *Clin Cancer Res.* 14 (12): 3966-74, Jun 2008.
243. Hippen KL, Harker-Murray P, Porter SB, Merkel SC, Londer A, Taylor DK, Bina M, Panoskaltsis-Mortari A, Rubinstein P, Van Rooijen N, Golovina TN, Suhoski MM, Miller JS, Wagner JE, June CH, Riley JL, Blazar BR.: Umbilical cord blood regulatory T cell (Treg) expansion and functional effects of tumor necrosis factor receptor (TNFR) family members OX40 and 4-1BB expressed on artificial antigen-presenting Cells (aAPCs). *Blood* 111(7): 2847-57, Jul. 2008.
244. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll RG, Orange JS, Urnov FD, Rebar EJ, Ando D, Gregory PD, Riley JL, Holmes MC, June CH.: Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. *Nat Biotechnol.* 7: 808-16, Jul. 26 2008.
245. Golovina TN, Mikheeva T, Suhoski MM, Aqui NA, Tai VC, Shan X, Liu R, Balcarcel RR, Fisher N, Levine BL, Carroll RG, Warner N, Blazar BR, June CH, Riley JL.: CD28 costimulation is essential for human T regulatory expansion and function. *J Immunol.* 181 (4): 2855-68, Aug. 2008.
246. Suhoski MM, Perez EE, Heltzer ML, Laney A, Shaffer LG, Saitta S, Nachman S, Spinner NB, June CH, Orange JS.: Monosomy 1p36 uncovers a role for OX40 in survival of activated CD4+ T cells. *Clin Immunol.* 128: 181-9, Aug. 2008.
247. Carroll, R.G., Carpenito, C., Shan, X., net-Desnoyers, G., Liu, R., Jiang, S., Albelda, S.M., Golovina, T., Coukos, G., Riley, J.L., Jonak, Z.L., June, C.H.: Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells *PLoS ONE* 3(9): e3289-98, Oct 2008.

248. Paulos Chrystal M, Suhoski Megan M, Plesa Gabriela, Jiang Tianying, Basu Samik, Golovina Tatiana N, Jiang Shuguang, Aqui Nicole A, Powell Daniel J, Levine Bruce L, Carroll Richard G, Riley James L, June Carl H: Adoptive immunotherapy: good habits instilled at youth have long-term benefits. *Immunologic Research* 42(1-3): 182-96, 2008.
249. Varela-Rohena Angel, Carpenito Carmine, Perez Elena E, Richardson Max, Parry Richard V, Milone Michael, Scholler John, Hao Xueli, Mexas Angela, Carroll Richard G, June Carl H, Riley James L: Genetic engineering of T cells for adoptive immunotherapy. *Immunologic research* 42(1-3): 166-81, 2008.
250. Varela-Rohena, A, Molloy, PE, Dunn, SM, Li, Y, Suhoski, MM, Carroll, RG, Milicic, A, Mahon, T, Sutton, DH, Laugel, B, Moysey, R, Cameron, BJ, Vuidepot, A, Purbhoo, MA, Cole, DK, Phillips, RE, June, CH, Jakobsen, BK, Sewell, AK, Riley, JL: Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. *Nature Medicine* 14(12): 1390-1395, Dec 2008.
251. Carpenito Carmine, Milone Michael C, Hassan Raffit, Simonet Jacqueline C, Lakhal Mehdi, Suhoski Megan M, Varela-Rohena Angel, Haines Kathleen M, Heitjan Daniel F, Albelda Steven M, Carroll Richard G, Riley James L, Pastan Ira, June Carl H: Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. *Proceedings of the National Academy of Sciences of the United States of America* 106(9): 3360-5, Mar 2009.
252. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH: Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. *Molecular Therapy* 17(8): 1453-64, May 2009 Notes: PMID: 1938429.
253. Riley James L, June Carl H, Blazar Bruce R: Human T regulatory cell therapy: take a billion or so and call me in the morning. *Immunity* 30(5): 656-65, May 2009.
254. Wang Gary P, Levine Bruce L, Binder Gwendolyn K, Berry Charles C, Malani Nirav, McGarrity Gary, Tebas Pablo, June Carl H, Bushman Frederic D: Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. *Molecular Therapy* 17(5): 844-50, May 2009.
255. Rapoport Aaron P, Stadtmauer Edward A, Aqui Nicole, Vogl Dan, Chew Anne, Fang Hong-Bin, Janofsky Stephen, Yager Kelly, Veloso Elizabeth, Zheng Zhaohui, Milliron Todd, Westphal Sandra, Cotte Julio, Huynh Hong, Cannon Andrea, Yanovich Saul, Akpek Gorgun, Tan Ming, Virts Kristen, Ruehle Kathleen, Harris Carolynn, Philip Sunita, Vonderheide Robert H, Levine Bruce L, June Carl H: Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. *Clinical Cancer Research* 15(13): 4499-507, Jul 2009.
256. June CH, Blazar BR, Riley JL: Engineering lymphocyte subsets: tools, trials and tribulations. *Nature Reviews Immunology* 9(10): 704-16, Oct 2009.

257. Nakazawa Yozo, Huye Leslie E, Dotti Gianpietro, Foster Aaron E, Vera Juan F, Manuri Pallavi R, June Carl H, Rooney Cliona M, Wilson Matthew H: Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. *Journal of Immunotherapy* 32(8): 826-36, Oct 2009.
258. Zhou Qing, Bucher Christoph, Munger Meghan E, Highfill Steven L, Tolar Jakub, Munn David H, Levine Bruce L, Riddle Megan, June Carl H, Vallera Daniel A, Weigel Brenda J, Blazar Bruce R: Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. *Blood* 114(18): 3793-802, Oct 2009.
259. Alagkiozidis Ioannis, Facciabene Andrea, Carpenito Carmine, Benencia Fabian, Jonak Zdenka, Adams Sarah, Carroll Richard G, Gimotty Phyllis A, Hammond Rachel, Danet-Desnoyers Gwen-ael, June Carl H, Powell Daniel J, Coukos George: Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. *Journal of Translational Medicine* 7: 104, Dec 2009.
260. Alagkiozidis, I., Facciabene, A., Carpenito, C., Benencia, F., Jonak, Z., Adams, S., Carroll, R. G., Gimotty, P. A., Hammond, R., Danet-Desnoyers, G. A., June, C. H., Powell, D. J., Jr., Coukos, G.: Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. *J Transl Med* 7: 104, 2009.
261. June, C. H., Blazar, B. R., Riley, J. L.: Engineering lymphocyte subsets: tools, trials and tribulations. *Nat Rev Immunol* 9(10): 704-16, 2009.
262. Tammana Syam, Huang Xin, Wong Marianna, Milone Michael C, Ma Linan, Levine Bruce L, June Carl H, Wagner John E, Blazar Bruce R, Zhou Xianzheng: 4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies. *Human Gene Therapy* 21(1): 75-86, Dec 2009.
263. Paulos CM, June CH: Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. *Journal of Clinical Investigation* 120(1): 76-80, Jan 2010.
264. Amarnath, S, Costanzo, CM, Mariotti, J, Ullman, JL, Telford, WG, Kapoor, V, Riley, JL, Levine, BL, June, CH, Fong, T: Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1. *PLoS Biol. Public Library of Science*, 8(2): e1000302. Feb 2010.
265. Serman, D. H., Recio, A., Haas, A. R., Vachani, A., Katz, S. I., Gillespie, C. T., Cheng, G., Sun, J., Moon, E., Pereira, L., Wang, X., Heitjan, D. F., Litzky, L., June, C. H., Vonderheide, R. H., Carroll, R. G., Albelda, S. M.: A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-beta Gene Transfer for Mesothelioma and Metastatic Pleural Effusions. *Mol Ther* 18(4): 852-60, April 2010.
266. Amarnath S, Flomerfelt FA, Costanzo CM, Foley JE, Mariotti J, Konecki DM, Gangopadhyay A, Eckhaus M, Wong S, Levine BL, June CH, Fowler DH: Rapamycin generates anti-apoptotic human

Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. *Autophagy* 6(4): E pub ahead of print, May 2010.

267. Bishop, MR, Aleya, EP, Cario, MS, Falkenburg, JH, June, CH, Kroger, N, Little, RF, Miller, JS, Porter, D, Ritz, J, van Besien, K, Wayne, AS, Weisdorf, DJ, Wu, R, Bishop, MR: Introduction to the Reports from the National Cancer Institute 1st International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant* 16(5): 563-4, May 2010.

268. Cairo, M. S., Jordan, C. T., Maley, C. C., Chao, C., Melnick, A., Armstrong, S. A., Shlomchik, W., Molldrem, J., Ferrone, S., Tycko, B., Mackall, C., Zitvogel, L., Bishop, M. R., Giralt, S. A., June, C. H.: NCI 1st International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse Following Allogeneic Stem Cell Transplantation Unrelated to Graft Versus Tumor Effects: State of the Science. *Biol Blood Marrow Transplant* 16(6): 709-28, June 2010.

269. Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Valleria DA, Azuma M, Levine BL, June CH, Murphy WJ, Munn DH, Blazar BR: Program death-1 (PD-1) signaling and regulatory T cells (Tregs) collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes (CTLs) in advanced acute myeloid leukemia (AML). *Blood Epub Jne* 22(14): 2484-93, Jun 2010.

270. Paulos Chrystal M, Carpenito Carmine, Plesa Gabriela, Suhoski Megan M, Varela-Rohena Angel, Golovina Tatiana N, Carroll Richard G, Riley James L, June Carl H: The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. *Science translational medicine* 2(55): 55ra78, Oct 2010.

271. Sluijter B J R, van den Hout M F C M, Stam A G M, Lougheed S M, Suhoski M M, van den Eertwegh A J M, van den Tol M P, van Leeuwen P A M, Meijer S, Scheper R J, June C H, de Gruijl T D, Santegoets S J A M: 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes. *Clinical immunology (Orlando, Fla.)* 137(2): 221-33, Nov 2010.

272. Zhao Yangbing, Moon Edmund, Carpenito Carmine, Paulos Chrystal M, Liu Xiaojun, Brennan Andrea L, Chew Anne, Carroll Richard G, Scholler John, Levine Bruce L, Albelda Steven M, June Carl H: Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. *Cancer research* 70(22): 9053-61, Nov 2010.

273. Brunstein Claudio G, Miller Jeffrey S, Cao Qing, McKenna David H, Hippen Keli L, Curtsinger Julie, Defor Todd, Levine Bruce L, June Carl H, Rubinstein Pablo, McGlave Philip B, Blazar Bruce R, Wagner John E: Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. *Blood* 117(3): 1061-70, Jan 2011.

274. Cannon Paula, June Carl: Chemokine receptor 5 knockout strategies. *Current opinion in HIV and AIDS* 6(1): 74-9, Jan 2011.

275. Rapoport Aaron P, Aqui Nicole A, Stadtmauer Edward A, Vogl Dan T, Fang Hong-Bin, Cai Ling, Janofsky Stephen, Chew Anne, Storek Jan, Akpek Gorgun, Badros Ashraf, Yanovich Saul, Tan Ming T, Veloso Elizabeth, Pasetti Marcela F, Cross Alan, Philip Sunita, Murphy Heather, Bhagat Rita, Zheng Zhaohui, Milliron Todd, Cotte Julio, Cannon Andrea, Levine Bruce L, Vonderheide Robert H, June Carl H: Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. *Blood* 117(3): 788-97, Jan 2011.
276. Stadtmauer Edward A, Vogl Dan T, Luning Prak Eline, Boyer Jean, Aqui Nicole A, Rapoport Aaron P, McDonald Kenyetta R, Hou Xiaoling, Murphy Heather, Bhagat Rita, Mangan Patricia A, Chew Anne, Veloso Elizabeth A, Levine Bruce L, Vonderheide Robert H, Jawad Abbas F, June Carl H, Sullivan Kathleen E: Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. *Blood* 117(1): 63-71, Jan 2011.
277. Kohn Donald B, Dotti Gianpietro, Brentjens Renier, Savoldo Barbara, Jensen Michael, Cooper Laurence Jn, June Carl H, Rosenberg Steven, Sadelain Michel, Heslop Helen E: CARs on track in the clinic. *Molecular therapy : the journal of the American Society of Gene Therapy* 19(3): 432-8, Mar 2011.
278. Wilen Craig B, Wang Jianbin, Tilton John C, Miller Jeffrey C, Kim Kenneth A, Rebar Edward J, Sherrill-Mix Scott A, Patro Sean C, Secreto Anthony J, Jordan Andrea P O, Lee Gary, Kahn Joshua, Aye Pyone P, Bunnell Bruce A, Lackner Andrew A, Hoxie James A, Danet-Desnoyers Gwenn A, Bushman Frederic D, Riley James L, Gregory Philip D, June Carl H, Holmes Michael C, Doms Robert W: Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. *PLoS Pathogens* 7(4): e1002020, Apr 2011.
279. Hippen Keli L, Merkel Sarah C, Schirm Dawn K, Sieben Christine M, Sumstad Darin, Kadidlo Diane M, McKenna David H, Bromberg Jonathan S, Levine Bruce L, Riley James L, June Carl H, Scheinberg Phillip, Douek Daniel C, Miller Jeffrey S, Wagner John E, Blazar Bruce R: Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. *Science Translational Medicine* 3(83): 83ra41, May 2011.
280. Hippen K L, Merkel S C, Schirm D K, Nelson C, Tennis N C, Riley J L, June C H, Miller J S, Wagner J E, Blazar B R: Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. *American Journal of Transplantation* 11(6): 1148-57, Jun 2011.
281. Serman Daniel H, Haas Andrew, Moon Edmund, Recio Adriana, Schwed Daniel, Vachani Anil, Katz Sharyn I, Gillespie Colin T, Cheng Guanjin, Sun Jing, Papasavvas Emmanouil, Montaner Luis J, Heitjan Daniel F, Litzky Leslie, Friedberg Joseph, Culligan Melissa, June Carl H, Carroll Richard G, Albelda Steven M: A Trial of Intrapleural Adenoviral-mediated Interferon- α 2b Gene Transfer for Malignant Pleural Mesothelioma. *American Journal of Respiratory and Critical Care Medicine* 184(12): 1395-9, Jun 2011.
282. Moon Edmund K, Carpenito Carmine, Sun Jing, Wang Liang-Chuan S, Kapoor Veena, Predina Jarrod, Powell Daniel J, Riley James L, June Carl H, Albelda Steven M: Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human t cells

expressing a mesothelin-specific chimeric antibody receptor. *Clinical Cancer Research* 17(14): 4719-30, Jul 2011.

283. Song De-Gang, Ye Qunrui, Carpenito Carmine, Poussin Mathilde, Wang Li-Ping, Ji Chunyan, Figini Mariangela, June Carl H, Coukos George, Powell Daniel J: In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). *Cancer Research* 71(13): 4617-27, Jul 2011.

284. Hippen Keli L, Riley James L, June Carl H, Blazar Bruce R: Clinical perspectives for regulatory T cells in transplantation tolerance. *Seminars in Immunology* 23(6): 462-8, Aug 2011.

285. Kalos Michael, Levine Bruce L, Porter David L, Katz Sharyn, Grupp Stephan A, Bagg Adam, June Carl H: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. *Science translational medicine* 3(95): 95ra73, Aug 2011.

286. Porter David L, Levine Bruce L, Kalos Michael, Bagg Adam, June Carl H: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *The New England journal of medicine* 365(8): 725-33, Aug 2011.

287. Barrett David M, Zhao Yangbing, Liu Xiaojun, Jiang Shuguang, Carpenito Carmine, Kalos Michael, Carroll Richard G, June Carl H, Grupp Stephan A: Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells. *Human gene therapy Sep* 2011.

288. Barrett David M, Seif Alix E, Carpenito Carmine, Teachey David T, Fish Jonathan D, June Carl H, Grupp Stephan A, Reid Gregor S D: Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. *Blood* 118(15): e112-7, Oct 2011.

289. Chu Christina S, Boyer Jean, Schullery Daniel S, Gimotty Phyllis A, Gamerman Victoria, Bender James, Levine Bruce L, Coukos George, Rubin Stephen C, Morgan Mark A, Vonderheide Robert H, June Carl H: Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. *Cancer Immunology Immunotherapy* Oct 2011.

290. Gattinoni Luca, Lugli Enrico, Ji Yun, Pos Zoltan, Paulos Chrystal M, Quigley Máire F, Almeida Jorge R, Gostick Emma, Yu Zhiya, Carpenito Carmine, Wang Ena, Douek Daniel C, Price David A, June Carl H, Marincola Francesco M, Roederer Mario, Restifo Nicholas P: A human memory T cell subset with stem cell-like properties. *Nature medicine* 17(10): 1290-7, Oct 2011.

291. Butler Scott L, Valdez Hernan, Westby Michael, Perros Manos, June Carl H, Jacobson Jeffrey M, Levy Yves, Cooper David A, Douek Daniel, Lederman Michael M, Tebas Pablo: Disease-Modifying Therapeutic Concepts for HIV in the Era of Highly Active Antiretroviral Therapy. *Journal of Acquired Immune Deficiency Syndromes* 58(3): 297-303, Nov 2011.

292. Hardy Nancy M, Mossoba Miriam E, Steinberg Seth M, Fellowes Vicki, Yan Xiao-Yi, Hakim Frances T, Babb Rebecca R, Avila Daniele, Gea-Banacloche Juan, Sportès Claude, Levine Bruce L, June Carl H, Khuu Hahn M, Carpenter Ashley E, Krumlauf Michael C, Dwyer Andrew J, Gress Ronald E, Fowler Daniel H, Bishop Michael R: Phase I Trial of Adoptive Cell Transfer with Mixed-Profile

Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* 17(21): 6878-6887, Nov 2011.

293. Alagkiozidis Ioannis, Facciabene Andrea, Tsiatas Marinos, Carpenito Carmine, Benencia Fabian, Adams Sarah, Jonak Zdenka, June Carl H, Powell Daniel J, Coukos George: Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. *Journal of Translational Medicine* 9: 77, 2011.

294. Amarnath, S., Mangus, C. W., Wang, J. C., Wei, F., He, A., Kapoor, V., Foley, J. E., Massey, P. R., Felizardo, T. C., Riley, J. L., Levine, B. L., June, C. H., Medin, J. A., Fowler, D. H.: The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells. *Sci Transl Med* 3(111): 111ra120, Dec 2011.

295. Fox, B. A., Schendel, D. J., Butterfield, L. H., Aamdal, S., Allison, J. P., Ascierto, P. A., Atkins, M. B., Bartunkova, J., Bergmann, L., Berinstein, N., Bonorino, C. C., Borden, E., Bramson, J. L., Britten, C. M., Cao, X., Carson, W. E., Chang, A. E., Characiejus, D., Choudhury, A. R., Coukos, G., de Gruijl, T., Dillman, R. O., Dolstra, H., Dranoff, G., Durrant, L. G., Finke, J. H., Galon, J., Gollob, J. A., Gouttefangeas, C., Grizzi, F., Guida, M., Hakansson, L., Hege, K., Herberman, R. B., Hodi, F. S., Hoos, A., Huber, C., Hwu, P., Imai, K., Jaffee, E. M., Janetzki, S., June, C. H., Kalinski, P., Kaufman, H. L., Kawakami, K., Kawakami, Y., Keilholtz, U., Khleif, S. N., Kiessling, R., Kotlan, B., Kroemer, G., Lapointe, R., Levitsky, H. I., Lotze, M. T., Maccalli, C., Maio, M., Marschner, J. P., Mastrangelo, M. J., Masucci, G., Melero, I., Nelief, C., Murphy, W. J., Nelson, B., Nicolini, A., Nishimura, M. I., Odunsi, K., Ohashi, P. S., O'Donnell-Tormey, J., Old, L. J., Ottensmeier, C., Papamichail, M., Parmiani, G., Pawelec, G., Proietti, E., Qin, S., Rees, R., Ribas, A., Ridolfi, R., Ritter, G., Rivoltini, L., Romero, P. J., Salem, M. L., Scheper, R. J., Seliger, B., Sharma, P., Shiku, H., Singh-Jasuja, H., Song, W., Straten, P. T., Tahara, H., Tian, Z., van Der Burg, S. H., von Hoegen, P., Wang, E., Welters, M. J., Winter, H., Withington, T., Wolchok, J. D., Xiao, W., Zitvogel, L., Zwierzina, H., Marincola, F. M., Gajewski, T. F., Wigginton, J. M., Disis, M. L.: Defining the Critical Hurdles in Cancer Immunotherapy. *J Transl Med* 9(1): 214, 2011.

296. Frigault, M. J., June, C. H.: Predicting cytokine storms: it's about density. *Blood* 118(26): 6724-6, 2011.

297. Grupp Stephan A, June Carl H: Adoptive cellular therapy. *Current Topics in Microbiology and Immunology* 344: 149-72, 2011.

298. Porter David L, Kalos Michael, Zheng Zhaohui, Levine Bruce, June Carl: Chimeric Antigen Receptor Therapy for B-cell Malignancies. *Journal of Cancer* 2: 331-2, 2011.

299. Ye Qunrui, Loisiou Maria, Levine Bruce L, Suhoski Megan M, Riley James L, June Carl H, Coukos George, Powell Daniel J: Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. *Journal of Translational Medicine* 9: 131, 2011.

300. Bear, A.S., Morgan, R.A., Cornetta, K., June, C.H., Binder-Scholl, G., Dudley, M.E., Feldman, S.A., Rosenberg, S.A., Shurtleff, S.A., Rooney, C.M., Heslop, H. E., Dotti, G: Replication-Competent Retroviruses in Gene-Modified T Cells Used in Clinical Trials: Is It Time to Revise the Testing Requirements? *Molecular Therapy*. Nature Publishing Group, 20(2): 246-249, 2012.
301. Hardy, N. M., Fellowes, V., Rose, J. J., Odom, J., Pittaluga, S., Steinberg, S. M., Blacklock-Schuver, B., Avila, D. N., Memon, S., Kurlander, R. J., Khuu, H. M., Stetler-Stevenson, M., Mena, E., Dwyer, A. J., Levine, B. L., June, C. H., Reshef, R., Vonderheide, R. H., Gress, R. E., Fowler, D. H., Hakim, F. T., Bishop, M. R.: Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. *Blood* 2012.
302. June, C., Levine, B.: Blocking HIV's attack. *Sci Am* 306(3): 54-9, 2012.
303. Tchou, J, Wang, L, Selvan, B, Zhang, H, Conejo-Garcia, J, Borghaei, H, Vonderheide, RH, Albelda, SM, June, CH, Zhang, PJ: Mesothelin, a novel immunotherapy target for triple negative breast cancer. *Breast Cancer Res Treat* submitted, 2012.
304. Kandalaft Lana E, Powell Daniel J, Chiang Cheryl L, Tanyi Janos, Kim Sarah, Bosch Marnix, Montone Kathy, Mick Rosemarie, Levine Bruce L, Torigian Drew A, June Carl H, Coukos George: Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. *Oncoimmunology* 2(1): e22664, Jan 2013.
305. Kunii Naoki, Zhao Yangbing, Jiang Shuguang, Liu Xiaojun, Scholler John, Balagopalan Lakshmi, Samelson Lawrence E, Milone Michael C, June Carl H: Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. *Human gene therapy* 24(1): 27-37, Jan 2013.
306. McGarrity Gerard J, Hoyah Gloria, Winemiller April, Andre Kris, Stein David, Blick Gary, Greenberg Richard N, Kinder Clifford, Zolopa Andrew, Binder-Scholl Gwen, Tebas Pablo, June Carl H, Humeau Laurent M, Rebello Tessio: Patient monitoring and follow-up in lentiviral clinical trials. *The journal of gene medicine* 15(2): 78-82, Feb 2013.
307. Maier Dawn A, Brennan Andrea L, Jiang Shuguang, Binder-Scholl Gwendolyn K, Lee Gary, Plesa Gabriela, Zheng Zhaohui, Cotte Julio, Carpenito Carmine, Wood Travis, Spratt S Kaye, Ando Dale, Gregory Philip, Holmes Michael C, Perez Elena E, Riley James L, Carroll Richard G, June Carl H, Levine Bruce L: Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. *Human gene therapy* 24(3): 245-58, Mar 2013.
308. Fowler Daniel H, Mossoba Miriam E, Steinberg Seth M, Halverson David C, Stroncek David, Khuu Hahn M, Hakim Frances T, Castiello Luciano, Sabatino Marianna, Leitman Susan F, Mariotti Jacopo, Gea-Banacloche Juan C, Sportes Claude, Hardy Nancy M, Hickstein Dennis D, Pavletic Steven Z, Rowley Scott, Goy Andre, Donato Michele, Korngold Robert, Pecora Andrew, Levine Bruce L, June Carl H, Gress Ronald E, Bishop Michael R: Phase 2 clinical trial of rapamycin-resistant donor CD4⁺ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. *Blood* 121(15): 2864-74, Apr 2013.

309. Grupp Stephan A, Kalos Michael, Barrett David, Aplenc Richard, Porter David L, Rheingold Susan R, Teachey David T, Chew Anne, Hauck Bernd, Wright J Fraser, Milone Michael C, Levine Bruce L, June Carl H: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *The New England journal of medicine* 368(16): 1509-18, Apr 2013.
310. Maus Marcela V, June Carl H: Zoom Zoom: racing CARs for multiple myeloma. *Clinical cancer research : an official journal of the American Association for Cancer Research* 19(8): 1917-9, Apr 2013.
311. McCormack Emmet, Adams Katherine J, Hassan Namir J, Kotian Akhil, Lissin Nikolai M, Sami Malkit, Mujić Maja, Osdal Tereza, Gjertsen Bjørn Tore, Baker Deborah, Powlesland Alex S, Aleksic Milos, Vuidepot Annelise, Morteau Olivier, Sutton Deborah H, June Carl H, Kalos Michael, Ashfield Rebecca, Jakobsen Bent K: Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. *Cancer immunology, immunotherapy : CII* 62(4): 773-85, Apr 2013.
312. Levine Bruce L, June Carl H: Perspective: assembly line immunotherapy. *Nature* 498(7455): S17, Jun 2013.
313. Riese Matthew J, Wang Liang-Chuan S, Moon Edmund K, Joshi Rohan P, Ranganathan Anjana, June Carl H, Koretzky Gary A, Albelda Steven M: Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. *Cancer research* 73(12): 3566-77, Jun 2013.
314. Kalbasi Anusha, June Carl H, Haas Naomi, Vapiwala Neha: Radiation and immunotherapy: a synergistic combination. *The Journal of clinical investigation* 123(7): 2756-63, Jul 2013.
315. Kalos Michael, June Carl H: Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. *Immunity* 39(1): 49-60, Jul 2013.
316. Kumar Anita J, Hexner Elizabeth O, Frey Noelle V, Luger Selina M, Loren Alison W, Reshef Ran, Boyer Jean, Smith Jacqueline, Stadtmauer Edward A, Levine Bruce L, June Carl H, Porter David L, Goldstein Steven C: Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation* 19(7): 1094-101, Jul 2013.
317. Lanitis Evripidis, Poussin Mathilde, Klattenhoff Alex W, Song Degang, Sandaltzopoulos Raphael, June Carl H, Powell Daniel J: Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. *Cancer immunology research* 1(1): 43-53, Jul 2013.
318. Maus Marcela V, Haas Andrew R, Beatty Gregory L, Albelda Steven M, Levine Bruce L, Liu Xiaojun, Zhao Yangbing, Kalos Michael, June Carl H: T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. *Cancer immunology research* 1(1): 26-31, Jul 2013.
319. Barrett David M, Liu Xiaojun, Jiang Shuguang, June Carl H, Grupp Stephan A, Zhao Yangbing: Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. *Human gene therapy* 24(8): 717-27, Aug 2013.

320. Cameron Brian J, Gerry Andrew B, Dukes Joseph, Harper Jane V, Kannan Vivekanandan, Bianchi Frayne C, Grand Francis, Brewer Joanna E, Gupta Minnal, Plesa Gabriela, Bossi Giovanna, Vuidepot Annelise, Powlesland Alex S, Legg Alison, Adams Katherine J, Bennett Alan D, Pumphrey Nicholas J, Williams Daniel D, Binder-Scholl Gwendolyn, Kulikovskaya Irina, Levine Bruce L, Riley James L, Varela-Rohena Angel, Stadtmauer Edward A, Rapoport Aaron P, Linette Gerald P, June Carl H, Hassan Namir J, Kalos Michael, Jakobsen Bent K: Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. *Science translational medicine* 5(197): 197ra103, Aug 2013.
321. Linette Gerald P, Stadtmauer Edward A, Maus Marcela V, Rapoport Aaron P, Levine Bruce L, Emery Lyndsey, Litzky Leslie, Bagg Adam, Carreno Beatriz M, Cimino Patrick J, Binder-Scholl Gwendolyn K, Smethurst Dominic P, Gerry Andrew B, Pumphrey Nick J, Bennett Alan D, Brewer Joanna E, Dukes Joseph, Harper Jane, Tayton-Martin Helen K, Jakobsen Bent K, Hassan Namir J, Kalos Michael, June Carl H: Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. *Blood* 122(6): 863-71, Aug 2013.
322. Santegoets Saskia J A M, Turksma Annelies W, Suhoski Megan M, Stam Anita G M, Albelda Steve M, Hooijberg Erik, Scheper Rik J, van den Eertwegh Alfons J M, Gerritsen Winald R, Powell Daniel J, June Carl H, de Gruijl Tanja D: IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. *Journal of translational medicine* 11: 37, 2013.
323. Tebas, P., Stein, D., Binder-Scholl, G., Mukherjee, R., Brady, T., Rebello, T., Humeau, L., Kalos, M., Papasavvas, E., Montaner, L.J., et al.: Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long anti-sense to HIV. *Blood* 121: 1524-1533, 2013.
324. Barrett, D.M., Singh, N., Liu, X., Jiang, S., June, C.H., Grupp, S.A., and Zhao, Y.: Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. *Cytotherapy* 16: 619-630, 2014.
325. Barrett, D.M., Singh, N., Porter, D.L., Grupp, S.A., and June, C.H.: Chimeric antigen receptor therapy for cancer. *Annu Rev Med* 65: 333-347, 2014.
326. Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G., Chew, A., Zhao, Y., Levine, B.L., Albelda, S.M., et al.: Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies. *Cancer Immunol Res* 2: 112-120, 2014.
327. Didigu, C.A., Wilen, C.B., Wang, J., Duong, J., Secreto, A.J., Danet-Desnoyers, G.A., Riley, J.L., Gregory, P.D., June, C.H., Holmes, M.C., et al.: Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. *Blood* 123: 61-69, 2014.
328. Gill, S., Tasian, S.K., Ruella, M., Shestova, O., Li, Y., Porter, D.L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S.A., et al.: Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. *Blood* 123: 2343-2354, 2014.

329. Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S.E., Frigault, M.J., Lee, J., Posey, A.D., Jr., Scholler, J., Scholler, N., et al.: ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. *Blood* 124: 1070-1080, 2014.
330. June, C.H.: Toward Synthetic Biology with Engineered T Cells: A Long Journey Just Begun. *Hum Gene Ther* 25: 779-784, 2014.
331. June, C.H., Maus, M.V., Plesa, G., Johnson, L.A., Zhao, Y., Levine, B.L., Grupp, S.A., and Porter, D.L.: Engineered T cells for cancer therapy. *Cancer Immunol Immunother* 2014.
332. Li, Y.R., Xian, R.R., Ziober, A., Conejo-Garcia, J., Perales-Puchalt, A., June, C.H., Zhang, P.J., and Tchou, J.: Mesothelin expression is associated with poor outcomes in breast cancer. *Breast Cancer Res Treat* 2014.
333. Maude, S., Frey, N., Shaw, P., Aplenc, R., Barrett, D., Bunin, N., Chew, A., Gonzalez, V., Zheng, Z., Lacey, S., et al: Sustained Remissions with Chimeric Antigen Receptor T Cells For Leukemia. *N Engl J Med* 2014.
334. Maus, M., and June, C.H.: CARTs on the road for myeloma. *Clin Cancer Res* 20: 3899-3901, 2014.
335. Maus, M.V., Fraietta, J.A., Levine, B.L., Kalos, M., Zhao, Y., and June, C.H.: Adoptive Immunotherapy for Cancer or Viruses. *Annu Rev Immunol* 32: 189-225, 2014.
336. Maus, M.V., Grupp, S.A., Porter, D.L., and June, C.H.: Antibody modified T cells: CARs take the front seat for hematologic malignancies. *Blood* 123: 2326-2635, 2014.
337. Moon, E.K., Wang, L.C., Dolfi, D.V., Wilson, C.B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Pure, E., Milone, M.C., et al.: Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors. *Clin Cancer Res* 20: 4262-4273, 2014.
338. Rapoport, A.P., Aqui, N.A., Stadtmauer, E.A., Vogl, D.T., Xu, Y.Y., Kalos, M., Cai, L., Fang, H.B., Weiss, B.M., Badros, A., et al.: Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells. *Clin Cancer Res* 20: 1355-1365, 2014.
339. Singh, N., Liu, X., Hulitt, J., Jiang, S., June, C.H., Grupp, S.A., Barrett, D.M., and Zhao, Y.: Nature of tumor control by permanently and transiently-modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. *Cancer Immunol Res pii: canimm.0051*, 2014.
340. Tchou, J., Zhang, P.J., Bi, Y., Satija, C., Marjumdar, R., Stephen, T.L., Lo, A., Chen, H., Mies, C., June, C.H., et al.: Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. *Hum Pathol* 44: 2549-2557, 2014.
341. Tebas, P., Stein, D., Tang, W., Frank, I., Wang, S., Lee, G., Spratt, S., Surosky, R., Giedlin, M., Nichol, G., et al.: Gene Editing of CCR5 in Autologous CD4 T-cells of Persons Infected with HIV. *N Engl J Med* 370: 901-910, 2014.

342. Vonderheide, R.H., and June, C.H.: Engineering T cells for cancer: our synthetic future. *Immunol Rev* 257: 7-13, 2014.
343. Wang, L.C., Lo, A., Scholler, J., Sun, J., Majumdar, R.S., Kapoor, V., Antzis, M., Cotner, C.E., Johnson, L.A., Durham, A.C., et al. 2014. : Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. *Cancer Immunol Res* 2: 154-166, 2014.
344. Gill Saar, June Carl H: Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. *Immunological reviews* 263(1): 68-89, Jan 2015.
345. Johnson Laura A, Scholler John, Ohkuri Takayuki, Kosaka Akemi, Patel Prachi R, McGettigan Shannon E, Nace Arben K, Dentchev Tzvete, Thekkat Pramod, Loew Andreas, Boesteanu Alina C, Cogdill Alexandria P, Chen Taylor, Fraietta Joseph A, Kloss Christopher C, Posey Avery D, Engels Boris, Singh Reshma, Ezell Tucker, Idamakanti Neeraja, Ramones Melissa H, Li Na, Zhou Li, Plesa Gabriela, Seykora John T, Okada Hideho, June Carl H, Brogdon Jennifer L, Maus Marcela V: Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. *Science translational medicine* 7(275): 275ra22, Feb 2015.
346. June Carl H, Riddell Stanley R, Schumacher Ton N: Adoptive cellular therapy: a race to the finish line. *Science translational medicine* 7(280): 280ps7, Mar 2015.
347. Frigault Matthew J, Lee Jihyun, Basil Maria Ciocca, Carpenito Carmine, Motohashi Shinichiro, Scholler John, Kawalekar Omkar U, Guedan Sonia, McGettigan Shannon E, Posey Avery D, Ang Sonny, Cooper Laurence J N, Platt Jesse M, Johnson F Brad, Paulos Chrystal M, Zhao Yangbing, Kalos Michael, Milone Michael C, June Carl H: Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. *Cancer immunology research* 3(4): 356-67, Apr 2015.
348. June Carl H: Serial Killers and Mass Murderers: Engineered T Cells Are up to the Task. *Cancer immunology research* 3(5): 470-2, May 2015.
349. Mossoba Miriam E, Halverson David C, Kurlander Roger, Schuver Bazetta Blacklock, Carpenter Ashley, Hansen Brenna, Steinberg Seth M, Ali Syed Abbas, Tajeja Nishant, Hakim Frances T, Gea-Banacloche Juan, Sportes Claude, Hardy Nancy M, Hickstein Dennis D, Pavletic Steven Z, Khuu Hanh, Sabatini Marianna, Stroncek David, Levine Bruce L, June Carl H, Mariotti Jacopo, Rixe Olivier, Fojo Antonio Tito, Bishop Michael R, Gress Ronald E, Fowler Daniel H: High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. *Clinical Cancer Research* 21(19): 4312-20, Jun 2015.
350. Zsiros Emese, Duttagupta Priyanka, Dangaj Denarda, Li Hongzhe, Frank Renee, Garrabrant Thomas, Hagemann Ian S, Levine Bruce L, June Carl H, Zhang Lin, Wang Ena, Marincola Francesco M, Bedognetti Davide, Powell Daniel J, Tanyi Janos, Feldman Michael D, Kandalaft Lana E, Coukos George: The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. *Clinical Cancer Research* 21(12): 2840-50, Jun 2015.

351. Lo Albert, Wang Liang-Chuan S, Scholler John, Monslow James, Avery Diana, Newick Kheng, O'Brien Shaun, Evans Rebecca A, Bajor David J, Clendenin Cynthia, Durham Amy C, Buza Elizabeth L, Vonderheide Robert H, June Carl H, Albelda Steven M, Puré Ellen: Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. *Cancer research* 75(14): 2800-10, Jul 2015.
352. Barrett David M, Grupp Stephan A, June Carl H: Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. *Journal of immunology (Baltimore, Md. : 1950)* 195(3): 755-61, Aug 2015.
353. Kenderian S S, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrisette J J D, Scholler J, Song D, Porter D L, Carroll M, June C H, Gill S: CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. *Leukemia* 29(8): 1637-47, Aug 2015.
354. Rapoport Aaron P, Stadtmauer Edward A, Binder-Scholl Gwendolyn K, Goloubeva Olga, Vogl Dan T, Lacey Simon F, Badros Ashraf Z, Garfall Alfred, Weiss Brendan, Finklestein Jeffrey, Kulikovskaya Irina, Sinha Sanjoy K, Kronsberg Shari, Gupta Minnal, Bond Sarah, Melchiori Luca, Brewer Joanna E, Bennett Alan D, Gerry Andrew B, Pumphrey Nicholas J, Williams Daniel, Tayton-Martin Helen K, Ribeiro Lilliam, Holdich Tom, Yanovich Saul, Hardy Nancy, Yared Jean, Kerr Naseem, Philip Sunita, Westphal Sandra, Siegel Don L, Levine Bruce L, Jakobsen Bent K, Kalos Michael, June Carl H: NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. *Nature medicine* 21(8): 914-21, Aug 2015.
355. Garfall Alfred L, Maus Marcela V, Hwang Wei-Ting, Lacey Simon F, Mahnke Yolanda D, Melenhorst J Joseph, Zheng Zhaohui, Vogl Dan T, Cohen Adam D, Weiss Brendan M, Dengel Karen, Kerr Naseem D S, Bagg Adam, Levine Bruce L, June Carl H, Stadtmauer Edward A: Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. *The New England journal of medicine* 373(11): 1040-7, Sep 2015.
356. Liu Xiaojun, Jiang Shuguang, Fang Chongyun, Yang Shiyu, Olalere Devvora, Pequignot Edward C, Cogdill Alexandria P, Li Na, Ramones Melissa, Granda Brian, Zhou Li, Loew Andreas, Young Regina M, June Carl H, Zhao Yangbing: Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. *Cancer research* 75(17): 3596-607, Sep 2015.
357. Porter David L, Hwang Wei-Ting, Frey Noelle V, Lacey Simon F, Shaw Pamela A, Loren Alison W, Bagg Adam, Marcucci Katherine T, Shen Angela, Gonzalez Vanessa, Ambrose David, Grupp Stephan A, Chew Anne, Zheng Zhaohui, Milone Michael C, Levine Bruce L, Melenhorst Jan J, June Carl H: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Science translational medicine* 7(303): 303ra139, Sep 2015.
358. Posey Avery D, Kawalekar Omkar U, June Carl H: Measurement of intracellular ions by flow cytometry. *Current protocols in cytometry / editorial board, J. Paul Robinson, managing editor ... [et al.]* 72: 9.8.1-9.8.21, 2015.

359. Garfall Alfred L, Stadtmauer Edward A, June Carl H: Chimeric Antigen Receptor T Cells in Myeloma. *The New England journal of medicine* 374(2): 194, Jan 2016.
360. Brunstein Claudio G, Miller Jeffrey S, McKenna David H, Hippen Keli L, DeFor Todd E, Sumstad Darin, Curtsinger Julie, Verneris Michael R, MacMillan Margaret L, Levine Bruce L, Riley James L, June Carl H, Le Chap, Weisdorf Daniel J, McGlave Philip B, Blazar Bruce R, Wagner John E: Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. *Blood* 127(8): 1044-51, Feb 2016.
361. Gracias Donald T, Boesteanu Alina C, Fraietta Joseph A, Hope Jennifer L, Carey Alison J, Mueller Yvonne M, Kawalekar Omkar U, Fike Adam J, June Carl H, Katsikis Peter D: Phosphatidylinositol 3-Kinase p110 δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections. *Journal of immunology (Baltimore, Md. : 1950)* 196(3): 1186-98, Feb 2016.
362. Fraietta Joseph A, Beckwith Kyle A, Patel Prachi R, Ruella Marco, Zheng Zhaohui, Barrett David M, Lacey Simon F, Melenhorst Jan Joseph, McGettigan Shannon E, Cook Danielle R, Zhang Changfeng, Xu Jun, Do Priscilla, Hulitt Jessica, Kudchodkar Sagar B, Cogdill Alexandria P, Gill Saar, Porter David L, Woyach Jennifer A, Long Meixiao, Johnson Amy J, Maddocks Kami, Muthusamy Natarajan, Levine Bruce L, June Carl H, Byrd John C, Maus Marcela V: Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. *Blood* 127(9): 1117-27, Mar 2016.
363. Kawalekar Omkar U, O' Connor Roddy S, Fraietta Joseph A, Guo Lili, McGettigan Shannon E, Posey Avery D, Patel Prachi R, Guedan Sonia, Scholler John, Keith Brian, Snyder Nathaniel W, Blair Ian A, Milone Michael C, June Carl H: Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. *Immunity* 44(3): 712, Mar 2016.
364. Liu Xiaojun, Ranganathan Raghuveer, Jiang Shuguang, Fang Chongyun, Sun Jing, Kim Soyeon, Newick Kheng, Lo Albert, June Carl H, Zhao Yangbing, Moon Edmund K: A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. *Cancer research* 76(6): 1578-90, Mar 2016.
365. Hexner Elizabeth O, Luger Selina M, Reshef Ran, Jeschke Grace R, Mangan James K, Frey Noelle V, Frank Dale M, Richman Lee P, Vonderheide Robert H, Aqui Nicole A, Rosenbach Misha, Zhang Yi, Chew Anne, Loren Alison W, Stadtmauer Edward A, Levine Bruce L, June Carl H, Emerson Stephen G, Porter David L: Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. *American journal of hematology* 91(5): 453-60, May 2016.
366. Zsiros Emese, Dangaj Denarda, June Carl H, Kandalaft Lana E, Coukos George: Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy. *Oncoimmunology* 5(5): e1062210, May 2016.
367. Liu X, Barrett D M, Jiang S, Fang C, Kalos M, Grupp S A, June C H, Zhao Y: Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. *Blood cancer journal* 6(6): e430, Jun 2016.

368. Posey Avery D, Schwab Robert D, Boesteanu Alina C, Steentoft Catharina, Mandel Ulla, Engels Boris, Stone Jennifer D, Madsen Thomas D, Schreiber Karin, Haines Kathleen M, Cogdill Alexandria P, Chen Taylor J, Song Decheng, Scholler John, Kranz David M, Feldman Michael D, Young Regina, Keith Brian, Schreiber Hans, Clausen Henrik, Johnson Laura A, June Carl H: Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. *Immunity* 44(6): 1444-54, Jun 2016.
369. Ruella Marco, Kenderian Saad S, Shestova Olga, Fraietta Joseph A, Qayyum Sohail, Zhang Qian, Maus Marcela V, Liu Xiaobin, Nunez-Cruz Selene, Klichinsky Michael, Kawalekar Omkar U, Milone Michael, Lacey Simon F, Mato Anthony, Schuster Stephen J, Kalos Michael, June Carl H, Gill Saar, Wasik Mariusz A: The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. *Clinical Cancer Research* 22(11): 2684-96, Jun 2016.
370. Chen Fang, Teachey David T, Pequignot Edward, Frey Noelle, Porter David, Maude Shannon L, Grupp Stephan A, June Carl H, Melenhorst Jan J, Lacey Simon F: Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. *Journal of immunological methods* 434: 1-8, Jul 2016.
371. Jenkins Christopher L, Bagarazzi Mark L, Kiem Hans-Peter, Levine Arnold J, Ando Dale, June Carl H, Reid Tony, Emery David W: Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical Trials. *Molecular therapy : the journal of the American Society of Gene Therapy* 24(7): 1173-7, Aug 2016.
372. Lu Yunjie, Hippen Keli L, Lemire Amanda L, Gu Jian, Wang Weizhi, Ni Xuhao, Ranganathan Parvathi, Levine Bruce L, Riley James L, June Carl H, Turka Laurence A, Munn David H, Garzon Ramiro, Lu Ling, Blazar Bruce R: miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. *Blood* 128(10): 1424-35, Sep 2016.
373. Ruella Marco, Barrett David M, Kenderian Saad S, Shestova Olga, Hofmann Ted J, Perazzelli Jessica, Klichinsky Michael, Aikawa Vania, Nazimuddin Farzana, Kozlowski Miroslaw, Scholler John, Lacey Simon F, Melenhorst Jan J, Morrisette Jennifer J D, Christian David A, Hunter Christopher A, Kalos Michael, Porter David L, June Carl H, Grupp Stephan A, Gill Saar: Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. *The Journal of clinical investigation* 126(10): 3814-3826, Oct 2016.
374. Ruella Marco, June Carl H: Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. *Current hematologic malignancy reports* 11(5): 368-84, Oct 2016.
375. Leslie George J, Wang Jianbin, Richardson Max W, Haggarty Beth S, Hua Kevin L, Duong Jennifer, Secreto Anthony J, Jordon Andrea P O, Romano Josephine, Kumar Kritika E, DeClercq Joshua J, Gregory Philip D, June Carl H, Root Michael J, Riley James L, Holmes Michael C, Hoxie James A: Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. *PLoS pathogens* 12(11): e1005983, Nov 2016.

376. Posey Avery D, Clausen Henrik, June Carl H: Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety. *Immunity* 45(5): 947-948, Nov 2016.
377. Rubin Courtney B, Elenitsas Rosalie, Taylor Laura, Lacey Simon F, Kulikovskaya Irina, Gupta Minnal, Melenhorst Jan J, Loren Alison, Frey Noelle, June Carl H, Porter David, Rosenbach Misha: Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. *Journal of the American Academy of Dermatology* 75(5): 1054-1057, Nov 2016.
378. June Carl H: Drugging the Undruggable Ras - Immunotherapy to the Rescue? *The New England journal of medicine* 375(23): 2286-2289, 12 2016.
379. Kohrt Holbrook E, Tumei Paul C, Benson Don, Bhardwaj Nina, Brody Joshua, Formenti Silvia, Fox Bernard A, Galon Jerome, June Carl H, Kalos Michael, Kirsch Ilan, Kleen Thomas, Kroemer Guido, Lanier Lewis, Levy Ron, Lysterly H Kim, Maecker Holden, Marabelle Aurelien, Melenhorst Jos, Miller Jeffrey, Melero Ignacio, Odunsi Kunle, Palucka Karolina, Peoples George, Ribas Antoni, Robins Harlan, Robinson William, Serafini Tito, Sondel Paul, Vivier Eric, Weber Jeff, Wolchok Jedd, Zitvogel Laurence, Disis Mary L, Cheever Martin A: Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. *Journal for immunotherapy of cancer* 4: 15, 2016.
380. Singh Nathan, Kulikovskaya Irina, Barrett David M, Binder-Scholl Gwendolyn, Jakobsen Bent, Martinez Daniel, Pawel Bruce, June Carl H, Kalos Michael D, Grupp Stephan A: T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. *Oncoimmunology* 5(1): e1040216, 2016.
381. Teachey David T, Lacey Simon F, Shaw Pamela A, Melenhorst J Joseph, Maude Shannon L, Frey Noelle, Pequignot Edward, Gonzalez Vanessa E, Chen Fang, Finklestein Jeffrey, Barrett David M, Weiss Scott L, Fitzgerald Julie C, Berg Robert A, Aplenc Richard, Callahan Colleen, Rheingold Susan R, Zheng Zhaohui, Rose-John Stefan, White Jason C, Nazimuddin Farzana, Wertheim Gerald, Levine Bruce L, June Carl H, Porter David L, Grupp Stephan A: Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. *Cancer discovery* 6(6): 664-79, 06 2016.
382. Chong Elise A, Melenhorst J Joseph, Lacey Simon F, Ambrose David E, Gonzalez Vanessa, Levine Bruce L, June Carl H, Schuster Stephen J: PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. *Blood* 129(8): 1039-1041, Feb 2017.
383. Fitzgerald Julie C, Weiss Scott L, Maude Shannon L, Barrett David M, Lacey Simon F, Melenhorst J Joseph, Shaw Pamela, Berg Robert A, June Carl H, Porter David L, Frey Noelle V, Grupp Stephan A, Teachey David T: Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. *Critical care medicine* 45(2): e124-e131, Feb 2017.
384. McKenna David H, Sumstad Darin, Kadidlo Diane M, Batdorf Bjorn, Lord Colin J, Merkel Sarah C, Koellner Christine M, Curtsinger Julie M, June Carl H, Riley James L, Levine Bruce L, Miller Jeffrey S, Brunstein Claudio G, Wagner John E, Blazar Bruce R, Hippen Keli L: Optimization of cGMP

purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. *Cytotherapy* 19(2): 250-262, Feb 2017.

385. Ren Jiangtao, Zhang Xuhua, Liu Xiaojun, Fang Chongyun, Jiang Shuguang, June Carl H, Zhao Yangbing: A versatile system for rapid multiplex genome-edited CAR T cell generation. *Oncotarget* 8(10): 17002-17011, Mar 2017.

386. Fajardo Carlos Alberto, Guedan Sonia, Rojas Luis Alfonso, Moreno Rafael, Arias-Badia Marcel, de Sostoa Jana, June Carl H, Alemany Ramon: Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy. *Cancer research* 77(8): 2052-2063, Apr 2017.

387. Tanyi Janos L, Stashwick Caitlin, Plesa Gabriela, Morgan Mark A, Porter David, Maus Marcela V, June Carl H: Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells. *Journal of immunotherapy* (Hagerstown, Md. : 1997) 40(3): 104-107, Apr 2017.

388. Hippen K L, O'Connor R S, Lemire A M, Saha A, Hanse E A, Tennis N C, Merkel S C, Kelekar A, Riley J L, Levine B L, June C H, Turka L A, Kean L S, MacMillan M L, Miller J S, Wagner J E, Munn D H, Blazar B R: In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* May 2017.

389. Ren Jiangtao, Liu Xiaojun, Fang Chongyun, Jiang Shuguang, June Carl H, Zhao Yangbing: Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. *Clinical cancer research : an official journal of the American Association for Cancer Research* 23(9): 2255-2266, May 2017.

390. Liu Xiaojun, Jiang Shuguang, Fang Chongyun, Li Hua, Zhang Xuhua, Zhang Fuqin, June Carl H, Zhao Yangbing: Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation. *Protein & cell* 8(7): 514-526, Jul 2017.

391. O'Rourke Donald M, Nasrallah MacLean P, Desai Arati, Melenhorst Jan J, Mansfield Keith, Morrisette Jennifer J D, Martinez-Lage Maria, Brem Steven, Maloney Eileen, Shen Angela, Isaacs Randi, Mohan Suyash, Plesa Gabriela, Lacey Simon F, Navenot Jean-Marc, Zheng Zhaohui, Levine Bruce L, Okada Hideho, June Carl H, Brogdon Jennifer L, Maus Marcela V: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Science translational medicine* 9(399), Jul 2017.

392. June Carl H, Warshauer Jeremy T, Bluestone Jeffrey A: Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy? *Nature medicine* 23(8): 1004, Aug 2017.

393. Long Meixiao, Beckwith Kyle, Do Priscilla, Mundy Bethany L, Gordon Amber, Lehman Amy M, Maddocks Kami J, Cheney Carolyn, Jones Jeffrey A, Flynn Joseph M, Andritsos Leslie A, Awan Farrukh, Fraietta Joseph A, June Carl H, Maus Marcela V, Woyach Jennifer A, Caligiuri Michael A, Johnson Amy J, Muthusamy Natarajan, Byrd John C: Ibrutinib treatment improves T cell number and function in CLL patients. *The Journal of clinical investigation* 127(8): 3052-3064, Aug 2017.

394. Cornetta Kenneth, Duffy Lisa, Turtle Cameron J, Jensen Michael, Forman Stephen, Binder-Scholl Gwendolyn, Fry Terry, Chew Anne, Maloney David G, June Carl H: Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. *Molecular therapy : the journal of the American Society of Gene Therapy* Sep 2017.
395. Hu Biliang, Ren Jiangtao, Luo Yanping, Keith Brian, Young Regina M, Scholler John, Zhao Yangbing, June Carl H: Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18. *Cell reports* 20(13): 3025-3033, Sep 2017.
396. Mueller Karen Thudium, Maude Shannon L, Porter David L, Frey Noelle, Wood Patricia, Han Xia, Waldron Edward, Chakraborty Abhijit, Awasthi Rakesh, Levine Bruce L, Melenhorst J Joseph, Grupp Stephan A, June Carl H, Lacey Simon F: Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. *Blood* Sep 2017.
397. Abou-El-Enein Mohamed, Cathomen Toni, Ivics Zoltán, June Carl H, Renner Matthias, Schneider Christian K, Bauer Gerhard: Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment. *Cell stem cell* 21(4): 427-430, Oct 2017.
398. Obstfeld Amrom E, Frey Noelle V, Mansfield Keith, Lacey Simon F, June Carl H, Porter David L, Melenhorst Jan J, Wasik Mariusz A: Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy; clinicopathological insights. *Blood* Oct 2017.
399. Ruella Marco, Klichinsky Michael, Kenderian Saad S, Shestova Olga, Ziober Amy, Kraft Daniel O, Feldman Michael, Wasik Mariusz A, June Carl H, Gill Saar: Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. *Cancer discovery* 7(10): 1154-1167, Oct 2017.
400. Singh Nathan, Shi Junwei, June Carl H, Ruella Marco: Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer. *Current hematologic malignancy reports* Oct 2017.
401. Hege Kristen M, Bergsland Emily K, Fisher George A, Nemunaitis John J, Warren Robert S, McArthur James G, Lin Andy A, Schlom Jeffrey, June Carl H, Sherwin Stephen A: Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. *Journal for immunotherapy of cancer* 5: 22, 2017.
402. Kawalekar Omkar, June Carl H, Milone Michael C: Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA. *Methods in molecular biology (Clifton, N.J.)* 1584: 443-450, 2017.
403. Kenderian Saad S, June Carl H, Gill Saar: Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia. *Methods in molecular biology (Clifton, N.J.)* 1633: 267-276, 2017.
404. Alcantara, M., Tesio, M., June, C. H., Houot, R.: CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. *Leukemia* 32(11): 2307-2315, 2018.

405. Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H., O'Rourke, D. M.: CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. *20(11)*: 1429-1438, 2018.
406. Beatty, G. L., O'Hara, M. H., Lacey, S. F., Torigian, D. A., Nazimuddin, F., Chen, F., Kulikovskaya, I. M., Soulen, M. C., McGarvey, M., Nelson, A. M., Gladney, W. L., Levine, B. L., Melenhorst, J. J., Plesa, G., June, C. H.: Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. *Gastroenterology* 155(1): 29-32, 2018.
407. Boyiadzis, M. M., Dhodapkar, M. V., Brentjens, R. J., Kochenderfer, J. N., Neelapu, S. S., Maus, M. V., Porter, D. L., Maloney, D. G., Grupp, S. A., Mackall, C. L., June, C. H., Bishop, M. R.: Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. *J Immunother Cancer* 6(1): 137, 2018.
408. Castellarin, M., Watanabe, K., June, C. H., Kloss, C. C., Posey, A. D., Jr.: Driving cars to the clinic for solid tumors. *Gene Ther* 25(3): 165-175, 2018.
409. Cornetta, K., Duffy, L., Turtle, C. J., Jensen, M., Forman, S., Binder-Scholl, G., Fry, T., Chew, A., Maloney, D. G., June, C. H.: Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. *Mol Ther* 26(1): 280-288, 2018.
410. Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrisette, J. J. D., DeNizio, J. E., Reddy, S., Hwang, Y., Gohil, M., Kulikovskaya, I., Nazimuddin, F., Gupta, M., Chen, F., Everett, J. K., Alexander, K. A., Lin-Shiao, E., Gee, M. H., Liu, X., Young, R. M., Ambrose, D., Wang, Y., Xu, J., Jordan, M. S., Marcucci, K. T., Levine, B. L., Garcia, K. C., Zhao, Y., Kalos, M., Porter, D. L., Kohli, R. M., Lacey, S. F., Berger, S. L., Bushman, F. D., June, C. H., Melenhorst, J. J.: Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. *Nature* 558(7709): 307-312, 2018.
411. Ghassemi, S., Nunez-Cruz, S., O'Connor, R. S., Fraietta, J. A., Patel, P. R., Scholler, J., Barrett, D. M., Lundh, S. M., Davis, M. M., Bedoya, F., Zhang, C., Leferovich, J., Lacey, S. F., Levine, B. L., Grupp, S. A., June, C. H., Melenhorst, J. J., Milone, M. C.: Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. *Cancer Immunol Res* 6(9): 1100-1109, 2018.
412. Guedan, S., Posey, A. D., Jr., Shaw, C., Wing, A., Da, T., Patel, P. R., McGettigan, S. E., Casado-Medrano, V., Kawalekar, O. U., Uribe-Herranz, M., Song, D., Melenhorst, J. J., Lacey, S. F., Scholler, J., Keith, B., Young, R. M., June, C. H.: Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. *JCI Insight* 3(1), 2018.
413. June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., Milone, M. C.: CAR T cell immunotherapy for human cancer. *Science* 359(6382): 1361-1365, 2018.
414. June, C. H., Sadelain, M.: Chimeric Antigen Receptor Therapy. *N Engl J Med* 379(1): 64-73, 2018.

415. Kloss, C. C., Lee, J., Zhang, A., Chen, F., Melenhorst, J. J., Lacey, S. F., Maus, M. V., Fraietta, J. A., Zhao, Y., June, C. H.: Dominant-Negative TGF-beta Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. *Mol Ther* 26(7): 1855-1866, 2018.
416. Marcucci, K. T., Jadowsky, J. K., Hwang, W. T., Suhoski-Davis, M., Gonzalez, V. E., Kulikovskaya, I., Gupta, M., Lacey, S. F., Plesa, G., Chew, A., Melenhorst, J. J., Levine, B. L., June, C. H.: Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. *Mol Ther* 26(1): 269-279, 2018.
417. Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B. L., Wood, P., Taran, T., Leung, M., Mueller, K. T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M. A., Grupp, S. A.: Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *N Engl J Med* 378(5): 439-448, 2018.
418. Migliorini, D., Dietrich, P. Y., Stupp, R., Linette, G. P., Posey, A. D., Jr., June, C. H.: CAR T-Cell Therapies in Glioblastoma: A First Look. *Clin Cancer Res* 24(3): 535-540, 2018.
419. Mueller, K. T., Waldron, E., Grupp, S. A., Levine, J. E., Laetsch, T. W., Pulsipher, M. A., Boyer, M. W., August, K. J., Hamilton, J., Awasthi, R., Stein, A. M., Sickert, D., Chakraborty, A., Levine, B. L., June, C. H., Tomassian, L., Shah, S. S., Leung, M., Taran, T., Wood, P. A., Maude, S. L.: Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. *Clin Cancer Res* 24(24): 6175-6184, 2018.
420. O'Connor, R. S., Guo, L., Ghassemi, S., Snyder, N. W., Worth, A. J., Weng, L., Kam, Y., Philipson, B., Trefely, S., Nunez-Cruz, S., Blair, I. A., June, C. H., Milone, M. C.: The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. *Sci Rep* 8(1): 6289, 2018.
421. Ruella, M., June, C. H.: Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans. *Mol Ther* 26(6): 1401-1403, 2018.
422. Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., Nazimuddin, F., Bhoj, V. G., Orlando, E. J., Fry, T. J., Bitter, H., Maude, S. L., Levine, B. L., Nobles, C. L., Bushman, F. D., Young, R. M., Scholler, J., Gill, S. I., June, C. H., Grupp, S. A., Lacey, S. F., Melenhorst, J. J.: Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. *Nat Med* 24(10): 1499-1503, 2018.
423. Shah, N. N., Nagle, S. J., Torigian, D. A., Farwell, M. D., Hwang, W. T., Frey, N., Nasta, S. D., Landsburg, D., Mato, A., June, C. H., Schuster, S. J., Porter, D. L., Svoboda, J.: Early positron emission tomography/computed tomography as a predictor of response after CTL019

chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. *Cytotherapy* 20(12): 1415-1418, 2018.

424. Steentoft, C., Migliorini, D., King, T. R., Mandel, U., June, C. H., Posey, A. D., Jr.: Glycan-directed CAR-T cells. *Glycobiology* 28(9): 656-669, 2018.

425. Svoboda, J., Rheingold, S. R., Gill, S. I., Grupp, S. A., Lacey, S. F., Kulikovskaya, I., Suhoski, M. M., Melenhorst, J. J., Loudon, B., Mato, A. R., Nasta, S. D., Landsburg, D. J., Youngman, M. R., Levine, B. L., Porter, D. L., June, C. H., Schuster, S. J.: Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. *Blood* 132(10): 1022-1026, 2018.

426. Tanyi, J. L., Bobisse, S., Ophir, E., Tuyaearts, S., Roberti, A., Genolet, R., Baumgartner, P., Stevenson, B. J., Iseli, C., Dangaj, D., Czerniecki, B., Semilietof, A., Racle, J., Michel, A., Xenarios, I., Chiang, C., Monos, D. S., Torigian, D. A., Nisenbaum, H. L., Michielin, O., June, C. H., Levine, B. L., Powell, D. J., Jr., Gfeller, D., Mick, R., Dafni, U., Zoete, V., Harari, A., Coukos, G., Kandalaft, L. E.: Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. *Sci Transl Med* 10(436), 2018.

427. Uribe-Herranz, M., Bittinger, K., Rafail, S., Guedan, S., Pierini, S., Tanes, C., Ganetsky, A., Morgan, M. A., Gill, S., Tanyi, J. L., Bushman, F. D., June, C. H., Facciabene, A.: Gut microbiota modulates adoptive cell therapy via CD8alpha dendritic cells and IL-12. *JCI Insight* 3(4), 2018.

428. Watanabe, K., Kuramitsu, S., Posey, A. D., Jr., June, C. H.: Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology. *Front Immunol* 9: 2486, 2018.

429. Watanabe, K., Luo, Y., Da, T., Guedan, S., Ruella, M., Scholler, J., Keith, B., Young, R. M., Engels, B., Sorsa, S., Siurala, M., Havunen, R., Tahtinen, S., Hemminki, A., June, C. H.: Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. *JCI Insight* 3(7), 2018.

430. Wing, A., Fajardo, C. A., Posey, A. D., Jr., Shaw, C., Da, T., Young, R. M., Alemany, R., June, C. H., Guedan, S.: Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager. *Cancer Immunol Res* 6(5): 605-616, 2018.

431. Yin, Y., Boesteanu, A. C., Binder, Z. A., Xu, C., Reid, R. A., Rodriguez, J. L., Cook, D. R., Thokala, R., Blouch, K., McGettigan-Croce, B., Zhang, L., Konradt, C., Cogdill, A. P., Panjwani, M. K., Jiang, S., Migliorini, D., Dahmane, N., Posey, A. D., Jr., June, C. H., Mason, N. J., Lin, Z., O'Rourke, D. M., Johnson, L. A.: Checkpoint Blockade Reverses Anergy in IL-13Ralpha2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. *Mol Ther Oncolytics* 11: 20-38, 2018.

432. Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, Wang T, Bedi K, Morley MP, Linares Saldana RA, Bolar NA, McDaid K, Assenmacher

CA, Smith CL, Wirth D, June CH, Margulies KB, Jain R, Pure E, Albelda SM, and Epstein JA. Targeting cardiac fibrosis with engineered T cells. *Nature*. 2019;573(7774):430-3.

433. Benci JL, Johnson LR, Choa R, Xu Y, Qiu J, Zhou Z, Xu B, Ye D, Nathanson KL, June CH, Wherry EJ, Zhang NR, Ishwaran H, Hellmann MD, Wolchok JD, Kambayashi T, and Minn AJ. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. *Cell*. 2019;178(4):933-48.e14.

434. Choi BD, Maus MV, June CH, and Sampson JH. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. *Clin Cancer Res*. 2019;25(7):2042-8.

435. Chong EA, Levine BL, Grupp SA, Davis MM, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, Hwang WT, Chong ER, June CH, and Schuster SJ. CAR T cell viability release testing and clinical outcomes: is there a lower limit? *Blood*. 2019;134(21):1873-5.

436. Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, and Milone MC. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. *J Clin Invest*. 2019;129(6):2210-21.

437. Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, Levine BL, Siegel DL, Stadtmauer EA, Vogl DT, Waxman A, Rapoport AP, Milone MC, June CH, and Melenhorst JJ. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. *Blood advances*. 2019;3(19):2812-5.

438. Garfall AL, and June CH. Trispecific antibodies offer a third way forward for anticancer immunotherapy. *Nature*. 2019;575(7783):450-1.

439. Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, and June CH. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. *JCI insight*. 2019;4(4).

440. Guedan S, Ruella M, and June CH. Emerging Cellular Therapies for Cancer. *Annu Rev Immunol*. 2019;37:145-71.

441. Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, and Beatty GL. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. *Mol Ther*. 2019;27(11):1919-29.

442. He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, Kranz DM, and Schreiber H. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. *JCI insight*. 2019; 4(23):e135306. doi: 10.1172/jci.insight.135306.

443. June CH. Emerging Use of CRISPR Technology - Chasing the Elusive HIV Cure. *N Engl J Med*. 2019;381(13):1281-3.
444. Nobles CL, Reddy S, Salas-McKee J, Liu X, June CH, Melenhorst JJ, Davis MM, Zhao Y, and Bushman FD. iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. *Genome Biol*. 2019;20(1):14.
445. Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, Van Arnem J, Melenhorst JJ, Mohan D, DiNofia AM, Luo M, Cherian S, Fromm JR, Wertheim G, Thomas-Tikhonenko A, Paessler M, June CH, Luning Prak ET, Bhoj VG, Grupp SA, Maude SL, and Rheingold SR. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. *Blood advances*. 2019;3(22):3539-49.
446. Riley RS, June CH, Langer R, and Mitchell MJ. Delivery technologies for cancer immunotherapy. *Nat Rev Drug Discov*. 2019;18(3):175-96.
447. Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, and Gill S. A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells. *Blood*. 2019.
448. Singh N, and June CH. Boosting engineered T cells. *Science*. 2019;365(6449):119-20.
449. Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Levine BL, Tomassian L, Shah S, Leung M, Huang PH, Awasthi R, Mueller KT, Wood PA, and June CH. Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells. *CPT: pharmacometrics & systems pharmacology*. 2019;8(5):285-95.
450. van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, and van der Windt GJW. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+) T cells and impede CAR T-cell efficacy. *Blood*. 2019;134(1):44-58.
451. Wang S, O'Rourke DM, Chawla S, Verma G, Nasrallah MP, Morrisette JJD, Plesa G, June CH, Brem S, Maloney E, Desai A, Wolf RL, Poptani H, and Mohan S. Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma. *Br J Cancer*. 2019;120(1):54-6.
452. Agarwal S, and June CH. Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19. *Cancer Discov*. 2020;10(6):775-8.
453. Billingsley MM, Singh N, Ravikumar P, Zhang R, June CH, and Mitchell MJ. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. *Nano letters*. 2020;20(3):1578-89.
454. Castellarin M, Sands C, Da T, Scholler J, Graham K, Buza E, Fraietta JA, Zhao Y, and June CH. A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. *JCI insight*. 2020;5(14).

455. Chaudhury A, Zhu X, Chu L, Goliaei A, June CH, Kearns JD, and Stein AM. Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches. *J Clin Pharmacol.* 2020;60 Suppl 1:S147-s59.
456. Diorio C, Shaw PA, Pequignot E, Orlenko A, Chen F, Aplenc R, Barrett DM, Bassiri H, Behrens E, DiNofia AM, Gonzalez V, Koterba N, Levine BL, Maude SL, Meyer NJ, Moore JH, Paessler M, Porter DL, Bush JL, Siegel DL, Davis MM, Zhang D, June CH, Grupp SA, Melenhorst JJ, Lacey SF, Weiss SL, and Teachey DT. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. *Blood advances.* 2020;4(20):5174-83.
457. Fajgenbaum DC, and June CH. Cytokine Storm. *N Engl J Med.* 2020;383(23):2255-73.
458. Finck A, Gill SI, and June CH. Cancer immunotherapy comes of age and looks for maturity. *Nature communications.* 2020;11(1):3325.
459. Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, and Porter DL. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. *J Clin Oncol.* 2020;38(5):415-22.
460. Ghassemi S, Martinez-Becerra FJ, Master AM, Richman SA, Heo D, Leferovich J, Tu Y, García-Cañaveras JC, Ayari A, Lu Y, Wang A, Rabinowitz JD, Milone MC, June CH, and O'Connor RS. Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design. *Mol Ther Methods Clin Dev.* 2020;18:595-606.
461. Guedan S, Madar A, Casado-Medrano V, Shaw C, Wing A, Liu F, Young RM, June CH, and Posey AD, Jr. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. *J Clin Invest.* 2020;130(6):3087-97.
462. He X, Feng Z, Ma J, Ling S, Cao Y, Gurung B, Wu Y, Katona BW, O'Dwyer KP, Siegel DL, June CH, and Hua X. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. *Blood.* 2020;135(10):713-23.
463. Jacobson JM, Jadowsky JK, Lacey SF, Fraietta JA, Plesa G, Chono H, Lee DH, Kulikovskaya I, Bartoszek C, Chen F, Tian L, Dimitri A, Levine BL, Veloso EA, Hwang WT, and June CH. Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. *Mol Ther.* 2020.
464. Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O'Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, and Gill S. Human chimeric antigen receptor macrophages for cancer immunotherapy. *Nat Biotechnol.* 2020;38(8):947-53.
465. Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, and Beatty GL. Dual Targeting of

Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. *Mol Ther.* 2020;28(11):2367-78.

466. Moore JB, and June CH. Cytokine release syndrome in severe COVID-19. *Science.* 2020;368(6490):473-4.

467. Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, and Bushman FD. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. *J Clin Invest.* 2020;130(2):673-85.

468. Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, Haris M, Wilson NE, Liu F, Gabunia K, Scholler J, Montine TJ, Bhoj VG, Reddy R, Mohan S, Maillard I, Kriegstein AR, June CH, Chang HY, Posey AD, Jr., and Satpathy AT. Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. *Cell.* 2020;183(1):126-42.e17.

469. Philipson BI, O'Connor RS, May MJ, June CH, Albelda SM, and Milone MC. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF- κ B signaling. *Science signaling.* 2020;13(625).

470. Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, and Gill SI. A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells. *Blood.* 2020;135(7):505-9.

471. Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, Weitzman MD, Frey NV, Maude SL, Grupp SA, June CH, Gill S, and Ruella M. Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. *Cancer Discov.* 2020;10(4):552-67.

472. Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, and June CH. CRISPR-engineered T cells in patients with refractory cancer. *Science.* 2020;367(6481).

473. Thakur A, Scholler J, Schalk DL, June CH, and Lum LG. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study. *J Cancer Res Clin Oncol.* 2020;146(8):2007-16.

474. Zhang Q, Orlando EJ, Wang HY, Bogusz AM, Liu X, Lacey SF, Strauser HT, Nunez-Cruz S, Nejati R, Zhang P, Brooks S, Watt C, Melenhorst JJ, June CH, Schuster SJ, and Wasik MA. Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome. *Blood.* 2020;136(17):1980-3.

475. Agarwal S, Wellhausen N, Levine BL, and June CH. Production of Human CRISPR-Engineered CAR-T Cells. *J Vis Exp*. 2021(169).
476. Bai Z, Lundh S, Kim D, Woodhouse S, Barrett DM, Myers RM, Grupp SA, Maus MV, June CH, Camara PG, Melenhorst JJ, and Fan R. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. *Journal for immunotherapy of cancer*. 2021;9(5).
477. Bernabei L, Tian L, Garfall AL, Melenhorst JJ, Lacey SF, Stadtmauer EA, Vogl DT, Gonzalez VE, Plesa G, Young RM, Waxman A, Levine BL, June CH, Milone MC, and Cohen AD. B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. *Br J Haematol*. 2021;193(4):851-5.
478. Chaudhury A, Zhu X, Chu L, Goliaei A, June CH, Kearns JD, and Stein AM. Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches. *J Clin Pharmacol*. 2020;60 Suppl 1:S147-s59.
479. Fajgenbaum DC, and June CH. Cytokine Storm. *N Engl J Med*. 2020;383(23):2255-73.
480. Wellhausen N, Agarwal S, Rommel PC, Gill SI, and June CH. Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy. *Curr Opin Immunol*. 2021;74:76-84.
481. Wang H, Chen H, Liu S, Zhang J, Lu H, Somasundaram R, Choi R, Zhang G, Ou L, Scholler J, Tian S, Dong L, Yeye G, Huang L, Connelly T, Li L, Huang A, Mitchell TC, Fan Y, June CH, Mills GB, Guo W, Herlyn M, and Xu X. Costimulation of $\gamma\delta$ TCR and TLR7/8 promotes V δ 2 T-cell antitumor activity by modulating mTOR pathway and APC function. *Journal for immunotherapy of cancer*. 2021;9(12).
482. Thakur A, Scholler J, Kubicka E, Bliemeister ET, Schalk DL, June CH, and Lum LG. Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells. *Front Immunol*. 2021;12:690437.
483. Tebas P, Jadowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, and Riley JL. CCR5-edited CD4⁺ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. *J Clin Invest*. 2021;131(7).
484. Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, Lacey SF, Roy NH, Burkhardt JK, Colomb F, Damra M, Abdel-Mohsen M, Liu T, Liu D, Standley DM, Young RM, Brogdon JL, Grupp SA, June CH, Maude SL, Gill S, and Ruella M. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. *Nat Med*. 2021;27(5):842-50.
485. Qazilbash MH, Saini NY, Soung-Chul C, Wang Z, Stadtmauer E, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura SJ, Zhang T, Anderson AJ, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen AD, Vogl DT, Dengel K, June CH, Champlin

RE, and Kwak LW. A Randomized Phase II Trial of Idiotypic Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. *Blood*. 2021.

486. Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, and Maude SL. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. *J Clin Oncol*. 2021;39(27):3044-55.

487. Manjunath SH, Cohen AD, Lacey SF, Davis MM, Garfall AL, Melenhorst JJ, Maxwell R, Arscott WT, Maity A, Jones JA, Plastaras JP, Stadtmauer EA, Levine BL, June CH, Milone MC, and Paydar I. The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. *Clin Cancer Res*. 2021;27(23):6580-90.

488. Levine JE, Grupp SA, Pulsipher MA, Dietz AC, Rives S, Myers GD, August KJ, Verneris MR, Buechner J, Laetsch TW, Bittencourt H, Baruchel A, Boyer MW, De Moerloose B, Qayed M, Davies SM, Phillips CL, Driscoll TA, Bader P, Schlis K, Wood PA, Mody R, Yi L, Leung M, Eldjerou LK, June CH, and Maude SL. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. *Journal for immunotherapy of cancer*. 2021;9(8).

489. Leahy AB, Newman H, Li Y, Liu H, Myers R, DiNofia A, Dolan JG, Callahan C, Baniewicz D, Devine K, Wray L, Aplenc R, June CH, Grupp SA, Rheingold SR, and Maude SL. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. *Lancet Haematol*. 2021;8(10):e711-e22.

490. Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M, Wang Y, Kulikovskaya I, Gupta M, Yoder T, DeNizio JE, Everett JK, Williams EF, Xu J, Scholler J, Reich TJ, Bhoj VG, Haines KM, Maus MV, Melenhorst JJ, Young RM, Jadowsky JK, Marcucci KT, Bradner JE, Levine BL, Porter DL, Bushman FD, Kohli RM, June CH, Davis MM, Lacey SF, Vahedi G, and Fraietta JA. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. *J Clin Invest*. 2021;131(16).

491. Johnson LR, Lee DY, Eacret JS, Ye D, June CH, and Minn AJ. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. *Cell*. 2021;184(19):4981-95.e14.

492. Jacobson JM, Jadowsky JK, Lacey SF, Fraietta JA, Plesa G, Chono H, Lee DH, Kulikovskaya I, Bartoszek C, Chen F, Tian L, Dimitri A, Levine BL, Veloso EA, Hwang WT, and June CH. Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. *Mol Ther*. 2021;29(2):626-35.

493. He X, Feng Z, Ma J, Zhang X, Ling S, Cao Y, Xing B, Wu Y, Wang L, Katona BW, June CH, and Hua X. CAR T cells targeting CD13 controllably induce eradication of acute myeloid leukemia with a single domain antibody switch. *Leukemia*. 2021;35(11):3309-13.

494. Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y, Tian L, Guedan S, Alexander KA, Zhang Z, Rommel PC, Singh N, Glastad KM, Richardson MW, Watanabe K, Tanyi JL, O'Hara MH, Ruella M, Lacey SF, Moon EK, Schuster SJ, Albelda SM, Lanier LL, Young RM, Berger SL, and June CH. An NK-like CAR T cell transition in CAR T cell dysfunction. *Cell*. 2021;184(25):6081-100.e26.
495. Gong N, Sheppard NC, Billingsley MM, June CH, and Mitchell MJ. Nanomaterials for T-cell cancer immunotherapy. *Nat Nanotechnol*. 2021;16(1):25-36.
496. Garcia-Canaveras JC, Heo D, Trefely S, Leferovich J, Xu C, Philipson BI, Ghassemi S, Milone MC, Moon EK, Snyder NW, June CH, Rabinowitz JD, and O'Connor RS. CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production. *Cells*. 2021;10(9).
497. Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, and Melenhorst JJ. Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nat Med*. 2021;27(3):561.
498. Fajgenbaum DC, and June CH. Cytokine Storm. Reply. *N Engl J Med*. 2021;384(16):e59.
499. Durgin JS, Henderson F, Jr., Nasrallah MP, Mohan S, Wang S, Lacey SF, Melenhorst JJ, Desai AS, Lee JYK, Maus MV, June CH, Brem S, O'Connor RS, Binder Z, and O'Rourke DM. Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. *Frontiers in oncology*. 2021;11:669071.
500. Dorff TB, Narayan V, Forman SJ, Zang PD, Fraietta JA, June CH, Haas NB, and Priceman SJ. Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer. *Clin Cancer Res*. 2021.
501. Chong EA, Ruella M, and Schuster SJ. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. *N Engl J Med*. 2021;384(7):673-4.
502. Bernabei L, Tian L, Garfall AL, Melenhorst JJ, Lacey SF, Stadtmauer EA, Vogl DT, Gonzalez VE, Plesa G, Young RM, Waxman A, Levine BL, June CH, Milone MC, and Cohen AD. B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. *Br J Haematol*. 2021;193(4):851-5.
503. Bai Z, Lundh S, Kim D, Woodhouse S, Barrett DM, Myers RM, Grupp SA, Maus MV, June CH, Camara PG, Melenhorst JJ, and Fan R. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. *Journal for immunotherapy of cancer*. 2021;9(5).
504. Agarwal S, Wellhausen N, Levine BL, and June CH. Production of Human CRISPR-Engineered CAR-T Cells. *J Vis Exp*. 2021(169).

505. Bai Z, Woodhouse S, Zhao Z, Arya R, Govek K, Kim D, Lundh S, Baysoy A, Sun H, Deng Y, Xiao Y, Barrett DM, Myers RM, Grupp SA, June CH, Fan R, Camara PG, and Melenhorst JJ. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. *Sci Adv.* 2022;8(23):eabj2820.
506. Baker DJ, and June CH. CAR T therapy extends its reach to autoimmune diseases. *Cell.* 2022;185(24):4471-3.
507. Billingsley MM, Hamilton AG, Mai D, Patel SK, Swingle KL, Sheppard NC, June CH, and Mitchell MJ. Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells. *Nano letters.* 2022;22(1):533-42.
508. Blumberg EA, Noll JH, Tebas P, Fraietta JA, Frank I, Marshall A, Chew A, Veloso EA, Carulli A, Rogal W, Gaymon AL, Schmidt AH, Barnette T, Jurek R, Martins R, Hudson BM, Chavda K, Bailey CM, Church SE, Noorchashm H, Hwang WT, June CH, and Hexner EO. A phase I trial of cyclosporine for hospitalized patients with COVID-19. *JCI insight.* 2022;7(11).
509. Castelli S, Young RM, and June CH. Off-the-shelf CAR T cells to treat cancer. *Cell Res.* 2022;32(12):1036-7.
510. Dhodapkar KM, Cohen AD, Kaushal A, Garfall AL, Manalo RJ, Carr AR, McCachren SS, Stadtmauer EA, Lacey SF, Melenhorst JJ, June CH, Milone MC, and Dhodapkar MV. Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. *Blood Cancer Discov.* 2022;3(6):490-501.
511. Diorio C, Shraim R, Myers R, Behrens EM, Canna S, Bassiri H, Aplenc R, Burudpakdee C, Chen F, DiNofia AM, Gill S, Gonzalez V, Lambert MP, Leahy AB, Levine BL, Lindell RB, Maude SL, Melenhorst JJ, Newman H, Perazzelli J, Seif AE, Lacey SF, June CH, Barrett DM, Grupp SA, and Teachey DT. Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. *Clin Cancer Res.* 2022;28(17):3804-13.
512. Dorff TB, Narayan V, Forman SJ, Zang PD, Fraietta JA, June CH, Haas NB, and Priceman SJ. Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer. *Clin Cancer Res.* 2022;28(4):576-84.
513. Feng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, Shan Q, Miller S, Hojnacki T, Ma J, Katona BW, Gade TPF, Schrader J, Metz DC, June CH, and Hua X. Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. *Nat Cancer.* 2022;3(5):581-94.
514. Finck AV, Blanchard T, Roselle CP, Golinelli G, and June CH. Engineered cellular immunotherapies in cancer and beyond. *Nat Med.* 2022;28(4):678-89.
515. Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R,

Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, and Stadtmauer EA. Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. *Blood Cancer Discov.* 2022.

516. Giles JR, Manne S, Freilich E, Oldridge DA, Baxter AE, George S, Chen Z, Huang H, Chilukuri L, Carberry M, Giles L, Weng NP, Young RM, June CH, Schuchter LM, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Huang AC, Shi J, and Wherry EJ. Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers. *Immunity.* 2022;55(3):557-74.e7.

517. Gill S, Vides V, Frey NV, Hexner EO, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon AL, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov M, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, and Porter DL. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. *Blood advances.* 2022;6(21):5774-85.

518. Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, Li P, Lin JX, Escuin-Ordinas H, Da T, Kremer SV, Sun AL, Castelli S, Agarwal S, Scholler J, Song D, Rommel PC, Radaelli E, Young RM, Leonard WJ, Ribas A, June CH, and Garcia KC. Potentiating adoptive cell therapy using synthetic IL-9 receptors. *Nature.* 2022;607(7918):360-5.

519. Lee IK, Noguera-Ortega E, Xiao Z, Todd L, Scholler J, Song D, Liouisa M, Lohith K, Xu K, Edwards KJ, Farwell MD, June CH, Albelda SM, Puré E, and Sellmyer MA. Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74. *Clin Cancer Res.* 2022;28(24):5330-42.

520. Mai D, June CH, and Sheppard NC. In vivo gene immunotherapy for cancer. *Sci Transl Med.* 2022;14(670):eabo3603.

521. Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, Gill SI, Loren AW, Tian L, Kulikovskaya I, Gupta M, Ambrose DE, Davis MM, Fraietta JA, Brogdon JL, Young RM, Chew A, Levine BL, Siegel DL, Alanio C, Wherry EJ, Bushman FD, Lacey SF, Tan K, and June CH. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. *Nature.* 2022;602(7897):503-9.

522. Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE, Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, and Haas NB. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. *Nat Med.* 2022;28(4):724-34.

523. Newman H, Li Y, Liu H, Myers RM, Tam V, DiNofia A, Wray L, Rheingold SR, Callahan C, White C, Baniewicz D, Winestone LE, Kadauke S, Diorio C, June CH, Getz K, Aplenc R, Teachey DT,

- Maude SL, Grupp SA, Bona K, and Barz Leahy A. Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. *Blood*. 2022.
524. Qazilbash MH, Saini NY, Cha SC, Wang Z, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura S, Zhang T, Anderson A, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen A, Vogl DT, Dengel K, June CH, Champlin R, and Kwak LW. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. *Blood*. 2022;139(9):1289-301.
525. Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK, Mui BL, Albelda SM, Puré E, June CH, Aghajanian H, Weissman D, Parhiz H, and Epstein JA. CAR T cells produced in vivo to treat cardiac injury. *Science*. 2022;375(6576):91-6.
526. Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, and Ruella M. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. *Nat Med*. 2022;28(4):713-23.
527. Smole A, Benton A, Poussin MA, Eiva MA, Mezzanotte C, Camisa B, Greco B, Sharma P, Minutolo NG, Gray F, Bear AS, Baroja ML, Cummins C, Xu C, Sanvito F, Goldgewicht AL, Blanchard T, Rodriguez-Garcia A, Klichinsky M, Bonini C, June CH, Posey AD, Jr., Linette GP, Carreno BM, Casucci M, and Powell DJ, Jr. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. *Cancer Cell*. 2022;40(12):1470-87.e7.
528. Uslu U, and June CH. CAR T-cell Therapy Meets Clonal Hematopoiesis. *Blood Cancer Discov*. 2022;3(5):382-4.
529. Wellhausen N, Agarwal S, Rommel PC, Gill SI, and June CH. Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy. *Curr Opin Immunol*. 2022;74:76-84.
530. Young RM, Engel NW, Uslu U, Wellhausen N, and June CH. Next-Generation CAR T-cell Therapies. *Cancer Discov*. 2022;12(7):1625-33. (531-555)
531. June CH. The Unlikely Development of CAR T Cells: a Brief History and Prospects for the Future. *Keio J Med*. 2023;72(1):26.
532. Haas AR, Golden RJ, Litzky LA, Engels B, Zhao L, Xu F, Taraszka JA, Ramones M, Granda B, Chang WJ, Jadowsky J, Shea KM, Runkle A, Chew A, Dowd E, Gonzalez V, Chen F, Liu X, Fang C, Jiang S, Davis MM, Sheppard NC, Zhao Y, Fraietta JA, Lacey SF, Plesa G, Melenhorst JJ, Mansfield K, Brogdon JL, Young RM, Albelda SM, June CH, and Tanyi JL. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. *Mol Ther*. 2023;31(8):2309-25.

533. Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, Kopp M, Li Y, Pattada N, Zhong W, Guo W, Scholler J, Liouisia M, Assenmacher CA, June CH, Albelda SM, and Puré E. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. *bioRxiv*. 2023.
534. Zhong W, Xiao Z, Qin Z, Yang J, Wen Y, Yu Z, Li Y, Sheppard NC, Fuchs SY, Xu X, Herlyn M, June CH, Puré E, and Guo W. Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors. *Cancer Res*. 2023;83(16):2790-806.
535. Glisovic-Aplenc T, Diorio C, Chukinas JA, Veliz K, Shestova O, Shen F, Nunez-Cruz S, Vincent TL, Miao F, Milone MC, June CH, Teachey DT, Tasian SK, Aplenc R, and Gill S. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. *Blood advances*. 2023;7(16):4418-30.
536. Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, Kopp M, Li Y, Pattada N, Zhong W, Guo W, Scholler J, Liouisia M, Assenmacher CA, June CH, Albelda SM, and Puré E. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. *Nature communications*. 2023;14(1):5110.
537. Tang Y, Liu W, Kadu S, Johnson O, Hasanali ZS, Kelly AR, Shestov AA, Greenblat E, Holmes M, Wang LP, Shih N, O'Connor RS, Garfall A, Allman D, Vogl DT, Cohen AD, June CH, and Sheppard NC. Exploiting the CD200-CD200R Immune Checkpoint Axis in Multiple Myeloma to Enhance CAR-T Therapy. *Blood*. 2023.
538. Hamilton AG, Swingle KL, Joseph RA, Mai D, Gong N, Billingsley MM, Alameh MG, Weissman D, Sheppard NC, June CH, and Mitchell MJ. Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering. *Adv Healthc Mater*. 2023;12(30):e2301515.
539. Newman H, Li Y, Liu H, Myers RM, Tam V, DiNofia A, Wray L, Rheingold SR, Callahan C, White C, Baniewicz D, Winestone LE, Kadauke S, Diorio C, June CH, Getz KD, Aplenc R, Teachey DT, Maude SL, Grupp SA, Bona K, and Leahy AB. Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. *Blood*. 2023;141(6):609-19.
540. Uslu U, Da T, Assenmacher CA, Scholler J, Young RM, Tchou J, and June CH. Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma. *Sci Adv*. 2023;9(2):eade2526.
541. Baker DJ, Arany Z, Baur JA, Epstein JA, and June CH. CAR T therapy beyond cancer: the evolution of a living drug. *Nature*. 2023;619(7971):707-15.
542. Uslu U, and June CH. T-cell Therapies Targeting Multiple Cancer Antigens: The Power of Many. *Cancer Immunol Res*. 2023;11(7):865.
543. Watanabe K, Gomez AM, Kuramitsu S, Siurala M, Da T, Agarwal S, Song D, Scholler J, Rotolo A, Posey AD, Rook AH, Haun PL, Ruella M, Young RM, and June CH. Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma. *Blood advances*. 2023;7(14):3416-30.

544. Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, and Stadtmauer EA. Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy. *Blood Cancer Discov.* 2023;4(2):118-33.
545. Uribe-Herranz M, Beghi S, Ruella M, Parvathaneni K, Salaris S, Kostopoulos N, George SS, Pierini S, Krimitz E, Costabile F, Ghilardi G, Amelsberg KV, Lee YG, Pajarillo R, Markmann C, McGettigan-Croce B, Agarwal D, Frey N, Lacey SF, Scholler J, Gabunia K, Wu G, Chong E, Porter DL, June CH, Schuster SJ, Bhoj V, and Facciabene A. Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy. *Mol Ther.* 2023;31(3):686-700.
546. Mai D, Johnson O, Reff J, Fan TJ, Scholler J, Sheppard NC, and June CH. Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells. *Proc Natl Acad Sci U S A.* 2023;120(12):e2218632120.
547. Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, Zhang P, Tchou J, Matlawski T, Cervini A, Shea J, Gilmore J, Lledo L, Dengel K, Marshall A, Wherry EJ, Linette GP, Brennan A, Gonzalez V, Kulikovskaya I, Lacey SF, Plesa G, June CH, Vonderheide RH, and Mitchell TC. Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. *Cancer Res Commun.* 2023;3(5):821-9.
548. Noll JH, Levine BL, June CH, and Fraietta JA. Beyond youth: Understanding CAR T cell fitness in the context of immunological aging. *Semin Immunol.* 2023;70:101840.
549. Zhang C, Kadu S, Xiao Y, Johnson O, Kelly A, O'Connor RS, Lai M, Kong H, Srivatsa S, Tai V, Greenblatt E, Holmes M, Riley JL, June CH, and Sheppard NC. Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function. *Cancer Immunol Res.* 2023;11(11):1524-37.
550. Bobisse S, Bianchi V, Tanyi JL, Sarivalasis A, Missiaglia E, Pétremand R, Benedetti F, Torigian DA, Genolet R, Barras D, Michel A, Mastroiannis SA, Zsiros E, Dangaj Laniti D, Tsourti Z, Stevenson BJ, Iseli C, Levine BL, Speiser DE, Gfeller D, Bassani-Sternberg M, Powell DJ, Jr., June CH, Dafni U, Kandalaft LE, Harari A, and Coukos G. A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer. *Nat Cancer.* 2023;4(10):1410-7.
551. Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, Gohil M, Chen L, Hong SA, Ravikumar P, Rennels AK, Salas-Mckee J, Kong W, Ruella M, Davis MM, Plesa G, Fraietta JA, Porter DL, Young RM, and June CH. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. *Immunity.* 2023;56(10):2388-407.e9.
552. Tsuchida CA, Brandes N, Bueno R, Trinidad M, Mazumder T, Yu B, Hwang B, Chang C, Liu J, Sun Y, Hopkins CR, Parker KR, Qi Y, Hofman L, Satpathy AT, Stadtmauer EA, Cate JHD, Eyquem J,

Fraietta JA, June CH, Chang HY, Ye CJ, and Doudna JA. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. *Cell*. 2023;186(21):4567-82.e20.

553. Wellhausen N, O'Connell RP, Lesch S, Engel NW, Rennels AK, Gonzales D, Herbst F, Young RM, Garcia KC, Weiner D, June CH, and Gill SI. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. *Sci Transl Med*. 2023;15(714):eadi1145.

554. Amit U, Uslu U, Verginadis, II, Kim MM, Motlagh SAO, Diffenderfer ES, Assenmacher CA, Bicher S, Atoche SJ, Ben-Josef E, Young RM, June CH, and Koumenis C. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer. *Proc Natl Acad Sci U S A*. 2024;121(31):e2403002121.

555. Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, Nabavizadeh A, Jarocho D, Martins R, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz R, Jadowsky JK, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Sun Y, Gladney W, Barrett D, Nasrallah MP, Hwang WT, Ming GL, Song H, Siegel DL, June CH, Hexner EO, Binder ZA, and O'Rourke DM. Intrathecal bivalent CAR T cells targeting EGFR and IL13R α 2 in recurrent glioblastoma: phase 1 trial interim results. *Nat Med*. 2024;30(5):1320-9.

556. Bai Z, Feng B, McClory SE, de Oliveira BC, Diorio C, Gregoire C, Tao B, Yang L, Zhao Z, Peng L, Sferruzza G, Zhou L, Zhou X, Kerr J, Baysoy A, Su G, Yang M, Camara PG, Chen S, Tang L, June CH, Melenhorst JJ, Grupp SA, and Fan R. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. *Nature*. 2024;634(8034):702-11.

557. Baker DJ, and June CH. Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases. *Cell*. 2024;187(18):4826-8.

558. Berjis A, Muthumani D, Aguilar OA, Pomp O, Johnson O, Finck AV, Engel NW, Chen L, Plachta N, Scholler J, Lanier LL, June CH, and Sheppard NC. Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation. *Nature communications*. 2024;15(1):3937.

559. Berjis A, Muthumani D, Sheppard NC, and June CH. Swiss army knife T cell: one T cell many tumor targets. *Cell Res*. 2024;34(1):5-6.

560. Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, Farooki SN, Frost BF, Loken MR, Gaymon AL, Frazee D, Rogal W, Frey N, Hexner EO, Luger SM, Loren AW, Martin ME, McCurdy SR, Perl AE, Stadtmauer EA, Brogdon JL, Fraietta JA, Hwang WT, Siegel DL, Plesa G, Aplenc R, Porter DL, June CH, and Gill SI. Cytokine-mediated CAR T therapy resistance in AML. *Nat Med*. 2024;30(12):3697-708.

561. Chang JF, Wellhausen N, Engel NW, Landmann JH, Hopkins CR, Salas-McKee J, Bear AS, Selli ME, Agarwal S, Jadowsky JK, Linette GP, Gill S, June CH, Fraietta JA, and Singh N. Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors. *Cancer Immunol Res*. 2024;12(9):1136-46.

562. Feng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, Shan Q, Miller S, Hojnacki T, Ma J, Katona BW, Gade TPF, Siegel DL, Schrader J, Metz DC, June CH, and Hua X. Author Correction: Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. *Nat Cancer*. 2024;5(4):691.
563. Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrisette JJD, Caponetti GC, Paruzzo L, Harris JC, Chong EA, Susanibar Adaniya SP, Svoboda J, Nasta SD, Ugwuanyi OH, Landsburg DJ, Fardella E, Waxman AJ, Chong ER, Patel V, Pajarillo R, Kulikovskaya I, Lieberman DB, Cohen AD, Levine BL, Stadtmauer EA, Frey NV, Vogl DT, Hexner EO, Barta SK, Porter DL, Garfall AL, Schuster SJ, June CH, and Ruella M. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. *Nat Med*. 2024;30(4):984-9.
564. Gong N, Han X, Xue L, Billingsley MM, Huang X, El-Mayta R, Qin J, Sheppard NC, June CH, and Mitchell MJ. Author Correction: Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager. *Nat Biomed Eng*. 2024;8(5):664.
565. Gong N, Han X, Xue L, Billingsley MM, Huang X, El-Mayta R, Qin J, Sheppard NC, June CH, and Mitchell MJ. Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager. *Nat Biomed Eng*. 2024;8(5):513-28.
566. Jadowsky JK, Chang JF, Spencer DH, Warrington JM, Levine BL, June CH, Fraietta JA, and Singh N. Regulatory Considerations for Genome-Edited T-cell Therapies. *Cancer Immunol Res*. 2024;12(9):1132-5.
567. Jadowsky JK, Leskowitz R, McKenna S, Karar J, Ma Y, Dai A, Plesa G, Chen F, Alexander K, Petrella J, Gong N, Hwang WT, Farrelly O, Barber-Rotenberg J, Christensen S, Gonzalez VE, Chew A, Fraietta JA, and June CH. Long-term stability of clinical-grade lentiviral vectors for cell therapy. *Mol Ther Methods Clin Dev*. 2024;32(1):101186.
568. Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, Ciceri F, Ruggeri A, Snowden J, Heslop HE, Mackall CL, June CH, Sureda AM, and Perales MA. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. *Nat Med*. 2024;30(2):338-41.
569. Mai D, Boyce T, Mehta A, Reff J, Scholler J, Sheppard NC, and June CH. ZFP36 disruption is insufficient to enhance the function of mesothelin-targeting human CAR-T cells. *Scientific reports*. 2024;14(1):3113.
570. Mai D, Harro C, Sanyal A, Rommel PC, Sheppard NC, and June CH. Stem Loop Mediated Transgene Modulation in Human T Cells. *ACS Synth Biol*. 2024;13(12):3897-907.
571. Metzloff AE, Padilla MS, Gong N, Billingsley MM, Han X, Merolle M, Mai D, Figueroa-Espada CG, Thatte AS, Haley RM, Mukalel AJ, Hamilton AG, Alameh MG, Weissman D, Sheppard NC, June CH, and Mitchell MJ. Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy. *Adv Mater*. 2024;36(26):e2313226.

572. Myers RM, Devine K, Li Y, Lawrence S, Leahy AB, Liu H, Vernau L, Callahan C, Baniewicz D, Kadauke S, McGuire R, Wertheim GB, Kulikovskaya I, Gonzalez VE, Fraietta JA, DiNofia AM, Hunger SP, Rheingold SR, Aplenc R, June CH, Grupp SA, Wray L, and Maude SL. Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia. *Blood advances*. 2024;8(9):2182-92.
573. O'Connell RP, Liaw K, Wellhausen N, Chuckran CA, Bhojnagarwala PS, Bordoloi D, Park D, Shupin N, Kulp D, June CH, and Weiner D. Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma. *Journal for immunotherapy of cancer*. 2024;12(6).
574. Posey AD, Jr., Young RM, and June CH. Future perspectives on engineered T cells for cancer. *Trends in cancer*. 2024;10(8):687-95.
575. Roselle C, Horikawa I, Chen L, Kelly AR, Gonzales D, Da T, Wellhausen N, Rommel PC, Baker D, Suhoski M, Scholler J, O'Connor RS, Young RM, Harris CC, and June CH. Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with $\Delta 133p53\alpha$. *Proc Natl Acad Sci U S A*. 2024;121(10):e2317735121.
576. Ruella M, and June CH. CAR T-cell Resistance to Oncogenic Transformation. *Blood Cancer Discov*. 2024;5(4):229-33.
577. Schett G, and June CH. CAR T cells in autoimmune disease: On the road to remission. *Immunity*. 2024;57(12):2705-9.
578. Schett G, Müller F, Taubmann J, Mackensen A, Wang W, Furie RA, Gold R, Haghighi A, Merkel PA, Caricchio R, D'Agostino MA, Locatelli F, June CH, and Mougiakakos D. Advancements and challenges in CAR T cell therapy in autoimmune diseases. *Nat Rev Rheumatol*. 2024;20(9):531-44.
579. Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, and Powell DJ, Jr. Editor's Note: In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB). *Cancer Res*. 2024;84(4):639.
580. Tang Y, Liu W, Kadu S, Johnson O, Hasanali ZS, Kelly A, Shestov A, Pajarillo R, Greenblatt E, Holmes M, Wang LP, Shih N, O'Connor RS, Ruella M, Garfall AL, Allman D, Vogl DT, Cohen A, June CH, and Sheppard NC. Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy. *Blood*. 2024;143(2):139-51.
581. Tebas P, Jadowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, and Riley JL. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. *J Clin Invest*. 2024;134(9).
582. Tilsed CM, Sadiq BA, Papp TE, Areesawangkit P, Kimura K, Noguera-Ortega E, Scholler J, Cerda N, Aghajanian H, Bot A, Mui B, Tam Y, Weissman D, June CH, Albelda SM, and Parhiz H. IL7

increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation. *Proc Natl Acad Sci U S A*. 2024;121(13):e2319856121.

583. Uslu U, Castelli S, and June CH. CAR T cell combination therapies to treat cancer. *Cancer Cell*. 2024;42(8):1319-25.

584. Uslu U, and June CH. Beyond the blood: expanding CAR T cell therapy to solid tumors. *Nat Biotechnol*. 2024.

585. Uslu U, Sun L, Castelli S, Finck AV, Assenmacher CA, Young RM, Chen ZJ, and June CH. The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion. *Nature communications*. 2024;15(1):3933.

586. Vittayawacharin P, Kongtim P, Chu Y, June CH, Bollard CM, and Ciurea SO. Adoptive cellular therapy after hematopoietic stem cell transplantation. *Am J Hematol*. 2024;99(5):910-21.

587. Wellhausen N, Baek J, Gill SI, and June CH. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance. *Nature reviews Cancer*. 2024;24(9):614-28.

588. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, and June CH. Editor's Note: Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor. *Cancer Res*. 2024;84(21):3702.

589. Baker DJ, Levine BL, and June CH. Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells. *Lancet*. 2025;405(10480):751-4.

590. Uslu U, and June CH. Beyond the blood: expanding CAR T cell therapy to solid tumors. *Nat Biotechnol*. 2025;43(4):506-15.

591. Jadowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, and Fraietta JA. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. *Nat Med*. 2025;31(4):1134-44.

592. Blanchard T, Faridi P, Xu C, Bear AS, Rasool RU, Huang G, Lim TCC, Ayala R, Gabunia K, Ji M, Posey AD, Jr., Scholler J, Asangani IA, Purcell AW, Linette GP, June CH, and Carreno BM. LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma. *Scientific reports*. 2025;15(1):13007.

593. Myers RM, DiNofia AM, Li Y, Diorio C, Liu H, Wertheim G, Fraietta JA, Gonzalez V, Plesa G, Siegel DL, Iannone E, Shinehouse L, Brogdon JL, Taylor C, Jadowsky JK, Hexner EO, Engels B, Baniewicz D, Callahan C, Ruella M, Aplenc R, Barz Leahy A, McClory SE, Rheingold SR, Wray L,

June CH, Maude SL, Frey NV, and Grupp SA. CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy. *Journal for immunotherapy of cancer*. 2025;13(4).

594. Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, and June C. From concept to cure: The evolution of CAR-T cell therapy. *Mol Ther*. 2025;33(5):2123-40.

595. Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, and June CH. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. *N Engl J Med*. 2025;392(18):1824-35.

596. Murad JP, Christian L, Rosa R, Ren Y, Lee EHJ, Lopez LS, Park AK, Yang J, Trac C, Adkins LN, Chang WC, Martinez C, June CH, Forman SJ, Ishihara J, Lee JK, Stern LA, and Priceman SJ. Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery. *bioRxiv*. 2025.

597. Engel NW, Steinfeld I, Ryan D, Anupindi K, Kim S, Wellhausen N, Chen L, Wilkins K, Baker DJ, Rommel PC, Jarocha D, Gohil M, Zhang Q, Milone MC, Fraietta JA, Davis M, Young RM, and June CH. Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells. *Proc Natl Acad Sci U S A*. 2025;122(20):e2427216122.

598. Shukla D, Gabunia K, McGettigan SE, Patel PR, Christensen S, Fan TJ, Song D, Luo Y, Wang Y, Wang H, Young RM, June CH, Scholler J, and Riley JL. CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target. *Cancer Immunol Res*. 2025;13(6):867-80.

599. Cabanski CR, Yang E, Stewart MD, Allen JD, Connolly JE, Dugan U, Greenberg PD, Mackall CL, June CH, Marson A, Maus MV, and Ribas A. Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials. *Journal for immunotherapy of cancer*. 2025;13(6).

600. Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A, Li JJ, Soldevila F, Chu DSH, Nguyen DP, Yong QC, Ross B, Nguyen M, Vestal J, Roberts S, Galvan D, Vega JB, Jhung D, Butcher M, Nguyen J, Zhang S, Fernandez C, Chen J, Herrera C, Kuo Y, Pica EM, Mondal G, Mammen AL, Scholler J, Tanis SP, Sievers SA, Frantz AM, Adams GB, Shawver L, Farzaneh-Far R, Rosenzweig M, Karmali PP, Bot AI, June CH, and Aghajanian H. In vivo CAR T cell generation to treat cancer and autoimmune disease. *Science*. 2025;388(6753):1311-7.

601. Zhong W, Qin Z, Yu Z, Yang J, Yan D, Engel NW, Sheppard NC, Fan Y, Radhakrishnan R, Xu X, Ma L, Fuchs SY, June CH, and Guo W. Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors. *Nat Cancer*. 2025;6(7):1157-72.

602. Anupindi K, Malachowski J, Hodson I, Zhu D, June CH, and Levine BL. The next innovations in chimeric antigen receptor T cell immunotherapies for cancer. *Cytotherapy*. 2025;27(7):795-811.

603. Cook DR, Boesteanu AC, Yin Y, Reid R, Roccograndi L, Dahmane N, Martinez-Lage M, O'Rourke DM, June CH, and Johnson LA. Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM. *Front Immunol.* 2025;16:1579925.
604. Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, Gopikrishna GK, Rech AJ, Nabavizadeh A, Bagley LJ, Park J, Jarocho D, Martins R, Sarmiento N, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz RM, Jadowsky JK, Mackey S, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Barrett D, Colbourn R, Nasrallah MP, Mourelatos Z, Hwang WT, Alanio C, Siegel DL, June CH, Hexner EO, Binder ZA, and O'Rourke DM. Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R α 2 in recurrent glioblastoma: a phase 1 trial. *Nat Med.* 2025;31(8):2778-87.
605. Scholler J, Song A, Deshmukh M, Song D, June CH, and Siegel DL. Engineering a Juxtamembrane-Targeting CAR T-Cell Against Mesothelin: A Novel Binder Resilient to Shed Antigen in Ovarian and Pancreatic Cancer. *bioRxiv.* 2025.
606. Nakamichi S, Yamada L, Roselle C, Horikawa I, June CH, and Harris CC. The senescence-inhibitory p53 isoform Δ 133p53 α : enhancing cancer immunotherapy and exploring novel therapeutic approaches for senescence-associated diseases. *Geroscience.* 2025.
607. Svoboda J, Hexner E, and June CH. Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. Reply. *N Engl J Med.* 2025;393(6):620.
608. Golinelli G, Scholler J, Roussel-Gervais A, Šakić A, Ilmjärv S, Song D, Gabunia K, Ji M, Fan TJ, Gupta A, Deshmukh M, Berjis A, Cuoghi Costantini R, Apodaca K, Sheppard NC, Kili S, Dominici M, Alessandrini M, June CH, and Levine BL. Multiplex engineering using microRNA-mediated gene silencing in CAR T cells. *Front Immunol.* 2025;16:1647433.
609. Obiozor CC, Day LW, Dube B, Edrah IE, Uzoka E, June CH, Levine BL, and Sammut SM. Cellular gene therapy access in Africa: a multifactorial feasibility analysis for implementation. *Cytotherapy.* 2025;27(9):1085-93.
610. Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, Gopikrishna GK, Rech AJ, Nabavizadeh A, Bagley LJ, Park J, Jarocho D, Martins R, Sarmiento N, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz RM, Jadowsky JK, Mackey S, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Barrett D, Colbourn R, Nasrallah MP, Mourelatos Z, Hwang WT, Alanio C, Siegel DL, June CH, Hexner EO, Binder ZA, and O'Rourke DM. Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R α 2 in recurrent glioblastoma: a phase 1 trial. *Nat Med.* 2025;31(9):3205.
611. June CH, and Aghajanian H. From bench to bloodstream: Lipid nanoparticles drive on-demand CAR-T cells. *Mol Ther.* 2025;33(9):4036-7.
612. Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang WT, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadowsky JK, Young RM, Berger SL, June CH, and O'Hara MH. Clinical

and molecular dissection of CAR T cell resistance in pancreatic cancer. *Cell Rep Med*. 2025;6(9):102301.

613. Bot A, Scharenberg A, Friedman K, Guey L, Hofmeister R, Andorko JI, Klichinsky M, Neumann F, Shah JV, Swayer AJ, Trudeau K, Weissman D, Stephan MT, Buchholz CJ, and June CH. In vivo chimeric antigen receptor (CAR)-T cell therapy. *Nat Rev Drug Discov*. 2025.
614. Murad JP, Christian L, Rosa R, Ren Y, Buckley AJ, Lee EHJ, Lopez LS, Park AK, Yang J, Yamaguchi Y, Trac C, Adkins LN, Chang WC, Martinez C, June CH, Forman SJ, Ishihara J, Lee JK, Stern LA, and Priceman SJ. Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. *Nat Biomed Eng*. 2025.
615. Lamplugh ZL, Wellhausen N, June CH, and Fan Y. Microenvironmental regulation of solid tumour resistance to CAR T cell therapy. *Nat Rev Immunol*. 2025.
616. Ramírez-Fernández Á, Dimitri AJ, Chen F, Bartoszek R, Chen GM, Córdoba-Espejo L, Zhou Y, Tang YH, Lin CT, Acosta R, Scholler J, Ghilardi G, Porazzi P, Pellicer M, Profitós-Pelejà N, Barta SK, Chew A, Jadowsky JK, Gonzalez VE, Siegel DL, Levine BL, Roué G, Ruella M, Lotze MT, June CH, Riley JL, and Fraietta JA. CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy. *Nat Biomed Eng*. 2025.
617. Castelli S, Wilson WV, Uslu U, Finck AV, Rommel PC, Assenmacher CA, Atoche SJ, Siurala M, Aznar MA, Young RM, and June CH. IL-9 signaling redirects CAR T cell fate toward CD8(+) memory and CD4(+) cycling states, enhancing antitumor efficacy. *Immunity*. 2026;59(1):195-212.e11.
618. Tilsed CM, Fong KP, Shi X, Akimova T, Wang L, Noguera-Ortega E, Krouse R, Bermudez A, Singhal S, Young RM, Eruslanov E, Watanabe K, Hancock WW, June CH, and Albelda S. CAR T cells targeting C-C motif chemokine receptor 4 (CCR4) selectively deplete human Tregs ex vivo and in vivo. *Blood advances*. 2025.
619. Wang H, Liu S, Sinha P, Liu F, Zhang X, Guo Y, Goncalves B, Zheng Q, Mou H, Yang J, Huang L, Miao F, Zeng T, Karakousis G, Huang AC, Mitchell T, Amaravadi R, Schuchter L, Milone M, Guo W, June C, Herlyn M, Fan Y, and Xu X. DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity. *Mol Ther*. 2025.
620. Finck AV, Wang Z, Gonzales D, Wellhausen N, Castelli S, Banerjee E, Aznar MA, Young RM, and June CH. Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy. *Proc Natl Acad Sci U S A*. 2025;122(51):e2518996122.
621. Rommel PC, Engel NW, Malachowski JK, Shukla D, Hodson IR, Gonzales D, van der Loo JCM, Young RM, Riley JL, Levine BL, and June CH. Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations. *Journal for immunotherapy of cancer*. 2026;14(1).

Research Publications, peer-reviewed reviews (partial listing):

1. Ertl Hildegund C J, Zaia John, Rosenberg Steven A, June Carl H, Dotti Gianpietro, Kahn Jeffrey, Cooper Laurence J N, Corrigan-Curay Jacqueline, Strome Scott E: Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. *Cancer Research* 71(9): 3175-81, May 2011.
2. June Carl H, Levine Bruce L: T cell engineering as therapy for cancer and HIV: our synthetic future. *Philosophical transactions of the Royal Society of London. Series B, Biological sciences* 370(1680): 20140374, Oct 2015.
3. Maus Marcela V, June Carl H: Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research* 22(8): 1875-84, Apr 2016.
4. Fesnak Andrew D, June Carl H, Levine Bruce L: Engineered T cells: the promise and challenges of cancer immunotherapy. *Nature reviews. Cancer* 16(9): 566-81, 08 2016.
5. June Carl H: Remote Controlled CARs: Towards a Safer Therapy for Leukemia. *Cancer immunology research* 4(8): 643, 08 2016.
6. Lederman Michael M, Cannon Paula M, Currier Judith S, June Carl H, Kiem Hans Peter, Kuritzkes Daniel R, Lewin Sharon R, Margolis David M, McCune Joseph M, Mellors John W, Schacker Timothy W, Sekaly Rafick P, Tebas Pablo, Walker Bruce D, Douek Daniel C: A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? *Pathogens & immunity* 1(1): 154-164, 2016.
7. Lim Wendell A, June Carl H: The Principles of Engineering Immune Cells to Treat Cancer. *Cell* 168(4): 724-740, Feb 2017.
8. Posey Avery D, June Carl H, Levine Bruce L: Cancer Killers. *Scientific American* 316(3): 38-43, Feb 2017.
9. Sampson John H, Maus Marcela V, June Carl H: Immunotherapy for Brain Tumors. *Journal of Clinical Oncology* 35(21): 2450-2456, Jul 2017.

Editorials, Reviews, Chapters, including participation in committee reports (print or other media):

1. June CH., Rabinovitch PS.: Flow cytometric measurement of cellular ionized calcium concentration. [Review] [91 refs] *Pathology & Immunopathology Research* 7(5): 409-32, 1988.
2. June CH., Rabinovitch PS.: Flow cytometric measurement of intracellular ionized calcium in single cells with indo-1 and fluo-3. [Review] [55 refs] *Methods in Cell Biology* 33: 37-58, 1990.
3. June CH., Rabinovitch PS.: Intracellular ionized calcium. [Review] [63 refs] *Methods in Cell Biology* 41: 149-74, 1994.
4. June C.H., Abe R., Rabinovitch P.S.: Measurement of intracellular calcium ions by flow cytometry. *Curr Protoc Cytom Chapter 9(Unit 9.8)*, 2001 Notes: PMID: 18770760

5. Yeh H., June CH.: Use of cell-based therapies for modification of host immune responses. [Review] [16 refs] *Developments in Biologicals* 112: 99-104, 2003.
6. June, Carl H. Moore, Jonni S.: Measurement of intracellular ions by flow cytometry. [Review] [58 refs] *Current Protocols in Immunology*(Chapter 5), Unit 5.5, Dec 2004.
7. Aqui Nicole A, June Carl H: Post-transplant adoptive T-cell immunotherapy. Best practice & research. *Clinical haematology* 21(3): 503-19, Sep 2008.
8. Lotze MT, Mapara MY, June CH.: Tumor immunology and immunotherapy. In *Clinical Immunology: principles and practice*. R.R. Rich, Fleisher, T.A., Shearer, W., Schroeder H.W., Frew A.J., and Weyand C.M. (eds.). Mosby/Elsevier, Page: 1181-1198, 2008.
9. June C., Holland S.: Fulfilling the promise of immunology for human health. *Clin Immunol* 132(2): 155-156, Nov 2009.
10. Lesinski Gregory B, Carson William E, Repasky Elizabeth A, Wei Wei-zen, Kalinski Pawel, Lotze Michael T, June Carl H, Petros William, Muthusamy Natarajan, Olencki Thomas: Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010. *Journal of immunotherapy* (Hagerstown, Md. : 1997) 33(7): 659-62, Sep 2010.
11. Bishop Michael R, Alyea Edwin P, Cairo Mitchell S, Falkenburg J H Frederik, June Carl H, Kröger Nicolaus, Little Richard F, Miller Jeffrey S, Pavletic Steven Z, Porter David L, Riddell Stanley R, van Besien Koen, Wayne Alan S, Weisdorf Daniel J, Wu Roy S, Giralt Sergio: National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. *Biology of Blood and Marrow Transplantation* 17(4): 443-54, Apr 2011.
12. Hoxie, J.A., June, C. H.: Novel Cell and Gene Therapies for HIV. HIV: from Biology to Prevention and Treatment. F.D. Bushman, G.J.Nabel, and R. Swanstrom (eds.). Cold Spring Harbor Press, Page: 345-365, 2011 Notes: articles online at www.perspectivesinmedicine.org.

Books:

[none]

Alternative Media:

[none]

Patents: (downloaded from Google Patents)

1. Zhao Y, Ren J, Liu X, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. Altering Gene Expression in Modified T Cells and Uses Thereof. US-2022154190-A1. 5/19/2022.
2. Siurala M, June CH, Posey A, Ribas A, Kalbasi A, inventors; The Trustees of The University of Pennsylvania; The Regents of The University of California, assignee. Selective stimulation of T cells in solid tumors using oncolytic viral delivery of orthogonal IL-2. WO-2022192346-A1. 9/15/2022.
3. Mitchell M, Billingsley M, Singh N, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. Lipid Nanoparticles and Formulations Thereof for CAR mRNA Delivery. US-2022378700-A1. 12/1/2022.
4. June CH, Zhao Y, inventors; The Trustees of The University of Pennsylvania, assignee. RNA engineered t cells for the treatment of cancer. US-2022170012-A1. 6/2/2022.
5. June CH, Young RM, Berger SL, Good CR, Gomez MAA, Kuramitsu S, inventors; The Trustees of The University of Pennsylvania, assignee. Compositions and methods for assessing and treating T cell dysfunction. WO-2022192249-A2. 9/15/2022.
6. June CH, Watanabe K, Young RM, Scholler J, Nishikawa H, inventors; The Trustees of The University of Pennsylvania; National Cancer Center, assignee. CCR4-targeting chimeric antigen receptor cell therapy. WO-2022173950-A1. 8/18/2022.
7. June CH, Powell DJ, JR., inventors; Novartis Ag; The Trustees of The University of Pennsylvania, assignee. CAR-expressing cells against multiple tumor antigens and uses thereof. US-2022089750-A1. 3/24/2022.
8. June CH, Liu X, Zhao Y, inventors; The Trustees of The University of Pennsylvania, assignee. Compositions and methods for T cell delivery of therapeutic molecules. AU-2021290352-A1. 2/3/2022.
9. June CH, Kalos MD, Levine BL, Milone MC, Porter DL, inventors; The Trustees of the University of Pennsylvania of Center For Technology Transfer, assignee. Use of chimeric antigen receptor-modified t cells to treat cancer. AU-2022201895-A1. 4/7/2022.
10. Johnson LR, Minn A, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. CAR-T delivery of synthetic peptide therapeutics. WO-2022204474-A1. 9/29/2022.
11. Gill S, Klichinsky M, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof. US-2022281947-A1. 9/8/2022.
12. Gill S, June CH, Klichinsky M, inventors; The Trustees of The University of Pennsylvania, assignee. Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof. AU-2022263479-A1. 12/8/2022.

13. Frigault MJ, Zhao Y, Scholler J, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer. US-2022056116-A1. 2/24/2022.
14. Byrd J, Dubovsky J, Fraietta J, Gill S, Glass D, Johnson A, et al., inventors; Novartis Ag; The Trustees of The University of Pennsylvania, assignee. Treatment of cancer using anti-CD19 chimeric antigen receptor. AU-2022200288-A1. 2/10/2022.
15. Brogdon J, June CH, Loew A, Maus M, Scholler J, inventors; Novartis Ag; The Trustees of The University of Pennsylvania, assignee. Treatment of cancer using humanized anti CD19 chimeric antigen receptor. AU-2022202024-A1. 4/14/2022.
16. Brogdon J, Choi E, Ebersbach HE, Glass DJ, Huet H, June CH, et al., inventors; The Trustees of The University of Pennsylvania; Novartis Ag, assignee. Treatment of cancer using humanized anti-BCMA chimeric antigen receptor. US-2022064316-A1. 3/3/2022.
17. Bitter H, Bordeaux JM, Brannetti B, Brogdon J, Dakappagari NK, Gill S, et al., inventors; Novartis Ag; The Trustees of The University of Pennsylvania, assignee. CD20 therapies; CD22 therapies; and combination therapies with a CD19 Chimeric Antigen Receptor (CAR) - expressing cell. AU-2021282477-A1. 1/6/2022.
18. Barrett DM, Bedoya F, Ghassemi S, June CH, Levine BL, Melenhorst JJ, et al., inventors; Novartis Ag; The Trustees of The University of Pennsylvania, assignee. Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells. AU-2022231783-A1. 11/10/2022.
19. Zhao Y, Shedlock DJ, June CH, Liu X, inventors; Novartis Ag; The Trustees of The University of Pennsylvania, assignee. Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules. US-2021317183-A1. 10/14/2021.
20. Wasik M, Sellers WR, Ruella M, Porter D, Muthusamy N, Murphy L, et al., inventors; Novartis Ag; Univ Pennsylvania, assignee. Cancer Treatment Using Anti-CD19 Chimeric Antigen Receptor. AR-118751-A2. 10/27/2021.
21. Riley JL, Paulos C, June CH, Levine BL, inventors; The Trustees of The University of Pennsylvania, assignee. ICOS critically regulates the expansion and function of inflammatory human Th17 cells. US-11001805-B2. 5/11/2021.
22. Riley JL, June CH, Blazar BR, Hippen K, inventors; The Trustees of The University of Pennsylvania; Regents of The University of Minnesota, assignee. Inducible regulatory T-cell generation for hematopoietic transplants. US-2021275650-A1. 9/9/2021.
23. Posey AD, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. Tn-MUC1 Chimeric Antigen Receptor (CAR) T Cell Therapy. US-2021338733-A1. 11/4/2021.
24. Posey A, June CH, Migliorini D, Chang H, Satpathy A, Parker K, inventors; The Trustees of The University of Pennsylvania; The Board of Trustees of The Leland Stanford Junior University,

assignee. Use of inhibitory chimeric receptors to prevent T cell-induced blood brain barrier damage. US-2021230246-A1. 7/29/2021.

25. Mitchell M, Billingsley M, Singh N, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. Lipid nanoparticles and formulations thereof for CAR mRNA delivery. CA-3155075-A1. 4/22/2021.

26. June CH, Zhao Y, Liu X, inventors; The Trustees of The University of Pennsylvania, assignee. Enhancing Activity of CAR T Cells by Co-Introducing a Bispecific Antibody. US-2021040234-A1. 2/11/2021.

27. June CH, Scholler J, Posey AD, Jr., inventors; The Trustees of The University of Pennsylvania, assignee. Use of the CD2 signaling domain in second-generation chimeric antigen receptors. US-2021371495-A1. 12/2/2021.

28. June CH, Keisuke W, Carrio SG, Hemminki A, Scholler J, Young RM, inventors; Novartis Ag; The Trustees of The University Of Pennsylvania, assignee. Combination therapy using a chimeric antigen receptor. US-2021038659-A1. 2/11/2021.

29. June CH, Carrio SG, Zhao Y, Scholler J, inventors; The Trustees of The University of Pennsylvania, assignee. Use of ICOS-based cars to enhance antitumor activity and CAR persistence. US-2021009652-A1. 1/14/2021.

30. GILL S, June CH, Posey AD, Powell DJ, Ruella M, inventors; The Trustees of The University of Pennsylvania, assignee. Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against t cell lymphomas and leukemias. AU-2019404302-A1. 8/5/2021.

31. Engels B, Idamakanti N, June CH, Loew A, Milone MC, Song H, et al., inventors; Novartis Ag; The Trustees of The University of Pennsylvania, assignee. Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy. AU-2021203790-A1. 7/8/2021.

32. Castellarin M, June C, inventors; The Trustees of The University of Pennsylvania, assignee. Compositions and methods for switchable CAR T cells using surface-bound sortase transpeptidase. AU-2019357846-A1. 5/20/2021.

33. Brogdon J, Gill S, June CH, Kalos MD, Loew A, Scholler J, inventors; Novartis Ag; The Trustees of The University of Pennsylvania, assignee. Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells. US-11028177-B2. 6/8/2021.

34. Riley JL, June CH, Blazar BR, Hippen K, inventors; The Trustees of The University of Pennsylvania; Regents of The University of Minnesota, assignee. Methods to Expand a T Regulatory Cell Master Cell Bank. US-2020263131-A1. 8/20/2020.

35. Orlando E, Fraietta JA, Melenhorst JJ, O'Connor R, June CH, inventors; Novartis Ag, assignee. Methods of making chimeric antigen receptor-expressing cells. MX-2020004229-A. 7/22/2020.

36. L. LB, June CH, Kalos MD, inventors; The Trustees of The University of Pennsylvania, assignee. Methods of assessing the suitability of transduced T cells for administration. AU-2020201949-A1. 4/23/2020.
37. June CH, Pure E, Wang L-C, Albelda S, Scholler J, inventors; The Trustees of The University of Pennsylvania; The Wistar Institute of Anatomy And Biology, assignee. Compositions and Methods for Targeting Stromal Cells for the Treatment of Cancer. US-2020079874-A1. 3/12/2020.
38. Johnson LR, June CH, Minn AJ, inventors; Novartis AG; The Trustees of the University of Pennsylvania, assignee. Immune-enhancing RNAs for combination with chimeric antigen receptor therapy. EP-3737408-A1. 11/18/2020.
39. Garfall A, Cohen AD, Milone MC, Plesa G, Stadtmauer EA, June CH, inventors; Novartis AG; The Trustees of The University of Pennsylvania, assignee. Bcma-targeting chimeric antigen receptor; CD19-targeting chimeric antigen receptor; and combination therapies. EP-3710040-A1. 9/23/2020.
40. Brogdon J, Beatty G, Glass DJ, June CH, Mannick J, Milone MC, et al., inventors; Novartis Ag; The Trustees of The University of Pennsylvania, assignee. Methods for B cell preconditioning in CAR therapy. US-2020339651-A1. 10/29/2020.
41. Scholler J, June CH, inventors; Novartis Ag; The Trustees Of The University of Pennsylvania, assignee. Chimeric antigen receptor therapy in combination with IL-15r and IL15. WO-2019160956-A1. 8/22/2019.
42. Powell DJ, Smole A, Posey AD, O'Rourke D, Yin Y, June C, et al., inventors; The Trustees of The University of Pennsylvania, assignee. Methods and compositions comprising a viral vector for expression of a transgene and an effector. WO-2019199689-A1. 10/17/2019.
43. Powell DJ, JR., June CH, inventors; The Trustees Of The University of Pennsylvania, assignee. Use of trans-signaling approach in chimeric antigen receptors. US-2019125797-A1. 5/2/2019.
44. Posey AD, June CH, Schwab RD, inventors; The Trustees of The University of Pennsylvania, assignee. Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis. WO-2019210207-A3. 11/28/2019.
45. Nobles CL, Bushman FD, Fraietta JA, Lacey S, Melenhorst JJ, June CH, inventors; Novartis Ag; The Trustees of The University of Pennsylvania, assignee. CAR T cell therapies with enhanced efficacy. WO-2019210153-A1. 10/31/2019.
46. Mueller KT, Wood P, (Michael) YZ, Taran T, Porter DL, Frey N, et al., inventors; Novartis AG; The Trustees Of The University of Pennsylvania, assignee. Therapeutic regimens for chimeric antigen receptor (CAR)- expressing cells. EP-3464375-A2. 4/10/2019.
47. June CH, Riley JL, Maus M, Kaskel A, Vonderheide R, inventors; The Trustees of The University of Pennsylvania, assignee. Activation and Expansion of T-Cells Using an Engineered Multivalent Signaling Platform as a Research Tool. US-2019177692-A1. 6/13/2019.

48. June CH, Milone M, Zhao Y, Lum LG, Thakur A, inventors; Univ Pennsylvania; Univ Wayne State, assignee. Methods and compositions for cells expressing a chimeric intracellular signaling molecule. HK-1257442-A1. 10/18/2019.
49. June CH, Milone M, Zhao Y, Lum L, Thakur A, inventors; Univ Pennsylvania; Univ Wayne State, assignee. Methods and compositions for cells expressing a chimeric intracellular signaling molecule. HK-1257441-A1. 10/18/2019.
50. June CH, Levine BL, Kalos MD, Gill S, inventors; The Trustees of The University of Pennsylvania, assignee. Compositions and Methods for Regulating CAR T Cells. US-2019367610-A1. 12/5/2019.
51. June CH, Levine BL, Chew A, Schuster SJ, inventors; The Trustees of The University of Pennsylvania, assignee. Methods for treating chronic lymphocytic leukemia (CLL). US-2019336530-A1. 11/7/2019.
52. Carrio SG, June CH, Posey AD, Scholler J, inventors; Novartis AG; The Trustees of The University of Pennsylvania; Sonia Guedan Carrio, assignee. Subset-optimized chimeric antigen receptor-containing T-cells. EP-3174546-B1. 10/30/2019.
53. Zhao Y, Liu X, June CH, inventors; Univ Pennsylvania, assignee. Compositions and methods of stimulating and expanding t cells. HK-1243334-A1. 7/13/2018.
54. Riley JL, June CH, Vonderheide RH, Aqui N, Suhoski M, inventors; The Trustees of The University of Pennsylvania, assignee. Innovative artificial antigen presenting cells and uses thereof. ES-2668538-T3. 5/18/2018.
55. June CH, Daniel J. Powell J, inventors; Novartis Ag and The Trustees of The University of Pennsylvania, assignee. CAR-expressing cells against multiple tumor antigens and uses thereof. US-2018044424-A1. 2/15/2018.
56. Daniel J. Powell J, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. Use of a trans-signaling approach in chimeric antigen receptors. US-10117896-B2. 11/6/2018.
57. Byrd J, Dubovsky J, Johnson A, June CH, Muthusamy N, Porter DL, et al., inventors; Novartis AG and The Trustees of The University of Pennsylvania, assignee. Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives. EP-3280795-A1. 2/14/2018.
58. Bushman FD, Fraietta JA, June CH, Melenhorst JJ, Nobles CL, Young RM, et al., inventors; Novartis AG and The Trustees of The University of Pennsylvania, assignee. CAR T cell therapies with enhanced efficacy. EP-3350320-A1. 7/25/2018.
59. Bushman FD, Fraietta JA, June CH, Melenhorst JJ, Nobles CL, Young RM, et al., inventors; Novartis Ag; Univ Pennsylvania, assignee. Car T cell therapies with enhanced efficacy. HK-1250517-A1. 12/21/2018.
60. Brogdon J, Ebersbach HE, Glass D, Huber T, Jascur J, June CH, et al., inventors; Novartis Pharma Ag, Novartis Institutes for Biomedical Research, Inc., China Novartis Institutes for Biomedical

Research and The Trustees of The University of Pennsylvania, assignee. Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor. US-2018118834-A1. 5/3/2018.

61. Brogdon J, Beatty G, Glass D, June CH, Mannick J, Milone M, et al., inventors; Novartis AG, assignee. Methods for B cell preconditioning in CAR therapy. US-2018334490-A1. 11/22/2018.
62. Barrett DM, Bedoya F, Ghassemi S, June CH, Levine BL, Melenhorst JJ, et al., inventors; Univ Pennsylvania, assignee. Methods for improving the efficacy and expansion of chimeric antigen receptor expressing cells. US-2018133296-A1. 5/17/2018.
63. Angst D, Byrd J, Dubovsky J, Fraietta JA, Gessier F, Gill S, et al., inventors; Novartis Ag; The Trustees of The University of Pennsylvania, assignee. Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives. US-2018140602-A1. 5/24/2018.
64. Anak O, Bilic S, Brogdon J, Cameron JS, Chou W, DRH, Jr., et al., inventors; Novartis Ag and The Trustees of The University of Pennsylvania, assignee. Combination therapies of chimeric antigen receptors and PD-1 inhibitors. CA-3032054-A1. 2/1/2018.
65. June CH, Carrio SG, Posey AD, Scholler J, inventors; Novartis Ag and The Trustees of The University of Pennsylvania, assignee. Subset-optimized chimeric antigen receptor-containing T-cells. US-2017209492-A1. 7/27/2017.
66. Gill S, Klichinsky M, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof. CA-2992742-A1. 2/2/2017.
67. Brogdon J, Johnson LA, June CH, Loew A, Maus M, Scholler J, et al., inventors; Novartis AG, assignee. Treatment of Cancer Using Humanized Anti-EGFRviii Chimeric Antigen Receptor. US-2017008963-A1. 1/12/2017.
68. Bedoya F, Ghassemi S, June CH, Kawalekar OU, Levine BL, Melenhorst JJ, et al., inventors; Univ Pennsylvania, assignee. Methods for improving the efficacy and expansion of immune cells. US-2017137783-A1. 5/18/2017.
69. Zhao Y, Ren J, Liu X, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. Altering gene expression in modified T cells and uses thereof. CA-2964948-A1. 5/6/2016.
70. Zhao Y, Liu X, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. Methods and compositions for modified T cells. CA-2964958-A1. 5/6/2016.
71. Zhao Y, Liu X, CHJ, inventors; The Trustees of The University of Pennsylvania, assignee. Compositions and methods of stimulating and expanding T cells. CA-2966035-A1. 5/6/2016.
72. Zhao Y, June CH, Liu X, inventors; The Trustees of The University of Pennsylvania, assignee. Compositions and methods for T cell delivery of therapeutic molecules. CA-2975147-A1. 8/4/2016.

73. Riley JL, June CH, Blazar BR, Hippen K, inventors; The Trustees of The University of Pennsylvania and Regents of The University of Minnesota, assignee. Inducible regulatory T-cell generation for hematopoietic transplants. US-9228172-B2. 1/5/2016.
74. June CH, Liu X, Shedlock DJ, Zhao Y, inventors; Novartis Ag and The Trustees of The University of Pennsylvania, assignee. Enhanced antigen presenting ability of CAR T cells by co-introduction of costimulatory molecules. WO-2015112626-A9. 10/13/2016.
75. June CH, Levine BL, Porter DL, Kalos MD, Milone MC, inventors; The Trustees of The University of Pennsylvania, assignee. Use of chimeric antigen receptor-modified T-cells to treat cancer. US-9499629-B2. 11/22/2016.
76. June CH, Levine BL, Kalos MD, Zhao Y, inventors; The Trustees of The University of Pennsylvania, assignee. Epitope Spreading Associated with CAR T-Cells. US-2016235787-A1. 8/18/2016.
77. Godfrey WR, June C, inventors; The Trustees of The University of Pennsylvania, assignee. Methods for the isolation and expansion of cord blood derived T regulatory cells. CA-2581063-C. 3/22/2016.
78. Engels B, Idamakanti N, June CH, Loew A, Milone MC, Song H, et al., inventors; Novartis Ag and The Trustees of The University of Pennsylvania, assignee. Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy. WO-2016044605-A1. 3/24/2016.
79. Brogdon J, Choi E, Ebersbach HE, Glass D, Huet H, June CH, et al., inventors; The Trustees of The University of Pennsylvania and Novartis Ag, assignee. Treatment of cancer using humanized anti-BCMA chimeric antigen receptor. US-2016046724-A1. 2/18/2016.
80. Blazar BR, June C, Godfrey WR, Carroll RG, Levine B, Riley JL, et al., inventors; The Trustees of The University of Pennsylvania, assignee. Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses. CA-2558777-C. 2/2/2016.
81. Bitter H, Bordeaux JM, Brannetti B, Brogdon J, Dakappagari NK, Gill S, et al., inventors; Novartis AG, assignee. CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (car)- expressing cell. US-2016362472-A1. 12/15/2016.
82. Bedoya F, Ghassemi S, June CH, Levine BL, Melenhorst JJ, Milone MC, et al., inventors; Univ Pennsylvania, assignee. Methods of making chimeric antigen receptor -expressing cells. US-2016185861-A1. 6/30/2016.
83. Beatty G, Engels B, Idamakanti N, June CH, Loew A, Song H, et al., inventors; Novartis Ag and The Trustees of The University of Pennsylvania, assignee. Human mesothelin chimeric antigen receptors and uses thereof. US-2016311917-A1. 10/27/2016.
84. Riley JL, Paulos C, June CH, Levine B, inventors; The Trustees of The University of Pennsylvania, assignee. ICOS critically regulates the expansion and function of inflammatory human Th17 cells. US-9133436-B2. 9/15/2015.

85. June CH, Porter DL, Maus M, Wasik M, Gill S, Fraietta J, et al., inventors; Novartis AG, assignee. Treatment of cancer using anti-CD19 chimeric antigen receptor. US-2015283178-A1. 10/8/2015.
86. Levine BL, Kalos MD, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. Use of CART19 to deplete normal B cells to induce tolerance. CA-2876734-A1. 1/16/2014.
87. June CH, Zhao Y, Liu X, inventors; The Trustees of The University of Pennsylvania, assignee. Enhancing activity of CAR T cells by co-introducing a bispecific antibody. CA-2876730-A1. 1/16/2014.
88. June CH, Riley JL, Maus M, Thomas A, Vonderheide R, inventors; The Trustees of The University of Pennsylvania, assignee. Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool. US-8637307-B2. 1/28/2014.
89. June CH, Pure E, Wang L-C, Albelda S, Scholler J, inventors; The Trustees of The University of Pennsylvania and The Wistar Institute of Anatomy and Biology, assignee. Compositions and methods for targeting stromal cells for the treatment of cancer. WO-2014055442-A9. 7/24/2014.
90. June CH, Levine BL, Kalos MD, Grupp S, inventors; The Trustees of The University of Pennsylvania and The Children's Hospital of Philadelphia, assignee. Toxicity management for anti-tumor activity of CARs. CA-2878928-A1. 1/16/2014.
91. June CH, Levine BL, Kalos MD, inventors; The Trustees of The University of Pennsylvania, assignee. Methods of assessing the suitability of transduced t cells for administration. CA-2878862-A1. 1/16/2014.
92. June CH, Levine BL, Kalos MD, inventors; The Trustees of The University of Pennsylvania, assignee. Compositions and methods for regulating CAR T cells. CA-2878856-A1. 1/16/2014.
93. J. B, S. G, C.H. J, M.D. K, A. L, J. S, inventors; Novartis AG, assignee. Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells. US-2014322212-A1. 10/30/2014.
94. Brogdon J, June CH, Loew A, Maus M, Scholler J, inventors; The Trustees of The University of Pennsylvania and Novartis Ag, assignee. Treatment of cancer using humanized anti-CD19 chimeric antigen receptor. US-2014271635-A1. 9/18/2014.
95. Riley JL, June CH, Blazar BR, Hippen K, inventors; The Trustees of The University of Pennsylvania, assignee. Methods to Expand a T Regulatory Cell Master Cell Bank. US-2013101567-A1. 4/25/2013.
96. June CH, Zhao Y, inventors; The Trustees of The University of Pennsylvania, assignee. Switch costimulatory receptors. CA-2842368-A1. 2/7/2013.
97. June CH, Zhao Y, inventors; The Trustees of The University of Pennsylvania, assignee. RNA engineered t cells for the treatment of cancer. CA-2848410-A1. 3/21/2013.

98. June CH, Scholler J, Posey AD, inventors; The Trustees of The University of Pennsylvania, assignee. Use of the CD2 signaling domain in second-generation chimeric antigen receptors. CA-2864489-A1. 8/29/2013.
99. June CH, Levine B, Chew A, Schuster SJ, inventors; The Trustees of The University of Pennsylvania, assignee. Methods for treating progressive multifocal leukoencephalopathy (PML). US-8415150-B2. 4/9/2013.
100. June CH, Kawalekar OU, Zhao Y, Scholler J, inventors; The Trustees of The University of Pennsylvania, assignee. Double transgenic T cells comprising a CAR and a TCR and their methods of use. WO-2013126726-A1. 8/29/2013.
101. June CH, Carrio SG, Zhao Y, Scholler J, inventors; The Trustees of The University of Pennsylvania, assignee. Use of ICOS-based CARs to enhance antitumor activity and CAR persistence. CA-2864688-A1. 8/29/2013.
102. Frigault MJ, Zhao Y, Scholler J, June CH, inventors; The Trustees of The University of Pennsylvania, assignee. Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer. CA-2863799-A1. 8/29/2013.
103. Coukos G, June CH, Powell DJ, inventors; The Trustees of The University of Pennsylvania, assignee. Compositions and methods for treating cancer. WO-2012099973-A2. 7/26/2012.
104. June CH, Thompson CB, Nabel GJ, Gray GS, Rennert PD, Freeman GJ, inventors; Office of Naval Research, Dana-Farber Cancer Institute, Genetics Institute, The Regents of The University of Michigan and Repligen Corporation, assignee. Methods for selectively stimulating proliferation of T cells. CA-2164226-C. 2/8/2011.
105. June CH, Carroll RG, Riley JL, Louis DCS, Levine BL, inventors; The United States of America as Represented by The Secretary of The Navy, assignee. Methods for downregulating CCR5 in T cells with anti-CD3 antibodies and anti-CD28 antibodies. US-7927595-B1. 4/19/2011.
106. June CH, inventor; United States of America as Represented by The Secretary of The Navy, assignee. Methods for modulating T cell responses by manipulating intracellular signal transduction. CA-2189055-C. 1/18/2011.
107. June CH, Thompson CB, Nabel GJ, Gray GS, Rennert PD, inventors; Genetics Institute, LLC, Regents of The University of Michigan and The United States of America as Represented by The Secretary of The Navy, assignee. Methods for selectively enriching TH1 and TH2 cells. US-7479269-B2. 1/20/2009.
108. Thompson CB, June CH, inventors; The Regents of The University of Michigan, assignee. Methods of treating autoimmune disease via CTLA-4 Ig. US-2008305092-A1. 12/11/2008.
109. June CH, Thompson CB, Kim S, inventors; United States of America as Represented by The Secretary of The Navy and The Regents of The University of Michigan, assignee. Improved methods for transfecting T cells. CA-2220226-C. 10/21/2008.

110. June CH, Thompson CB, inventors; Arch Development Corporation and The United States of America as Represented by The Secretary of The Navy, assignee. Methods for inhibiting T-cell survival, by inhibiting BCL-XL protein level. EP-1384781-B1. 4/30/2008.
111. Carroll RG, Shan X, Danet-Desnoyers G-a, June CH, inventors; Univ Pennsylvania, assignee. Modulation of regulatory T cells by human IL-18. WO-2008033499-A3. 8/14/2008.
112. Carroll RG, June CH, Riley JL, inventors; Univ Pennsylvania, assignee. Methods, compositions and kits relating to antigen presenting tumor cells. WO-2008027456-A3. 7/10/2008.
113. June CH, Thompson CB, Nabel GJ, Gray GS, Rennert PD, inventors; Genetics Institute, LLC, Regents of The University of Michigan and The United States of America as Represented by The Secretary of The Navy, assignee. Methods for selectively stimulating proliferation of T cells. US-7175843-B2. 2/13/2007.
114. June CH, Thompson CB, inventors; Arch Development Corporation and United States of America as Represented by The Secretary of The Navy, assignee. Methods for modulating T cell survival by modulating bcl-xl protein level. CA-2220012-C. 10/30/2007.
115. June CH, Criab B. Thompson SK, inventors; The United States of America as Represented by The Secretary of The Navy and The Regents of The University of Michigan, assignee. Methods for transfecting T cells. US-7172869-B2. 2/6/2007.
116. Riley JL, June CH, Vonderheide RH, Aqui N, Suhoski M, inventors; Univ Pennsylvania, assignee. Novel artificial antigen presenting cells and uses therefor. WO-2005118788-A3. 4/27/2006.
117. June CH, Thompson CB, Nabel GJ, Gray GS, Rennert PD, inventors; The Regents of The University of Michigan, Genetics Institute, LLC and The United States of America as Represented by The Secretary of the Navy, assignee. Methods for selectively stimulating proliferation of T cells. US-7144575-B2. 12/5/2006.
118. Fowler DH, Jung U, Gress RE, Levine B, June C, inventors; US Department of Health and Human Services, assignee. Rapamycin resistant T cells and therapeutic uses thereof. WO-2005003335-A9. 9/29/2005.
119. Thompson CB, June CH, inventors; The Regents of The University of Michigan and The United States of America as Represented by The Secretary of The Navy, assignee. Methods of treating autoimmune disease via CTLA-4 Ig. US-6685941-B1. 2/3/2004.
120. June CH, Thompson CB, Kim S, inventors; The Regents of The University of Michigan and The United States of America as Represented by The Secretary of the Navy, assignee. Methods for transfecting T cells. US-6692964-B1. 2/17/2004.
121. Riley J, June C, Maus M, inventors; The Trustees of The University of Pennsylvania, assignee. System and methods for promoting expansion of polyclonal and antigen-specific cytotoxic T lymphocytes in response to artificial antigen presenting cells. US-2003147869-A1. 8/7/2003.

122. June CH, Thompson CB, Nabel GJ, Gray GS, Rennert PD, inventors; Office of Naval Research and Repligen, assignee. Methods for selectively stimulating proliferation of T cells. US-2003099643-A1. 5/29/2003.
123. Fowler DH, Hou J, Jung U, Gress RE, Levine B, June C, inventors; The Government of The United States of America as Represented by The Secretary of Health and Human Services and The Trustees of The University of Pennsylvania, assignee. Procédes de generation de cellules CD4+ Th1 humaines. WO-03020904-A2. 3/13/2003.
124. Fowler DH, Hou J, Jung U, Gress RE, Bishop M, Levine B, et al., inventors; The Government of The United States of America as Represented by The Secretary of Health and Human Services and The Trustees of The University of Pennsylvania, assignee. Methodes de generation de cellules humaines Th2 CD4+ et utilisations associees. WO-03004625-A1. 1/16/2003.
125. Fowler D, Jung U, Medin JA, Gress RE, Erdmann A, Levine B, et al., inventors; The Government of The United States of America, as Represented by The Secretary of The Department of Health and Human Services and The Trustees of The University of Pennsylvania, assignee. Generation et utilisation de cellules TC1 et TC2. WO-03038062-A2. 5/8/2003.
126. June CH, Thompson CB, Nabel GJ, Gray GS, Rennert PD, Freeman GJ, inventors; Office of Naval Research, Dana-Farber Cancer Institute, Genetics Institute, The Regents of The University of Michigan and Repligen Corporation, assignee. Method for selectively stimulating proliferation of T cells. US-2002076407-A1. 6/20/2002.
127. June CH, Thompson CB, Nabel GJ, Gray GS, Rennert PD, inventors; Office of Naval Research, Dana-Farber Cancer Institute, Genetics Institute, The Regents of The University of Michigan and Repligen Corporation, assignee. Methods for selectively stimulating proliferation of t cells. US-2002115214-A1. 8/22/2002.
128. Thompson CB, June CH, Ledbetter JA, Lindsten T, inventors; Office of Naval Research, The Regents of The University of Michigan and Bristol-Myers Squibb Company, assignee. Immunotherapy involving CD28 stimulation. CA-2003455-C. 2/22/2000.
129. June CH, Thompson CB, Nabel GJ, Gray GS, Rennert PD, Freeman GJ, inventors; The United States of America as Represented by The Secretary of The Navy, The Regents of The University of Michigan and Dana-Farber Cancer Institute, assignee. Methods for selectively stimulating proliferation of T cells. US-5858358-A. 1/12/1999.
130. June CH, Craighead N, inventors; The United States of America as Represented by The Secretary of The Navy, assignee. Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody. US-5948893-A. 9/7/1999.
131. David N. Liebowitz CJ, inventor; Arch Development Corporation and the Henry M. Jackson Foundation for The Advancement of Military Medicine, assignee. Methods for treatment of tumors and tumor cells using ex vivo activated T cells. CA-2309206-A1. 5/20/1999.

132. Harlan DM, June CH, inventors; The United States of America as Represented by The Secretary of The Navy, assignee. Transgenic animal model for autoimmune diseases. US-5718883-A. 2/17/1998.
133. June CH, Thompson CB, Nabel GJ, Gray GS, Rennert PD, Freeman GJ, inventors; The United States of America, as Represented by The Secretary of The Navy, Repligen Corporation, The Regents of The University of Michigan and Dana-Farber Cancer Institute, assignee. Methods for selectively stimulating proliferation of T cells. CA-2191586-A1. 12/14/1995.
134. Thompson CB, June CH, inventors; The Regents of The University of Michigan, United States of America as Represented by The Secretary of the Navy, assignee. CD28 Pathway Immunoregulation. CA-2133075-A1. 10/14/1993.